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CEL   Carboxyl-ester lipase 
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DPED   Diabetes-pancreatic exocrine dysfunction 
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GRP94   Glucose-regulated protein 94 
GSIS   Glucose-stimulated insulin secretion 
GTT   Glucose tolerance test 
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HNF   Hepatocyte nuclear factor 
IGT   Impaired glucose tolerance 
IVGTT   Intravenous glucose tolerance test 
ITT   Insulin tolerance test 
KO   Knockout 
LDL   Low-density lipoprotein 
MODY   Maturity-onset diabetes of the young 
MIDD   Maternally inherited diabetes and deafness 
MRI   Magnetic resonance imaging 
NASH / NAFLD  Non-alcoholic steatohepatitis / Non-alcoholic fatty liver disease 
NGT   Normal glucose tolerance 
OGTT   Oral glucose tolerance test 
PCR   Polymerase chain reaction 
PEST domain  Proline (P), glutamate (E), serine (S), threonine (T) 
PEST   Pancreatic enzyme substitution therapy 
PNDM   Permanent neonatal diabetes mellitus 
TNDM   Temporary neonatal diabetes mellitus 
VNTR   Variable number of tandem repeats 
WT   Wild type
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1. INTRODUCTION 
1.1  Normal function and development of the pancreas 
1.1.1  Structure and function 
The pancreas is a mixed exocrine and endocrine organ that plays a central role in food 
digestion and glucose homeostasis. The two tissues have interacting functions; the exocrine 
part produces enzymes that digest polysacharides, lipids and proteins into their basic 
components (monosacharides, fatty acids and their backbones, and amino acids) thus 
enabling their uptake into the bloodstream, whereafter they are processed under the control 
of endocrine hormones. The endocrine part includes five distinct hormone-producing cell 
types organized into the islets of Langerhans. These islets are dispersed in the exocrine 
pancreatic tissue (Figure 1), consisting of acinar cells that produce and secrete digestive 
enzymes into ducts which transport the digestive enzymes to the intestine. There is an 
evolutionary variation ranging from no anatomical contact between endocrine and exocrine 
tissue in some groups of fish, via mixed exo-endocrine tissues in reptiles, to well-defined 
islets in higher vertebrates such as mammals (1). 
The exocrine pancreas 
The exocrine part of the pancreas makes up 80 % of the gland and consists of acinar cells, 
which are arranged in tubular or spherical cell groups with a central lumen (acini; Figure 2) 
(2). The lumens of the acini merge to form intralobular and then interlobular ducts that 
Figure 1. Hematoxylin-eosin-stained section  of a 
normal mouse pancreas demonstrating the 
distinctive anatomical compartmentilazation of 
exocrine and endocrine tissue, with the endocrine 
cells clustering in the islets of Langerhans. The 
organization in humans is similar.
Islet
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anastomose to become the main pancreatic duct, bringing the pancreatic secretions to the 
duodenum. Acinar cells are highly polarized serous epithelial cells, with rough 
endoplasmatic reticulum occupying about 20 % of the cell volume, filling most of the basal 
region, whereas zymogen granules fill the apical portion of the cells. After a large meal, a 
decrease in both the size and the number of zymogen granules is observed in concurrence 
with a substantial increase in pancreatic enzyme secretion and a more extensive Golgi 
apparatus (3). The zymogen granules contain 12 to 15 different digestive enzymes, each 
granule containing the entire complement although in variable concentrations (4-6). Most of 
the digestive enzymes are secreted as pro-enzymes that are subsequently activated at the 
encounter of trypsin, following the activation of trypsin by enterokinase cleavage of 
trypsinogen in the duodenum (2). Centroacinar and duct cells contribute in the production of 
pancreatic juice by the secretion of bicarbonate and water. The bicarbonate contributes to 
keeping the digestive enzymes inactive, as they have a slightly acidic pH-optimum. The 
secreted pancreatic juice amounts to about 1500-2500 ml per day. 
Ductule Acinus
Ach
(neural)
Secretin
(humoral)
Ach
(neural)
GRP
(neural)
VIP
(neural)
Digestive
enzymes
H2O
NaHCO3
Figure 2. Schematic illustration of the functional unit of the exocrine pancreas. Acetylcholine (Ach), 
secretin,  gastrin-releasing peptide (GRP), and vasoactive intestinal peptide (VIP) act as neural and 
humoral agonists to induce secretion of bicarbonate and water from the duct cells and digestive 
enzymes from the acinar cells. (Adapted from (2)). 
In the fasting state, human pancreatic exocrine secretion is cyclical and closely correlated 
with upper gastrointestinal motility. Postprandially, however, enzyme delivery into the 
duodenum increases rapidly to reach a maximum within 30 minutes to an hour, it then 
decreases slightly and stabilizes, and eventually the secretory rate decreases 3-4 hours 
postprandially to reach the interdigestive range. However, the degree and the duration of the 
secretory response are dependent on the caloric content, nutrient composition and physical 
properties of the meal (7). The secretion of digestive enzymes and hormones from the 
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exocrine pancreas is mediated by fatty acids of more than eight carbons in length, 
monoglycerides of these fatty acids, peptides, amino acids (particularly essential amino 
acids; the most potent are phenylalanine, valine, methionine, and tryptophan), and, to a 
lesser extent, glucose through neural and humoral pathways combined (2). The intestinal gut 
hormones produced by entero-endocrine cells of the duodenal mucosa play an important 
role, particularly secretin and cholecystokinin (CCK). The latter is the major humoral 
mediator of meal-stimulated enzyme secretion, probably through activation of afferent 
neurons in the duodenal mucosa since human acinar cells do not have CCK receptors (2; 8). 
Secretin is the main mediator of bicarbonate secretion by the duct cells. Removal of secretin 
reduces pancreatic enzyme output by 50 % and the pancreatic volume and bicarbonate 
secretion by 80 % (9). A vasovagal enteropancreatic reflex probably contributes to enzyme 
secretion and augments the effect of secretin on bicarbonate secretion via the 
neurotransmitter acetylcholine and its G-protein coupled muscarinic (M3) receptor. 
The endocrine pancreas 
The Islets of Langerhans, named after Paul Langerhans who first described them in 1869, 
constitute the endocrine compartment of the pancreas, amounting to about 2 % of the gland 
by weight (2). The main function of the endocrine pancreas is the secretion of hormones 
regulating growth and maintaining plasma glucose levels in a tight physiological range for 
optimal functioning of all tissues in the body. About two million islets are found in a human 
pancreas (10), with the highest density in the tail region. Each islet is a rounded cluster of 
cells of 100-200 μm in diameter, separated from the surrounding exocrine tissue by a fine 
capsule of reticular fibres and a basal lamina derived from endothelial cells (11). The 
endocrine cells form cords in close proximity to a rich network of fenestrated blood 
capillaries that surround and penetrate each islet. The capillaries are arranged in a so-called 
insula-acinar portal system that conveys blood from the islets to acinar cells, thus permitting 
the local action of islet hormones, particularly insulin, on the exocrine pancreas. This local 
effect is demonstrated by the fact that peri-insular acini have larger cells, nuclei, and 
zymogen granule regions and different ratios of specific digestive enzymes, than acini 
situated further away (2). The insula-acinar portal system runs in parallel to an arterial 
system supplying blood directly to the acinar tissue. Both sympathetic and parasympathetic 
nerve fibres converge on some of the islet cells (11). The islets in the pancreatic tail, body 
and anterior head deriving from the dorsal bud (see below) are in general more glucagon-
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rich than the PP-rich islets in the posterior head of the pancreas, deriving from the ventral 
bud (12). 
Four major types of cells are found in the islets, and in contrast to the acinar cells they 
appear to be specialized into secreting a single hormone each. The beta cells (ȕ-cells) secrete 
insulin, which reduces blood glucose levels by increasing glucose uptake into liver, muscle 
and fat, and by inhibiting glucose production in the liver. Insulin is synthesized in the form 
of preproinsulin, which is processed by the cleaving off of the signal peptide and the 
formation of disulfide bonds to yield proinsulin. Proinsulin is further cleaved into insulin 
(consisting of A and B chains) and the C-peptide (connecting peptide) in equimolar amounts. 
An increase in the serum glucose level is sensed by the beta cell and is the main stimulus for 
insulin secretion, resulting in a proportional increase in insulin secretion (13). The 
corresponding process is called the glucose-stimulated insulin secretion (GSIS; Figure 3). 
Insulin secretion is also stimulated by lipids (14), incretins (see below), neural input (15) and 
other hormones (16). 
Alpha cells (Į-cells) produce glucagon, which promotes the increase of blood glucose levels 
through activating glycogenolysis and gluconeogenesis at low blood glucose levels. The 
primary stimulus is hypoglycaemia. The main regulatory mechanism governing glucagon 
secretion is paracrine signalling, with zinc, insulin and GABA from beta cells and 
somatostatin from delta cells acting as inhibitors of glucagon secretion. The sympathetic 
nerves, the vagal nerve and several amino acids (arginine and alanine) stimulate glucagon 
secretion. The delta cells (į-cells) produce somatostatin inhibiting the secretion of the other 
endocrine pancreatic hormones, and the PP cells produce pancreatic polypeptide (PP) that 
inhibits the secretion of bicarbonate and enzymes from the exocrine pancreas. It has been 
estimated that each islet is composed of 70-80 % beta cells, 15-20 % alpha cells, 5 % delta 
cells and < 2 % PP-cells, with some variation depending on in which embryologically 
defined part of the pancreas the islets are located (10; 17). The number of beta cells may be 
relatively higher in mouse than human islets (77 % versus 55 %) and the number of alpha 
cells may be lower in mouse than human islets (18 % versus 38 %), as indicated by a recent 
study (18). Traditionally, the beta cells have been regarded to form the core of the islets, 
surrounded by the other cell types (19), but recently this model has been modified as 
confocal microscopy and multiple immuno-fluorescence indicate a somewhat more scattered 
distribution of beta, alpha and delta cells within the islets in humans (18). 
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Figure 3. Schematic presentation of the beta cell and processes leading to insulin secretions, 
including glucose-stimulated insulin secretion (GSIS). Incretins, illustrated by GLP-1, augment 
insulin secretion. The MODY-associated transcription factors HNF1A, HNF1B, HNF4A, IPF1 and 
NeuroD1 influence insulin secretion through regulation of the transcription of the insulin gene and 
genes involved in the transport and metabolism of glucose.The energy level of the beta cell 
(ATP/ADP ratio) is the major determinant of the level of insulin secretion. An increased ratio leads 
to the closure of ATP-dependent SUR1 channels (KATP -channels), with subsequent depolarization of 
the voltage-dependent Ca2+-channels, resulting in Ca2+ influx that signals the exocytosis of insulin. 
The incretin effect 
The phenomenon that a greater insulin release is achieved when nutrients are taken orally 
than intravenously is called the incretin effect (20). It is caused by incretins, hormones 
which are secreted from entero-endocrine cells and augment the glucose-stimulated secretion 
of insulin. In type 2 diabetes, the incretin effect has been shown to be markedly reduced 
(21), most likely as a consequence of the diabetic state (22). The two main incretins are 
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), 
secreted from the proximal and distal small intestine, respectively (20). Both act on specific 
G-protein-coupled receptors that stimulate cAMP formation and protein kinase A  (PKA) 
activation, promoting insulin exocytosis (Figure 3). GLP-1 also regulates proinsulin gene 
expression, inhibits glucagon secretion from alpha cells, promotes differentiation towards a 
more endocrine-like phenotype in human and rodent exocrine pancreatic cell lines, stimulate 
beta cell proliferation and preservation and reduces ER stress in murine islets in vivo (20). 
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ER stress is defined as conditions interfering with ER function, induced by accumulation of 
unfolded protein aggregates or by excessive protein traffic, resulting in decreased rate of 
protein translation, induction of the expression of chaperones and activation of the ER-
specific protein-degrading apparatus. Whereas nutrient intake is thought to directly regulate 
GIP, nutrient intake is believed to regulate GLP-1 via neural or endocrine factors (20). Both 
incretins are degraded by dipeptidyl peptidase-4 (DPP-4), and DPP-4 inhibitors as well as 
incretino-mimetics have recently been appproved for therapeutic use in diabetes (23). 
Glucagon secretion is augmented in a similar manner to the incretin effect by the entero-
endocrine hormones CCK and gastrin which are increased by a protein-rich meal (24). 
Furthermore, receptors for GLP-1, CCK and glucagon in the brain regulate energy uptake 
and utilization by inhibiting food intake (24). 
1.1.2  Development 
Both the endocrine and the exocrine parts of the pancreas in vertebrates are derived from 
endoderm (reviewed in ((17; 25)). Table 1 outlines genes that are active at different phases 
in pancreatic development. During organ specification, two buds arise from the gut 
endoderm on each side of the duodenum (day 28 in humans, day 9 (E9) in mice (26)) in 
response to signals from the adjacent mesodermal tissues. The ventral bud becomes the 
uncinate process and the posterior and inferior part of the pancreatic head, whereas the 
dorsal bud evolves into pancreatic body and the tail and the anterior part of the head. The 
buds fuse as the ventral bud moves dorsally during gut rotation (by day 56 in humans, E12.5 
in mice), at the same time forming the main pancreatic duct from a fusion of the dorsal and 
ventral pancreatic ducts made from extensive branching of the epithelial part of the 
pancreatic primordial. Ectopic pancreas growth is inhibited by Hedgehog signalling in the 
adjacent endoderm (27). 
During budding, PDX1 is expressed by ductal progenitor cells, giving rise to all adult 
pancreatic cells (17). PDX1 is required for both islet and acinar differentiation (28), and its 
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Table 1 Some genes involved in pancreatic development 
Gene name Main developmental role 
Organ specification
HLXB9 Early pancreas development, mainly dorsal bud
PTF1A Early pancreas development, mainly ventral bud
SHH Early pancreatic islet development
Growth
IPF1/PDX1 Epithelial factor required for epithelial proliferation, partly through interaction with 
Pbx1
FGF10 Mesenchymal factor stimulating the proliferation of pancreatic progenitors
ISL1 Growth-promoting factor in the dorsal mesenchyme
CDH2 Growth-promoting factor in the dorsal mesenchyme
PBX1 Growth-promoting factor in the epithelium and dorsal mesenchyme
PTF1A Epithelial factor probably required for epithelial proliferation
Specification and differentiation of endocrine and exocrine cell lines 
PTF1A Exocrine cell development
MIST1 Exocrine cell maintenance
NGN3 Key factor in islet cell development
HES1 Notch-pathway-mediated Ngn3 inhibition
DLL1 Notch-pathway-mediated Ngn3 inhibition
HNF6 Ngn3 stimulation; controls the development of pancreatic ducts
NEUROD1 Alpha/beta-cell development
NKX2B Beta cell development
NKX6A Beta cell development
PAX4 Beta cell development
ISL1 Beta cell development
PAX6 Beta cell development
HNF1A Maintenance of differentiated beta cells
HNF4A Maintenance of differentiated beta cells
(Based on (17; 25))
germline inactivation results in pancreatic aplasia (29). A recent study (30) shows that all of 
the Pdx1+ progenitors needed to make the pancreas are generated during the embryonic 
period spanning E8.5-12.5, and the size of this pool determins the final size of the pancreas; 
i.e., normal organ size cannot be restored if the progenitor pool size is reduced. 
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Mesenchymal-epithelial signalling is necessary for the normal growth and differentiation of 
the pancreatic epithelium (31). In the absence of mesenchyme or in the case of disrupted 
signalling, endocrine but not exocrine cells arise from the pancreatic epithelium (32; 33). 
Important signalling factors mediating the epithelio-mesenchymal interactions include the 
epidermal growth factor (EGF) and fibroblast growth factor (FGF) families (17; 33).  
A recent study (34) revealed that in humans, the pancreas by 9-11 weeks consists mainly of 
mesenchymal tissue infiltrated by branched epithelial structures and scattered hormone-
negative Neurogenin 3 (NGN3)-positive cells. NGN3 expression is necessary and sufficient 
for endocrine development (35) and is repressed by the Notch pathway (36). Clusters of 
endocrine cells producing either glucagon or insulin are observed by 15-19 weeks, while 
vascularised islet-like structures appear by 20-23 weeks. By 9-10 weeks, transcripts for 
insulin, glucagon, somatostatin, ghrelin and pancreatic polypeptide are present, and from 11-
23 weeks a progressive increase in the endocrine cell population is evident. The human 
equivalent of a mouse endocrine secondary transition has not been observed, neither 
morphologically nor on the expression level, possibly because this occurs at multiple foci 
without the temporal coincidence seen in mice (34). By contrast, exocrine genes show a 
marked transition around 11 weeks (34). PTF1A is necessary for exocrine cell differentiation 
(37), an early marker of which is carboxylester lipase (CEL) (38). Protoacinar structures 
emerge by 15-19 weeks, but amylase, a marker of the mature exocrine pancreas, is first 
detected at 23 weeks in typical acinar structures. HNF6 controls the development of 
pancreatic ducts (25). 
1.1.3  Imaging of the pancreas 
Due to the high risk of complications associated with biopsy taking, precise imaging is 
highly important for the diagnosis of pancreatic diseases. The pancreas is traditionally 
evaluated by various imaging techniques including ultrasonography (US) and computed 
tomography (CT) (the two most commonly used techniques), endoscopic ultrasonography 
(EUS), endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance 
imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP). Recently, 
technological advances have brought a host of new modalities. Table 2 describes the 
advantages, disadvantages and indications for the various techniques. 
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Imaging has long been important in the diagnosis of chronic pancreatitis, where some of the 
key pathological changes are irregularity and widening of the main pancreatic duct, cavities, 
intraductal calcifications and duct obstructions. ERCP represents the gold standard. It has 
been shown that MRCP correlate well with ERCP findings in patients with chronic 
pancreatitis including small duct disease (39; 40). Correlation between pancreatic function 
and imaging has been investigated in patients with clinically suspected chronic pancreatitis 
on US and CT as well as on EUS and ERCP (41; 42). Contrast-enhanced MRI has been 
reported to correlate with pancreatic exocrine function (43). 
Pancreatic volume has been investigated in various conditions. A reduction of 21 % in 
pancreatic volume and 29 % in the area comprising beta cells has been observed in patients 
with chronic pancreatitis (44). Pancreatic volume and pancreatic exocrine function measured 
by serum immunoreactive trypsin, have been reported to correlate (45). Radiological studies 
have reported reduced pancreatic volume in patients with type 1 diabetes and to lesser 
degree in patients with type 2 diabetes (45-47). The pancreatic size reduction in type 1 and 2 
diabetes is associated with diabetes duration in some (47) but not all (45; 46) studies, and 
reports of association of small pancreatic volume with insulin use (47) or reduced insulin 
secretion (46) have further been taken to support the hypothesis of reduced insulinotropic 
effects on the acinar cells as a mechanism for the reduction in pancreatic volume (48; 49). 
Pancreatic atrophy is also a common feature of maturity-onset diabetes of the young due to 
mutations in HNF1B (HNF1B-MODY, MODY5) (50; 51), and subjects with diabetes and 
pancreatic exocrine dysfunction caused by mutations in the carboxyl-ester lipase (CEL) gene 
display pancreatic atrophy and lipomatosis (52; 53).
Total pancreatic agenesis is extremely rare and most often associated with neonatal death, 
but survival is possible with proper diagnosis and treatment (2). Isolated dorsal or less 
commonly ventral pancreatic agenesis (sometimes seen in Cumming’s syndrome), on the 
other hand, may occur. A lack of any sign of the pancreas on a CT scan at the level of the 
splenic vein is usually taken into account for dorsal pancreatic agenesis. This anomaly is 
extremely rare and only some 20 cases have been reported (54). It may be asymptomatic and 
detected incidentally, but is more often associated with abdominal pain and/or diabetes and  
sometimes exocrine dysfunction (54-58). Familial occurrence has been reported (59). 
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Table 2  Methods for pancreatic imaging 
Method Advantages Disadvantages Indications 
Established methods
Abdominal US Wide availability. 
Inexpensive
Non-invasive.
No radiation or 
nephrotoxic agents 
Reduced visualization 
by body fat or bowel gas 
Limited accuracy for 
parenchymal 
abnormalities 
First imaging modality in patients 
with abdominal pain, especially in 
children.
Particularly useful in evaluating the 
biliary tree. 
CT Wide availability. 
Non-invasive
Radiation
Poor sensitivity to 
identify ductal 
abnormalities or subtle 
parenchymal changes in 
chronic pancreatitis 
Primary imaging modality of the 
pancreas in adults 
Useful for the diagnosis and staging 
of pancreatic cancer 
ERCP Allows brush cytology, 
stone removal and 
stricture dilatation 
Invasive. Risk of 
inducing pancreatitis. 
Gold standard for diagnosing chronic 
pancreatitis and delineating ductal 
anatomy 
EUS Allows fine-needle 
aspiration biopsies 
Invasive
Shortage of well trained 
endoscopists
Operator dependency. 
Limited accuracy in 
assessing tumour 
vascular involvement 
Most sensitive established method for 
detecting and local staging of 
pancreatic neoplasms 
Superior to CT for detecting 
malignant lymphadenopathy 
Detects subtle changes of early 
chronic pancreatitis
MRI Non-invasive 
No radiation 
Need for serial scans in 
ongoing disease. Costs. 
Evaluates acute pancreatitis better 
than CT 
Contrast enhanced imaging often 
useful
MRCP Non-invasive  Primarily used to diagnose bile duct 
stones, biliary tree abnormalities, 
ductal strictures or dilatation, IPMN 
and duct leaks. Non-invasive 
alternative to ERCP in selected 
patients with chronic pancreatitis. 
Novel methods    
S-MRCP  Larger studies needed Qualitative and quantitative 
assessment of pancreatic exocrine 
function; fairly good correlation with 
the endoscopic secretin test 
Evaluation of functional pancreatic 
duct obstruction. Improved 
visualization of ductal strictures, 
dilatations and leaks 
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Method Advantages Disadvantages Indications 
CEUS Wide availability. Low 
costs. No radiation. 
Non-invasive.
Non-toxic intravenous 
contrast agent that form 
micro-bubbles 
Short circulation time of 
contrast imaging 
Operator dependency 
Reduced visualization 
by body fat or bowel gas 
Provides information regarding subtle 
parenchymal abnormalities, correlates 
well with contrast CT 
EUS
elastography 
(strain
imaging) 
 Invasive 
Unlikely to replace the 
need for tissue sampling 
to diagnose malignancy 
Promising in the diagnosis of early 
chronic pancreatitis by assessing the 
amount of fibrous tissue present 
Distinguishing benign from malignant 
lesions
MDCT Increased resolution 
Improved vascular 
visualization
 Assessing malignancy of IPMN 
Improved visualization of vascular 
invasion in malignant disease 
OCT Extremely high 
resolution images of 
the pancreatic duct and 
periductal structures 
Invasive (endoscope). 
More studies needed 
Unlikely to replace the 
need for tissue sampling 
to diagnose malignancy 
May be useful in diagnosing early 
chronic pancreatitis (subtle changes in 
wall thickness or inflammation) 
Excellent accuracy for detecting 
neoplastic tissue 
MRS Qualitative and 
quantitative
information on the 
biochemical status and 
physiologic processes 
of an organ in vivo
More studies and some 
technical improvements 
needed
Might be a useful imaging adjunct in 
the differentiation of chronic focal 
pancreatitis from pancreatic 
carcinoma 
CEUS, contrast-enhanced ultrasound; CT, computed tomography; ERCP, endoscopic retrograde 
cholangiopancreatography; EUS, endoscopic ultrasound; IPMN, intraductal pancreatic mucinous 
neoplasms; MDCT, multidetector-row computed tomography; MRI, magnetic resonance imaging; 
MRCP, magnetic resonance cholangiopancreatography; MRS, magnetic resonance spectroscopy; 
OCT, optical coherence tomography; US, ultrasound. 
Based on (60; 61) 
1.2  Endocrine and exocrine pancreatic disease 
1.2.1.  Diabetes type 1 and 2 
The term diabetes mellitus characterizes a heterogeneous group of metabolic disorders 
characterized by hyperglycemia with disturbances of carbohydrate, fat and protein 
metabolism, resulting from defects in insulin secretion, insulin action or both (62). Hence, 
diabetes results from a failure to provide sufficient insulin to supply the needs of the insulin-
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sensitive organs. The onset of diabetes is defined clinically based on persistent 
hyperglycemia, using internationally recognized cut-off levels for fasting and stimulated 
blood glucose (63; 64). However, a clear preclinical phase can be detected at least for type 1 
diabetes, with signs of loss of the first phase insulin response by IVGTT prior to the 
development of glucose intolerance (65).
More than 170 million individuals worldwide are estimated to suffer from diabetes (66), 
yielding a prevalence of 2.8 %. The epidemic is rapidly growing, and the prevalence is 
projected to double by 2025 (67). The disease is associated with considerable morbidity, 
being the leading cause of adult blindness and chronic renal failure as well as a major risk 
factor for stroke, heart disease and birth defects (68). The excess mortality attributable to 
diabetes was estimated to be 2.9 million deaths worldwide in 2000, equivalent to 5.2 % of all 
deaths, and in the United States, diabetes was the sixth most common cause of death in 2005. 
In Norway, a 2004 report indicated that 90 000-120 000 individuals had a diagnosis of 
diabetes, yielding a sex- and  age-adjusted prevalence of 2.3 % (69). However, recent data 
suggest that more than 50 % of diabetes cases in the Norwegian population are undiagnosed 
at present, thus leading to an estimated true prevalence of 240 000 individuals or more  
(Kristian Midthjell, personal communication). The age-ajusted annual increase in the 
prevalence of diabetes was reported to be 0.4 % for women and 2.5 % for men in the 1990s   
(69), and the diabetes incidence is still increasing, particularly in men (Kristian Midthjell, 
personal communication). 
Type 2 diabetes accounts for more than 90 % of diabetes worldwide (70). While type 1 
diabetes is caused by insulin deficiency due to autoimmune destruction of pancreatic beta 
cells, type 2 diabetes develops as a consequence of insulin resistance; that is, impaired 
ability of muscle, fat and liver to respond to insulin, combined with a defect in the insulin 
secretory response to glucose by the beta cell (71). Longitudinal studies in high-risk 
individuals suggest that in type 2 diabetes, insulin resistance is an early phenomenon, 
occurring years before the detection of glucose intolerance, whereas the beta cell failure is a 
later event (72). 
Type 2 diabetes is thought to result from the complex interplay of a variety of pathways 
under the combined control of genetic and environmental factors (Figure 4). It has been 
estimated that 30-70 % of the risk for type 2 diabetes is attributable to genetics (73). The 
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Figure 4. Schematic presentation of the current model of the complex interaction of genetic and 
environmental factors in the pathogenesis of type 2 diabetes. (Adapted from (73).) 
importance of genetics is indicated by the higher concordance rate of type 2 diabetes in 
monozygotic versus dizygotic twins, the familial clustering of insulin sensitivity and insulin 
secretion, and the high prevalence of type 2 diabetes in certain ethnic groups such as the 
Pima Indians or Mexican Americans (73). 
Since 2006, technological advancement allowed high-throughput genome-wide association 
studies (GWAS), uncovering a number of new genetic loci associated with diabetes, of 
which at least 20 emerged as being consistently associated with risk of type 2 diabetes across 
multiple studies. Many of the risk genes are expressed in beta cells (74). Surprisingly, 
though, most of the observed associations were for signals close to genes that would not be 
considered typical candidate genes and they were in noncoding regions of the gene. 
Generally, the signals have small effect and their predictive value for the development of 
diabetes in an individual is limited or non-existent (75). Furthermore, nine of the strongest 
loci together accounted for only 7 % of the 30-60 % increase in the risk of type 2 diabetes 
typically observed in siblings of type 2 diabetes probands as compared to the general 
population (76). These results enforced a reconsideration of the degree of genetic 
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heterogeneity and possibly even the role of genetics itself in the pathogenesis of type 2 
diabetes (73). 
Whereas type 2 diabetes is thought to be primarily heterogeneous and polygenic with low 
penetrance for the risk alleles discovered to date, necessitating interaction with 
environmental factors, subgroups exist were diabetes is transmitted with a Mendelian 
dominant pattern of inheritance, including maturity-onset diabetes of the young (MODY), 
mitochondrial diabetes, neonatal diabetes, several syndromes of severe insulin resistance and 
other rare genetic syndromes. It is generally accepted that, together, the monogenic forms of 
type 2 diabetes account for somewhere between 1 and 5 %, most likely towards the lower 
end of the scale (77).
1.2.2  Maturity-onset diabetes of the young (monogenic beta cell 
diabetes)
Maturity-onset diabetes of the young (MODY) is originally a clinical diagnosis requiring an 
autosomal inheritance pattern, onset before 25 years of age in at least one family member 
and evidence of primary beta cell dysfunction (13). Molecular studies have since the 1990’s 
revealed the genetic background of MODY subtypes, of which at least eight are established  
(74). The MODY subtypes are all caused by rare  mutations in the coding sequence of genes, 
resulting in significant amino acid substitutions or truncated proteins, leading to 
hyperglycemia even in the absence of other diabetogenic exposures. Subsequent to reports of 
a dominant mutation in sulfonylurea receptor 1 [SUR1] giving rise to diabetes fulfilling the 
criteria for MODY except for an atypical age of onset in adult life, the term MODY has been 
suggested to be substituted by “monogenic diabetes mellitus” or “autosomal dominant type 2 
diabetes” (78; 79). Recently, a molecular genetic classification of the forms of monogenic 
beta cell diabetes has been proposed in which this group is divided into four subtypes (80):  
1) diabetes diagnosed before 6 months of age (usually associated with mutations in Kir6.2, 
INS or SUR1, or with abnormalities in chromosome 6q24); 2) familial, mild fasting 
hyperglycemia (associated with glucokinase mutation); 3) familial, young-onset diabetes 
(associated with HNF1A or HNF4A mutations); and 4) diabetes with extrapancreatic features 
(associated with HNF1B or mitochondrial m.3243A>G mutation). 
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Figure 5. The relative prevalences of the MODY subgroups in Norway, based on the Norwegian 
MODY Registry(81).CEL, carboxyl-ester lipase; HNF, hepatocyte nuclear factor; OHA, oral 
hypoglycaemic agent; MODY X, maturity-onset diabetes of the young lacking molecular diagnosis.
The prevalence of MODY in Europe has been estimated to 1-2 % of non-insulin dependent 
diabetes (82), although population-based data are lacking. A recent study of a defined 
Norwegian population (the HUNT2 Study) found a prevalence of MODY of 2.2 % of the 
subjects with diabetes, and a minimum prevalence of HNF1A–MODY (MODY3) of 0.4 % 
of the diabetic population (77). HNF1A–MODY seems to be the most prevalent form in 
Northern Europe (77), followed by GCK-MODY (MODY2) (83; 84) whereas the reverse 
seems to be the case in Southern Europe (85; 86). Different recruitment strategies for genetic 
testing may contribute to the regional variation in the ratio of GCK-MODY to HNF1A–
MODY, as blood glucose screening in young asymptomatic individuals would detect a 
higher proportion of GCK mutations. The relative prevalence of the MODY subgroups in 
Norway are shown in Figure 5. 
All the MODY subtypes are due to heterozygous mutations. Table 3 outlines some of their 
respective characteristics. The recently discovered CEL-MODY is described in chapter 
1.4.3. Whereas GCK-MODY is caused by mutations in glucokinase, the rate-limiting 
enzyme of glucolysis, resulting in mild fasting hyperglycemia due to defect glucose sensing  
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Table 3  Genes involved in monogenic beta cell dysfunction in MODY and associated 
pancreatic exocrine dysfunction or structural abnormalities of the pancreas 
Gene name Chrom. 
loc.
Cellular
function
Diabetes
phenotype
Exocrine pancreatic 
phenotype
Ref.
  HNF4A 20q12 Transcription 
factor
MODY1; beta cell 
dysfunction, liver test 
abnormalities 
(87)
  GCK 7p15 Glucose 
phosphorylatio
n
MODY2; mild life-long 
fasting hyperglycemia 
(88-
90)
  HNF1A 12q24 Transcription 
factor
MODY3; beta cell 
dysfunction, diabetes 
phenotype similar to 
HNF4A-MODY,
decreased renal 
threshold for glucosuria 
(91)
  IPF1 13q12 Homeodomain 
transcription
factor
MODY4;
Heterozygote: diabetes 
resembles type 2 
diabetes, milder than 
HNF1A-MODY (rare); 
homozygote: pancreatic 
agenesis and neonatal 
diabetes
Pancreatic
hypoplasia/agenesis 
(92;
93)
  HNF1B 17q21 Transcription 
factor
MODY5; Renal cysts 
and diabetes with 
genital malformations + 
liver test abnormalities; 
neonatal diabetes 
Exocrine
dysfunction; 
pancreatic atrophy 
(94)
 NEUROD1 2q32 Transcription 
factor
MODY6; milder 
diabetes than HNF1A-
MODY, more like type 
2 diabetes, insulin 
resistance (rare) 
(95)
  KLF11 2p25 TGF-beta 
inducible
transcription
factor
MODY7; similar to 
NEUROD1-MODY
(96)
  CEL 9q34.3 Lipid 
metabolism 
MODY8; beta cell 
dysfunction 
Exocrine
dysfunction; 
lipomatosis
(97;
98)
  INS 11p15.5 Hormone Rare MODY; beta cell 
dysfunction, permanent 
neonatal diabetes 
 (99-
101)
ABCC8
  (Sur1) 
11p15.1 Sulfonylurea 
receptor
Permanent and transient 
neonatal diabetes; late-
onset type 2 diabetes 
 (102; 
103)
See also Table 5. Adapted from (73).
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(85; 88; 89), the other traditional MODY forms are associated with dysfunction of 
transcription factors that normally regulate the insulin gene as well as genes encoding 
proteins involved in glucose transport and metabolism (104) and mitochondrial metabolism 
(105) resulting in defects in insulin secretion leading to reduced maximal stimulated insulin 
secretion (106-108): HNF4A (MODY1) (87), HNF1A  (91), IPF1 (MODY4) (92; 93), 
HNF1B (MODY5) (94) and NEUROD1 (MODY6) (95). Several of these genes interact 
closely in transcriptional networks controlling gene expression during embryonic 
development and during adulthood in tissues where they are coexpressed. Through binding 
sites in the predominantly beta cell specific alternative upstream (P2) promoter for HNF4A,
transcription factors HNF1A, HNF1B and IPF1 can activate HNF4A, and conversely HNF4A
can increase expression of HNF1A through a binding site in the HNF1A promoter (109-111). 
Mutations in both the HNF4A P2 and the HNF1A promoter are sufficient to result in MODY, 
underscoring the importance of this network (110).  
HNF1A-MODY is characterized by a severe and progressive insulin secretion defect, a 
retained sensitivity to sulfonylureas, and glucosuria due to a decreased renal threshold for 
glucose reabsorption, which may precede the development of diabetes (112). HNF1A
mutations have a high penetrance, with 63 % of carriers developing diabetes by 25 years of 
age and 96 % by 55 years (113). However, the clinical expression of HNF1A-MODY is 
highly variable even within the same family (114) and only about one-third of patients are 
treated with insulin after 15 years of diabetes duration, whereas others maintain glucose 
control by diet or oral hypoglycaemic agents (115). Patients typically present in their teens 
or early adult life with symptomatic diabetes. Fasting glucose levels often remain normal 
initially, but OGTT reveals an elevated 2h plasma glucose concentration (116) with a large 
increment value, typically >4.5 mmol/l. Factors contributing to an early age of onset of 
diabetes are mutations in the first six exons rather than the terminal exons (117), truncating 
rather than missense mutations (118), and intrauterine exposure to maternal diabetes (119). 
Sulfonylureas in low doses are recommended as the first-line treatment as the patients are 
very sensitive to sulfonylurea therapy (120-123), which acts on the KATP-channels to 
stimulate insulin release, thus bypassing the steps of glucose metabolism affected by the 
HNF1A mutation. Raised HDL-cholesterol levels are commonly observed, in contrast to the 
reduced levels seen in subjects with type 2 diabetes or the normal levels in subjects with 
type 1 diabetes (124). Still, the frequency of heart disease seems to be greater in patients 
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with HNF1A-MODY than in patients with type 1 diabetes despite a similar incidence of 
macrovascular complications (125).
HNF1B-MODY is a multi-system disorder, but renal disease is the predominant phenotype, 
present in all reported probands, which is why the alternative name of Renal cysts and 
diabetes (RCAD) syndrome has been suggested. The renal disease phenotypes include renal 
cysts (most frequent), renal dysplasia, renal-tract malformations and/or familial hypoplastic 
glomerulocystic kidney disease (126). Renal function ranges from normal to dialysis 
dependent or transplanted (127); about 50 % develop end-stage renal disease (ESRD) by the 
age of 45 years (128). Female genital tract malformations, gout and hyperuricemia are 
associated with HNF1B mutations (127; 129), and elevated liver enzymes may be observed 
(50). Furthermore, pancreatic atrophy and exocrine dysfunction are usually present when 
HNF1B mutations are associated with diabetes (50; 51; 130; 131). Birth weight is reduced as 
a result of reduced insulin secretion in utero (51). Half of all HNF1B mutation carriers 
develop early-onset diabetes presenting in a similar fashion to HNF1A diabetes, but HNF1B
mutation carriers are more insulin resistant (132). Because of the coexisting pancreatic 
atrophy and insulin resistance, HNF1B diabetes is not sensitive to sulfonylureas, and early 
insulin therapy is required (80). As 30-60 % of HNF1B mutations and deletions are 
spontaneous, a family history of renal disease or diabetes is not essential to prompt a screen 
for this disorder (133; 134). Even within a single pedigree there is wide variation in 
phenotypes, such that affected individuals with identical mutations may display different 
combinations and severities of organ involvement (127; 129; 134). 
Other forms of monogenic diabetes include neonatal diabetes and the maternally inherited 
diabetes and deafness syndrome (MIDD). Neonatal diabetes is diagnosed before six months 
of age and characterized as transient (TNDM; linked to chromosome 6q24 abnormalities in 
about 70 % of cases) (135) or persistent (PNDM; in 50 % of cases caused by mutations in 
KCNJ11 or ABCC8, encoding the Kir6.2 and SUR1 subunits, respectively, of the KATP
channel; also reported in complete GCK deficiency) (90; 102; 103; 136-139). Oral 
sulfonylurea provides the most effective therapy (137; 140). Mutations in the insulin gene 
(INS) can cause TNDM  (100; 101) and was recently reported to result in MODY (99). 
MIDD is caused by mitochondrial mutations, most frequently m.3243A>G, resulting in 
dysfunctional mitochondria and thereby disturbed ATP production, which leads to 
manifestations primarily in highly metabolically active organs (141). 
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1.2.3  Exocrine pancreatic dysfunction – diagnostic tests 
Exocrine pancreatic dysfunction may lead to malabsorption, increasing the risk of fat-soluble 
vitamin deficiency (vitamins A, D and E) and deficiency of energy nutrients derived from 
fat, carbohydrates and proteins. Maldigestion and steatorrhea secondary to exocrine 
pancreatic insufficiency has traditionally been acknowledged to occur when postprandial 
secretion of pancreatic enzymes is reduced to levels below 5-10 % of normal (7; 142; 143), 
illustrating the large functional reserve of the exocrine pancreas. A recent review (144) 
argues that the believed overproduction of pancreatic enzymes is over-estimated, referring to 
reports showing a three orders of magnitude lower specific activity of pancreatic lipase on 
meal triglycerides than indicated by previous in vitro studies, and hypothesizing that since 
the pH of the small intestine is substantially reduced in pancreatic exocrine insufficiency, 
lipase activity is further reduced. Steatorrhea arises when excessive lipid is excreted in the 
faeces, defined as >7 g fat/24 hours (>5 g fat/24 hours in children) provided a balanced pre-
test dietary fat intake, and this is traditionally used to define pancreatic insufficiency, i.e. 
uncompensated pancreatic exocrine dysfunction, which is the correlate of the end-stage 
exocrine pancreatic disease. 
Various diagnostic tests are used to investigate pancreatic exocrine function as outlined in 
Table 4. Adaptations of the titrimetric method first described by Van de Kamer (145) are 
most commonly used to measure faecal fat excretion. To improve the validity, it is 
recommended to add a non-absorbable marker in the diet or to determine fat loss as a 
percentage of daily fat intake. Some studies report that near infrared spectrometry represent 
a simpler analysis and acceptable sensitivity and specificity compared to the titrimetric 
method to determine fecal fat in the stool collections (146). Incomplete stool collection, 
delayed intestinal transit or inaccurate calculation of fat intake may lead to underestimation 
of fat excretion, whereas overestimation can occur in infants less than six months old whose 
immature pancreases may excrete as much as 15 % of dietary fat (147). The method does not 
detect mild and moderate reductions in pancreatic exocrine function, and the secretin test 
remain the gold standard to measure pancreatic function. This test use intravenous delivery 
of the secretory stimulant secretin alone or in combination with secretagogues such as CCK 
to stimulate the pancreas, and assesses collected fluid volume, ions and enzymes via 
intubation of the duodenum. The lack of a consensus standardized procedure is a problem at 
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Table 4  Some pancreatic function tests 
Test Description Advantages Disadvantages 
Direct tests    
Secretin
(+CCK)
IV secretin +/- CCK 
Measure volume and HCO3-
secretion into duodenum 
+/-enzyme concentrations 
Most sensitive and 
specific measurement 
of pancreatic function. 
Duodenal intubation 
IV hormones 
Not widely available 
Not well standardized 
Lundh test 
meal 
Oral ingestion of test meal  
Measurement of duodenal 
trypsin concentration (+ 
amylase, lipase) 
No IV hormones Requires duodenal 
intubation and normal 
small intestinal mucosa 
Not widely available. 
Indirect tests    
Fecal fat 72-hour stool collection  
Fat measurement in stool 
Preferably compared to a 
known dietary fat intake, e.g. 
a 100 g/day of fat diet 
Quantitative
measurement of 
steathorrea
Stol collection 
Cumbersome analysis 
Compliance problems 
with keeping diet/ 
reporting fat intake 
Triglyceride 
breath test 
Ingestion of 13C- or 14C-
labelled triglyceride meal, 
measurement of labelled CO2 
in exhaled breath 
Low cost, non-invasive 
Measure of 
steatorrhoea
Time-consuming (5-6 h) 
Limited sensitivity for 
mild dysfunction 
Fecal
elastase-1
ELISA assay measuring 
elastase-1 in a pea-size stool 
sample 
Do not detect mild or 
moderate dysfunction. 
Fecal
chymotrypsin 
Enzyme assay measuring 
chymotrypsin in a pea-size 
stool sample 
Easy to perform 
Small, one-time stool 
sample 
Room temperature  
No IVs or tubes 
NBT-PABA Oral ingestion of NBT-PABA 
with a meal 
PABA in serum / urine 
Fluorescein
dilaurate
Oral ingestion of fluorescein 
dilaurate with a meal 
Fluorescein in serum / urine 
Simple measurements 
for severe pancreatic 
dysfunction 
Do not detect mild or 
moderate dysfunction 
False positives with 
small bowel mucosal 
disease
Serum trypsin Measure trypsin in blood 
sample 
Simple, inexpensive  
Widely available 
Risk free 
Low sensitivity 
False positives reported 
in diabetes 
CCK, cholecystokinase; IV, intravenous;  NBT-PABA, N-benzoyl-tyrosyl para-aminobenzoic acid. 
Based on (2; 148) 
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least for research purposes. The Lundh test is a variant of this test, substituting a test meal 
for the secretagogue. Due to the invasive nature of the secretin test, and the cumbersome 
procedure and problems with compliance with stool collection and incorrect reports of fat 
intake with the Van de Kamer test, other tests have gained terrain in clinical practice. 
The faecal elastase-1 assay merits a brief description as this indirect test has become 
increasingly used since the beginning of the 1990s (for a review, see(149)). It is an ELISA 
assay most often based on two monoclonal antibodies, although a test based on polyclonal 
antibodies also exists (150). The original reference values were established using 100 
samples sent to the laboratory for microbiological culture of suspected gastrointestinal 
infection, and the stool water content was not reported. Since watery stools may affect 
elastase levels, alternative reference values have been launched based on lyophilized stool 
samples (151). Generally, it is agreed that a value of less than 200 μg elastase/g stool 
indicates mild to moderate exocrine dysfunction, whereas a value of less than 100 μg/g 
indicates severe exocrine dysfunction (152). Studies have reported an intra-assay variation 
of 5.8-6.4, an inter-assay variation of 7.7-8.8, and an intra-patient CV of 15 % based on daily 
repeated measurements (152; 153). Using 200 μg/g as cutoff, the specificity is reported to be 
in the range of 57-90 % compared to secretin tests or ERCP, and the sensitivity ranges 80-
100 % for severe exocrine dysfunction (100 % in five out of six studies) but only 0-65 % in 
mild exocrine dysfunction, in both cases compared to modifications of the secretin test or 
ERCP/Cambridge classification (152). Thus, the test is more useful in the diagnosis of 
severe than mild to moderate exocrine dysfunction. Unlike the fecal chymotrypsin test, the 
measured fecal elastase-1 level is not affected by pancreatic enzyme supplements (148), but 
false positive results are reported in primary intestinal disease such as celiac disease with 
mucosal atrophy (149), short bowel syndrome (154), pouchitis (155), severe protein 
malnutrition (155), in infants less than 14 days  (156) and in the case of non-lyophilized 
loose stools or diarrhoea (151).
1.2.4  Pancreatic exocrine dysfunction and combined exocrine and 
endocrine dysfunction 
The combination of exocrine and endocrine pancreatic disease or dysfunction is observed in 
a variety of contexts. For monogenic diseases, which frequently display a combination of 
endocrine and exocrine pancreatic disease, a common developmental cause may be 
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suspected (Tables 3 and 5). Since the discovery of insulin treatment in the 1920s there have 
been reports of reduced exocrine pancreatic function in patients with a primary diagnosis of 
diabetes mellitus (157-173); and pancreatic cancer, hereditary pancreatitis, idiopatic 
pancreatitis and fibrocalculous pancreatitis are recognized causes of secondary diabetes as 
discussed below.
Celiac disease is associated with type 1 diabetes through common HLA markers (174), and 
the prevalence of biopsy-verified celiac disease in type 1 diabetes is estimated at around 5 % 
(174-177). Both primary pancreatic exocrine dysfunction, probably due to prolonged 
malnutrition, and dysfunction secondary to impaired release of endogenous CCK and 
secretin are described in celiac disease (178-180).
In pancreatic cancer, about 80 % of subjects have impaired glucose tolerance or diabetes; 
however, there is ambiguity as to whether pancreatic cancer causes diabetes or the 
conditions associated with diabetes promote the development of pancreatic cancer (reviewed 
in (181)).
Chronic pancreatitis is a continuing inflammatory disease which eventually leads to 
morphologic changes characterized by irreversible destruction and fibrosis of the exocrine 
parenchyma, leading to exocrine pancreatic insufficiency and progressive endocrine failure 
resulting in diabetes (182). Subtypes of chronic pancreatitis include hereditary pancreatitis, 
idiopatic pancreatitis and other causes (reviewed in (183; 184) ). Diabetes is usually 
regarded as a secondary process to chronic pancreatitis and occurs more frequently in late- 
onset than early-onset pancreatitis (185; 186). The median age at onset of diabetes is 53 
years in hereditary pancreatitis (187). Althoug alcohol is the main cause of chronic 
pancreatitis in most developed countries, accounting for 60-70 % of the cases in male 
patients, genetic alterations emerge as an important factor in the pathogenesis (182). PRSS1
(protease, serine 1), encoding cationic trypsinogen, was the first gene in which mutations 
were associated with hereditary pancreatitis (188). It is proposed that pathogenic PRSS1
mutations cause pancreatitis through enhanced auto-activation of trypsinogen to trypsin or 
prevent prematurely activated trypsin from being inactivated by autolysis (182). Both 
duplication and triplication copy number variants of PRSS1 have been suggested to result in 
a gain of function in trypsin by a gene dosing effect, leading to both hereditary and 
idiopathic chronic pancreatitis (189; 190). In idiopathic chronic pancreatitis, heterozygous 
33
mutations both in CFTR (188; 191-193) and PRSS1 (188) have been associated with disease 
development. An increased risk of idiopathic pancreatitis has also been associated with 
variants in SPINK1 (particularly the mutation S34N) (194), and the risk is considerably 
increased in combination with a heterozygous CFTR mutation (191). Mutations involving 
the calcium sensing receptor (CASR) have been suggested to increase the risk of chronic 
pancreatitis, particularly in combination with SPINK1 mutations (195). Recently, loss-of-
function mutations in CTRC were identified as predisposing to chronic pancreatitis (196). 
On the other hand, PRSS2 mutation has been reported to be protective against chronic 
pancreatitis (197). 
Table 5  Genes causing pancreatic exocrine dysfunction or pancreatic structural 
abnormalities and reported associations with diabetes
Gene
name
Chrom.
loc.
Cellular
Function
Diabetes
phenotype
Exocrine pancreatic 
phenotype
Ref.
AIRE 21q22.3  APECED Exocrine dysfunction (198-
200)
PTF1A 10p12 Alpha subunit 
of PTF1 
Permanent neonatal 
diabetes with cerebellar 
agenesis
Pancreatic agenesis (201) 
CFTR 7q31.2 Chloride 
channel;
regulates other 
transport
pathways 
76 % diabetes by 30 
years; TNDM (case 
report)
Cystic fibrosis: 
exocrine dysfunction 
(202-
205)
SBDS 7q11 Involved with 
ribosomal RNA 
TNDM (case report) Shwachman-
Diamond syndrome 
(206;
207)
UBR1 15q15-
q21.1
E3 ubiquitin 
ligase
Early-onset DM (case 
report)
Johanson-Blizzard
syndrome 
(208;
209)
PRSS1 7q35 Cationic 
trypsinogen, 
protease
80 % diabetes by 80 
years 
Hereditary 
pancreatitis
(188)
(210)
PRSS7 21q21 Initiates 
activation of 
protease
proenzymes 
 Enteropeptidase 
deficiency 
(211)
EIF2AK3 2p12 Pancreatic 
eIF2-alpha
kinase
Wolcott-Rallison
Syndrome; permanent 
neonatal diabetes 
Pancreatic
hypoplasia and 
fibrosis
(212)
PI 14q32.1 Protease 
inhibitor
IGT (case report) Pancreatic fibrosis 
(case report) 
(213;
214)
See also Table 3. APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; 
IGT, impaired glucose tolerance; TNDM, transient neonatal diabetes mellitus. Adapted from (73). 
Tropical chronic pancreatitis (or tropical calcific pancreatitis) is a juvenile form of chronic 
calcific nonalcholic pancreatitis seen in tropical developing countries, characterized by 
recurrent abdominal pain in childhood, followed by diabetes and steatorrhea one to two 
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decades later (215). Calculi or micro-calculi are found on radiological examination, and 
pathological studies demonstrate atrophy and fibrosis of the pancreatic gland and ductal 
metaplasia (215). The disease is believed to start in the exocrine tissue with subsequent 
dysfunction of the islets (215), but others suggests two separate pathogenic mechanisms 
leading to pancreatic exocrine dysfunction and diabetes (216). The combined condition of 
tropical chronic pancreatitis and diabetes is commonly termed fibrocalculous pancreatic 
diabetes (FCPD), although the entity is debated and classified under “diabetes due to other 
types” in the latest WHO classification of diabetes. FCDP is characterized by insulin 
requirement (217). A recent study from southern India showed a population prevalence of 
0.02 % (217). 
Several recent papers have reported a high prevalence of exocrine dysfunction in subjects 
with type 1 and type 2 diabetes based on tests for fecal elastase I to assess pancreatic 
exocrine dysfunction (218-228). Other studies analyzing fecal fat excretion have revealed 
steatorrhea in a high percentage of these patients (228; 229). Diabetes has usually been 
regarded as the primary process and the main mechanism is thought to be that insulin 
deficiency removes the trophic stimulus of insulin on acinar cells (insulo-acinar axis; 
insulin-pancreatic axis). Alternative hypotheses propose diabetic neuropathy or vascular 
damage as culprits. The clinical implications of exocrine disease secondary to diabetes have 
been debated (160; 230; 231). 
1.2.5  Pancreatic enzyme substitution therapy (PEST) 
Oral pancreatic enzyme supplements constitute the main treatment of maldigestion 
secondary to exocrine pancreatic insufficiency (232). Because of problems related to acid-
mediated inactivation of lipase, enteric-coated microspheres are generally the preferred 
pharmacological formulation of pancreatic enzymes (233). Reports indicate that a minimal 
dose of 25 000-50 000 IU of lipase per meal is required (232), but higher doses may be 
needed (144). The efficacy of the treatment may be optimized by the administration of the 
medication along with or just after meals as opposed to just before meals (234). Others 
propose that further improvement can be obtained by adding H2-blockers or proton pump 
inhibitors (omeprazole) to those failing to normalize their fat excretion on enzyme 
supplements alone (235; 236). It is recognized, however, that fat excretion is seldom 
normalized by PEST, although most studies evaluating this matter have been performed on 
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patients with cystic fibrosis. Some previous studies have observed a detrimental effect of 
pancreatic enzyme replacement on glycemic control in patients with chronic pancreatitis 
(237), but a recent prospective multicenter study examining enzyme replacement in Type 1 
diabetes reported no effect on glycemic control (227). 
1.3  Experimental rodent models of pancreatic disease 
Most of the strains in use today derived from a limited number of founders from four 
subspecies of the house mouse (Mus musculus) that diverged approximately 1 million years 
ago (238). The classical studies of Coleman and Hummel (239) were the first to show that 
strain background affects diabetes susceptibility in mice. Strain background has been shown 
to influence most aspects of diabetes including insulin secretion, insulin resistance, and 
pancreatic characteristics such as beta cell survival and islet number; and strains also differ 
in their response to environmental factors like diet (238). A systematic compiling of 
phenotypic measurements across numerous mouse strains is found in The Mouse Phenome 
Database (www.jax.org/phenome). 
Spontaneous mutations have given rise to several valuable animal models. The obese (ob/ob)
mouse with a mutation in the gene for leptin (Lep) and the diabetes (db/db) mouse with a 
mutation in the leptin receptor (Lepr) gene are prominent examples (238), whereas the Akita 
mouse represents the only spontaneous mutation in mouse directly causing nonobese type 2 
diabetes (238). 
The development of gene targeted mouse models has transformed medicine by allowing the 
generation of disease models of human pathologies in a tractable mammalian system, thus 
enabling experimental dissection of disease states and identification of new therapy targets. 
Gene targeting has already produced more than five hundred different mouse models of 
human disorders. The importance of the creation of the technology for gene targeting in mice 
was underscored by the award of the Nobel Prize in Physiology or Medicine for 2007 to 
Mario R. Capecchi, Martin J. Evans and Oliver Smithies for their discoveries of “principles 
for introducing specific gene modifications in mice by the use of embryonic stem cells”. 
Gene targeting is used to create either knockout models through inactivation of single genes, 
or knock-in or over-expressing models by introducing a gene and a promoter into the mouse 
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genome. More than ten thousand mouse genes or about half of the genes in the mammalian 
genome have been knocked out to date and ongoing international efforts will make knockout 
mice for all genes available within the near future. 
The discovery by Martin Evans that chromosomally normal cell cultures could be 
established directly from embryonic stem (ES) cells and the demonstration by Mario 
Capecchi that homologous recombination could take place between introduced DNA and the 
chromosomes in mammalian cells thus repairing defective genes, were corner-stones in the 
development of genetically designed mouse models (240; 241). Tissue-specific gene 
knockout or over-expression enabled conditional targeting (242). Cre-lox technology is now 
widely used, and is based on the introduction of recognition sites for the enzyme Cre 
recombinase, so-called loxP sites, into existing genes. Mice carrying such “floxed” genes are 
then mated with transgenic mice expressing Cre recombinase in tissues defined by the 
promoter placed before the Cre recombinase gene, and the target gene of the offspring is 
modified in the selected tissue through Cre action (243). Temporal control over expression 
can be exerted through the introduction of an element into the promoter which requires a 
ligand for introduction, for instance tetracyclin, tamoxifen or type I-interferon (244). 
Expression is thereby induced only by the delivery of the selected drug. Finally, Cre-lox
technology can be used to replace an existing gene with another one (“knock-in”) (245). 
However, the generation of loxP-flanked alleles is often time-consuming, or of limited value 
due to the existence of multiple copies of the gene and/or pseudogenes in the genome in 
which undesired targeting events may occur. The recently described RNA interference 
(RNAi) method may overcome such limitations, but create only knockdown models (246). 
The C57BL/6 strain was created by Little in 1921 and is the most widely used of all inbred 
strains, accounting for about 14 % of all such uses, and it is the most commonly used 
reference strain in studies of diabetes. SNP analysis indicates that the strain is somewhat 
removed evolutionarily from the other inbred strains (238). Both protective and diabetes 
susceptibility alleles/phenotypes have been observed in the C57BL/6 strain. Data from the 
Mouse Phenome Database show that glucose and insulin levels of this strain are intermediate 
to those of the other strains (http://phenome.jax.org/pub-
cgi/phenome/mpdcgi?rtn=docs/home). However, studies have shown that the C57BL/6 
mouse is particularly susceptible to diet-induced obesity and hyperglycemia (238). It is less 
glucose-tolerant compared to C57BLKS/J, DBA/2 and 129X1 mice in a glucose tolerance 
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test (GTT) but more insulin-sensitive in an insulin tolerance test (ITT) than DBA/2 or 129X1 
mice (247; 248), suggesting that a defect in insulin secretion is the likely cause of the 
reduced glucose tolerance in C57BL/6 mice. Following a high-fat, high-simple carbohydrate 
diet, islets from C57BL/6 mice had markedly impaired insulin secretion in response to high 
glucose, primarily due to a defect in second-phase insulin secretion (249; 250); and the islets 
were unresponsive to intermediate glucose levels (251), consistent with a beta cell defect in 
glucose responsiveness. Compared to other strains, lean C57BL/6 mice have a relatively low 
total islet mass and beta cell mass per body mass, but the highest number and the smallest 
size of islets, indicating a great capacity for the beta cell mass to expand under stress (238) 
which explains why the introduction of Lepob/ob on C57BL/6 background induces severe 
insulin resistance but only moderate and transient hyperglycemia and not diabetes (238). 
The 129/Sv strain is heterogeneous and the phenotypic effects may differ between the 
various substrains. Substrains of 129/Sv have been employed for the majority of ES cell 
lines used in generating gene-targeted mice (knockout mice) (238). On both chow and high-
fat-diet feeding, the 129/Sv mice maintain low insulin levels and are more glucose tolerant 
than other strains (252), suggesting an increased insulin sensitivity consistent with the low 
beta cell mass in wild-type 129/Sv mice (253). Thus, the 129 strain is relatively resistant to 
genetic obesity-induced diabetes. Lean 129 mice with genetically induced defects in insulin 
signalling due to double heterozygosity for Irs1 and Insr mutations have only mild 
hyperinsulinemia with little insulin resistance and do not increase beta cell mass compared 
with wild-type 129 mice (253), in contrast to C57BL/6 mice. 
A summary of some existing transgenic mouse models for pancreatic disease including 
diabetes is given in Table 6. 
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Table 6  Some mouse models of gene disruption and the associated pancreatic 
phenotype
Gene Model Phenotype Refs.. 
AIRE KO        Exocrine inflammation on NOD background (254) 
ARNT KO Impaired insulin secretion (255) 
CFTR KO Dilated ducts and acinar atrophy (256) 
DLL1 KO Accelerated endocrine development  (257) 
E2F1 KO Pancreatic volume reduction and IGT (258) 
E2F1/E2F2 KO Acinar atrophy, beta cell loss, fatty infiltration (259) 
EIF2AK3 KO IGT, exocrine insufficiency, loss of beta cells (260; 
261)
GLUT2 KO Glucose intolerance, impaired insulin secretion, diabetes (262) 
HES1 KO Forms acini and islet structures from bile ducts (263) 
HLXB9 KO Dorsal pancreatic agenesis, mildly disturbed endocrine-cell 
differentiation
(264)
HNF1A KO IGT, reduced insulin content in beta cells (265) 
HNF1B KO Embryonic lethal, pancreatic agenesis if rescued (130) 
HNF4A KO Embryonic lethal, IGT in conditional knockouts (266) 
HNF6 KO IGT, aberrant islet morphogenesis (267) 
INSR KO Die within 7 days after birth from diabetic ketoacidosis (268) 
KO ȕIRKO: Loss of glucose-stimulated first-phase insulin secretion, 
small islets, reduced insulin content of islets 
(269)
INSR/IGF1R KO IGT, loss of beta cell mass (270) 
IPF1
(PDX1)
KO Pancreatic agenesis 
Beta cell mutants: Diabetes due to reduced insulin expression and 
beta cell dysfunction 
(271)
OE Apoptosis and fatty infiltration (exocrine OE) (272) 
IRS1 KO Mild insulin resistance, beta cell hyperplasia, hyperinsulinemia (273) 
IRS2 KO Severe insulin resistance, reduced beta cell mass, diabetes (274) 
ISL1 KO Islet and dorsal pancreatic agenesis (275) 
KRT8 OE Acinar inflammation, fatty infiltration (276) 
MIST1 KO Disorganized exocrine tissue (277) 
KO IGT and decreased islet size  (278) 
NEUROD1 KO Aberrant islet and entero-endocrine morphogenesis (279) 
NGN3 KO Endocrine cell agenesis (35) 
OE Accelerated endocrine development (257) 
NKX2B KO Aberrant islet morphogenesis (280) 
NKX6A KO Reduction of beta cells after secondary transition (281) 
PAX4 KO Absence of  beta and delta cells (282) 
PAX6 KO Absence of alpha cells (283) 
PBX1 KO Hypoplasia/aberrant differentiation of pancreas (284) 
PDK1 KO IGT, loss of beta cell mass (285) 
PI14 KO Isolated exocrine insufficiency, acinar apoptosis (286) 
PTF1A KO Exocrine pancreatic agenesis (287) 
RPH3AL KO Defective endocrine and exocrine exocytosis (288) 
SOCS1 KO Acinar inflammation, atrophy and apoptosis (289) 
TGFBR2 KO Acinar inflammation, fatty infiltration (290) 
TTC10 KO Disorganized exocrine tissue, ductal dilation (291) 
KO, knockout; OE, overexpressing model. Based on the OMIM database.
39
1.4  Carboxyl-ester lipase (CEL) 
1.4.1 The CEL gene and protein: Structure, expression, function 
The human CEL gene (292; 293) is located on chromosome 9q34.3 (294).  The gene consists 
of 11 exons (295) and encodes a protein of 745 amino acids including a signal peptide. The 
last exon contains a VNTR encoding a highly variable number of repeats; most frequently 16 
repeats of 11 amino acids (296), but repeat numbers from 7 to 21 have been observed (297; 
298). The gene is well conserved in all vertebrate species examined, but the variability of the 
VNTR between species is high, varying from no repeats in salmons (299) through three 
repeats in mice (300) and four in rats (301) to as much as 39 repeats in gorilla (302). While 
the mouse CEL is a single-copy gene spanning approximately 7.2 kb on the syntentic region 
of the homologous mouse chromosome 2 (303), in humans a pseudogene, CELL (or CELP),
is located in tandem with CEL 10 kb downstream of the end of CEL. The pseudogene lacks 
exon 2-7 and have differences in the coding sequence of exon 10 and 11 (295; 304), and 
although it is ubiquitously transcribed at the mRNA level it is not translated (292). It has 
been suggested that CEL has evolved from CELL by gene duplication and that the original 
gene has been inactivated during evolution (292).
CEL (also referred to as bile salt-dependent lipase, bile salt-stimulated lipase, bile-salt 
activated lipase precursor, cholesterol esterase or lysophospholipase) is an enzyme with 
broad specificity (292). Its main action is bile-salt dependent lipase activity to hydrolyze 
cholesterol esters into free cholesterol and fatty acids to facilitate their absorption in the 
small intestine, but a recent report demonstrates that CEL also has an important role in the 
absorption of dietary lipids such as triacylglycerols (TAG) and in the hydrolysis and 
absorption of retinyl esters, acting in concert with pancreatic triglyceride lipase (PTL) in a 
mutually compensatory way (292; 305). CEL also participates in chylomicron assembly and 
secretion in a mechanism mediated through its ceramide hydrolytic activity (293). A fraction 
of pancreatic CEL in the duodenum undergoes transcytosis via the lectin-like oxidized LDL 
receptor (LOX-1) (306) and is subsequently found in human plasma partly associated with 
apolipoprotein B-containing lipoproteins (293). In the circulation, CEL has been reported to 
be involved in several activities such as the induction of vascular smooth muscle 
proliferation (307), endothelial cell proliferation and chemotactic migration (308), thrombus 
formation through interaction with platelet CXCR4 (309) and a negative or protective effect 
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on atherosclerosis is debated (307; 310; 311). Furthermore, reports suggest that CEL 
participates directly in the selective uptake of cholesteryl esters in HDL in the liver (312). A 
recent report shows that CEL is removed from the circulation by renal filtration through 
unknown mechanisms and is eliminated in the urine of healthy persons (313). 
The catalytic properties of the CEL enzyme reside in the highly conserved N-terminal part of 
the protein, where the active site is formed by the catalytic triad Ser194-His435-Asp320 
(292). The carboxyl terminus of the protein regulates enzyme activity by forming hydrogen 
bonds with a surface loop partially covering the active site, thus partially shielding it (292). 
Bile salt binding to the bile salt binding site induces a conformational change involving the 
removal of the loop from the active site, enabling reaction with the substrate (314). In the 
absence of bile salts, crystal studies suggest a preformed catalytic site and a functional 
oxyanion hole explaining the activity of CEL on water-soluble esters (292). Crystal studies 
of truncated human CEL lacking the C-terminal PEST repeats, showed that in this protein 
the surface loop assumed a predominantly open conformation such that the active site was 
open, allowing direct access to water-soluble substances; and in the presence of a bile salt 
analogue the truncated protein failed to interact with bile salt, indicating that deletion of the 
PEST sequences may compromise the bile salt activation of CEL (315). However, other data 
indicate that deletions of parts of the C-terminal do not interfere with the catalytic activity of 
the enzyme (316; 317).  
The size of the CEL enzyme is highly variable, ranging from a molecular weight of 120-140 
kDa in humans to approximately 74 kDa in mouse. This size variation is due to the variable 
number of PEST repeats in the C-terminal end of the protein; three repeats are found in the 
mouse while in humans 16 repeats is most frequently found (318) although 56 % of 
individuals carry at least one polymorphic form of CEL (298). While associated with 
intracellular membranes by means of a folding complex involving the chaperone Grp94, 
CEL undergoes post-translational modifications first in the ER, where N-glycosylation at 
Asn187 is essential for correct folding and secretion, and then O-glycosylation of each 
tandem repeat of the PEST sequences in the Golgi apparatus (292) (Figure 6). The PEST 
sequence O-glycosylation is important for normal CEL secretion and for maintaining protein 
stability (319), and failure of O-glycosylation of CEL seems to lead to degradation by the 
proteasome-ubiquitin-dependent pathway (320). Furthermore, since the O-glycosylation
masks the PEST sequence it is hypothesized to rescue CEL from PEST-mediated 
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degradation (292). In the intestine the O-glycosylation prevents acidic and proteolytic 
damage of CEL (321). The PEST repeats may also be important for heparin binding and 
binding to cell surface receptors and thereby involved in the suggested effects of CEL in 
atherogenesis (322). 
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Figure 6. Schematic presentation of the secretory pathway of CEL and its association with the 
chaperone Grp94in pancreatic acinar cells. Red circles, CEL; blue circles, Grp94; CV, condensing 
vesicles; ZG, zymogen granules. Based on (292).
CEL is mainly expressed in the acinar cells of the exocrine pancreas and in lactating 
mammae, but low level expression at the protein level has also been reported in human fetal 
liver (323) and rat liver (292); and is found in and may be synthesized by human but not 
mouse macrophages and endothelial cells (311; 324). In contrast, CEL is not expressed in 
islets or beta cells (325) and was not found by screening of laser-captured beta cells (S. 
Bonner-Weir, personal communication). High-level expression of human CEL in the 
pancreas is dependent on a pancreas-specific enhancer element found in the 5’-upstream 
sequence of the CEL gene  in co-operation with two closely located cis elements, and a 
protein binding to a C/EBP-like motif is also necessary and probably prevents the binding of 
PTF1 to the partly overlapping potential PTF1 site (326). In contrast, in the mouse promoter 
a PTF1-binding site is mandatory for expression, and a more distal PTF1 interaction and a 
factor binding to the mDPE augment the effect of PTF1 binding to its site (326). Thus, 
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although CEL is expressed at comparable levels in the exocrine pancreas of both mouse and 
human, the most important regulatory factors in the promoters are different. 
1.4.2 Pathology associated with CEL
The recent discovery that mutations in CEL cause a syndrome of diabetes and pancreatic 
dysfunction is discussed below.  CEL has previously been linked to diabetes through a report 
of antibodies towards CEL in patients with type 1 diabetes (327), and Raeder et al. reported 
that single-base insertion polymorphisms in the CEL VNTR are associated with exocrine 
dysfunction in patients with type 1 diabetes (52). An association of CEL VNTR
polymorphisms involving less than 16 repeats with lower total and LDL cholesterol levels 
has been observed (297; 328). Interestingly, the human CEL gene maps to locus q34.3 on 
chromosome 9 (294), close to the ABO blood group antigen locus, which is linked to lipid 
phenotype and cardiovascular disease in humans (329). Furthermore, a correlation of CEL
VNTR polymorphisms with the risk of alcohol-induced pancreatitis has been reported (330). 
A link to the immune system has also been suggested by a report showing that variations in 
human milk CEL confers different binding capacities of dendritic cells affecting their 
inhibitory effect on HIV-1 transfer (331). CEL expression seems to be reduced in acinar cell 
carcinoma and is not observed in pancreatic adenocarcinoma (325).
1.4.3 The CEL syndrome - Diabetes and pancreatic exocrine 
dysfunction 
Raeder et al. identified two different single-base deletions in the CEL VNTR to cause a 
syndrome of diabetes and exocrine dysfunction (CEL-MODY; denoted DPED or MODY8 in 
the OMIM database) through a genome-wide screen in two families and subsequent 
positional cloning (52). The single-base deletion in Family 1 of the article (Del1; 
1686delT/C563fsX673) occurred in the first repeat on an allele of 14 repeats in which the 7th
and 8th repeats were missing compared to the consensus sequence, whereas the single-base 
deletion in Family 2 (Del4; 1785delC/C596fsX695) occurred in the fourth repeat on an allele 
of 16 repeats. Both deletions were observed in poly-C tracts, which are found in every 
VNTR repeat of CEL exon 11 and which are known mutation hotspots in several genes 
including HNF1A (332). Furthermore, both alleles with single-base deletions were predicted 
by in silico studies to lead to an altered C-terminal and loss of the PEST sequence and 
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several glycosylation sites, but encode downstream protein segments of considerable length 
(100 amino acids or more) before termination by a premature stop codon. Enzyme activity 
assays using stably transfected CHO cells revealed reduced protein stability and secretion 
rate of the mutant protein, but unaffected enzyme activity.  
Mutation carriers with Del1 had diabetes (N = 14), impaired glucose tolerance (IGT; N = 3), 
normal glucose tolerance (NGT; N=8) or uncertain glucose tolerance status (N = 8). 
Concerning the diabetic patients, more than half were using insulin, none had experienced 
ketoacidosis, and diabetes typically presented in the mid-thirties. They were further 
characterized by normal body mass index, moderately elevated concentrations of fasting 
glucose and 2-h glucose after an oral glucose tolerance test (OGTT), clearly elevated 
glycosylated haemoglobin (HbA1c), reduced fasting C-peptides and an impaired insulin 
response during an intravenous glucose tolerance test (IVGTT). IVGTT performed in 
mutation carriers with NGT revealed a modest but significant reduction in first phase insulin 
secretion on glucose stimulation, indicating an early beta cell dysfunction. The mutation 
carriers with IGT or NGT were generally considerably younger than the mutation carriers 
with diabetes. All tested mutation carriers had either severe (fecal elastase < 100 ȝg/g; N = 
30) or moderate (fecal elastase 100-200 ȝg/g; N = 3) fecal elastase deficiency (FED) 
suggesting exocrine pancreatic dysfunction, and this was supported by findings of increased 
fecal fat excretion in all ten diabetic subjects tested and reduced concentrations of fat-soluble 
vitamins A and E in the mutation carriers compared to controls. Pancreatic lipomatosis was 
reported in ten adult mutation carriers with diabetes and exocrine dysfunction (52) and also 
in non-diabetic children with CEL mutations (53), indicating that lipomatosis of the pancreas 
may be an early event involved in the pathogenesis of the DPED syndrome. 
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2.  AIMS OF THE PRESENT STUDY 
A number of recent studies have reported a three-to-tenfold increase in the prevalence of 
exocrine dysfunction in subjects with type 1 or type 2 diabetes, and a considerable 
proportion of these patients have steatorrhea with potential for complications. This fact does 
not seem to have attracted the attention it deserves, and the mechanisms behind the 
association are not clear. Previous studies of monogenic diseases have proved useful in the 
understanding of molecular mechanisms involved in diabetes, and transgenic mouse models 
have evolved as important tools for such studies. With this in mind, and wishing to shed 
some light on the mechanisms of exocrine-endocrine interplay in diabetes, we aimed to: 
1. investigate the existence of pancreatic exocrine dysfunction in two subtypes of 
diabetes, HNF1A-MODY and HNF1B-MODY (Papers I, III) 
2. examine whether diabetes and/or exocrine dysfunction was associated with structural 
abnormalities of the pancreas in HNF1A-MODY and HNF1B-MODY (Papers II, III) 
3. perform a more thorough clinical characterization of the recently discovered CEL-
MODY syndrome of diabetes and pancreatic exocrine dysfunction (Paper IV) 
4. explore the effects of pancreatic enzyme substitution on exocrine and endocrine 
pancreatic function in CEL-MODY (Paper IV) 
5. investigate the clinical, pathological and molecular characteristics of two potential 
mouse models for CEL-MODY (Papers V, VI) 
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3.  MAIN RESULTS 
Paper I describes the first prevalence study of exocrine dysfunction in patients with 
HNF1A-MODY. Subjects were recruited from the Norwegian MODY Registry, and 
compared to patients with type 1 diabetes recruited consecutively from an out-patient 
diabetes clinic as well as to non-diabetic controls. The paper reports that 13 % of adult 
HNF1A-MODY patients had exocrine dysfunction as defined by a fecal elastase level less 
than 200 ȝg/g, compared to 19 % of type 1 diabetes patients and 4 % of non-diabetic 
controls. Thus, the prevalence of exocrine dysfunction in HNF1A-MODY patients was 
similar to that in type 1 diabetes subjects in this and previous studies, and more than three 
times higher than in non-diabetic controls. Fecal elastase deficiency was inversely associated 
with age; however, the difference between HNF1A-MODY or type 1 diabetes patients and 
nondiabetic controls was maintained after controlling for age. Fecal fat excretion was 
increased in all investigated HNF1A-MODY patients with fecal elastase deficiency, 
underscoring the potential clinical importance of the exocrine dysfunction.   
Paper II is the first report of radiological investigations of pancreatic structure in HNF1A-
MODY patients and studies the putative association of any structural changes with 
pancreatic exocrine dysfunction. We invited all of the HNF1A-MODY patients in which 
exocrine dysfunction was identified in Paper I, and matched HNF1A-MODY controls 
without exocrine dysfunction, to undergo computed tomography of the pancreas by a 
standardized protocol. This was compared to groups of type 1 or 2 diabetes cases with 
exocrine dysfunction and their age- and gender-matched controls with normal exocrine 
function, and to non-diabetic control subjects recruited from a CT archive. The paper reports 
that the HNF1A-MODY patients had significantly reduced pancreatic volume compared to 
non-diabetic controls, as did the type 1 diabetes subjects. However, the reduction in 
pancreatic volume was less in HNF1A-MODY than in type 1 diabetes. A striking atrophy 
such as reported in HNF1B-MODY, was not observed; nor were typical changes seen in 
chronic pancreatitis or signs of pancreatic lipomatosis as reported to be associated with CEL-
MODY and other monogenic diseases. Pancreatic volume adjusted for body surface area was 
associated with fecal elastase levels, but exocrine dysfunction did not explain the reduction 
of pancreatic volume or the differences between pancreatic volumes in diabetes subtypes.  
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Paper III describes the clinical and radiological findings in five subjects from two families 
with HNF1B-MODY due to two different mutations in HNF1B. The paper reports agenesis 
of the pancreatic body and tail and a slightly atrophic pancreatic head in all of the patients as 
revealed by computed tomography and magnetic resonance cholangiopancreatography. 
Exocrine dysfunction as defined by fecal elastase deficiency was also reported in all patients, 
and several had vitamin deficiencies. The radiological findings strengthen the evidence for a 
critical role of HNF1B in the embryonic development of at least the dorsal pancreas. 
Paper IV reports the results of a treatment study with pancreatic enzyme supplements in 
nine family members from Family 1 in a previous paper by Raeder et al. describing a new 
syndrome of diabetes and pancreatic exocrine dysfunction due to mutations in the CEL gene 
(CEL-MODY, DPED). The study showed that pancreatic enzyme substitution alleviated 
symptoms of malabsorption, reduced steatorrhea, and normalized blood vitamin E levels in 
most patients, but did not affect glycemic control despite a slight weight increase with 
treatment. As anticipated, exocrine function as assessed by fecal elastase levels was not 
affected. During the study, a more thorough clinical characterization of twelve members of 
both families reported in the above mentioned paper revealed neurologic pathology. Five 
patients had carpal tunnel syndrome, three had high-signal white matter changes on MRI, 
and a majority of the patients had had slowing of nerve conduction compatible with a 
demyelinating neuropathy which was distinct from the neuropathological pattern normally 
seen as a complication of diabetes. 
Paper V describes the study of the pancreatic endocrine and exocrine function the carboxyl-
ester lipase knockout mouse (CELKO). Based on preliminary data suggesting that a 
mutation causing CEL-MODY induced reduced stability of the CEL protein, we wanted to 
investigate whether a knockout of the CEL gene would recapitulate the syndrome of CEL-
MODY in an existing CELKO mouse line. Mice of both genders were studied until twelve 
months of age on normal chow and on high fat diets challenging glucose homeostasis. 
However, only mild glucose intolerance was observed in mice with whole-body knockout of 
CEL, whereas the full phenotype of human CEL-MODY was not reproduced. Morpholgical 
studies of pancreatic sections did not reveal any consistent indications of preclinical disease. 
Our findings suggest that the pathogenic mechanisms involved in CEL-MODY are more 
complex than a simple loss of CEL function. 
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Paper VI describes the establishment and study of the TgCEL mouse, a transgenic mouse 
line expressing the human CEL gene carrying a delT-mutation previously demonstrated to be 
linked with CEL-MODY. The mouse line was created using Cre-Lox technology for 
pancreas-specific expression. Beta-gal staining and immunohistochemical investigations in 
offspring of cross-matings with Rosa26-beta-gal mice indicated transgenic expression 
restricted to the pancreatic acinar cells and 10-15 % of the beta cells. Expression of human 
CEL was verified by qRT-PCR. The mice were studied on normal chow diet at four, seven 
and nine months of age, and after a 12 weeks challenge with a 60 % high fat diet at 12 
months of age. After the high fat challenge, the mice were reverted to normal chow diet and 
followed by physiological testing until 22 months of age. None of the mice developed 
diabetes, and no signs of pancreatic endocrine or exocrine abnormality were detected. 
Interestingly, discrete areas of abnormal acinar tissue were observed in histological sections 
from two male mice, of which one was a TgCEL mouse whereas there was some uncertainty 
concerning the genotype of the other mouse. In conclusion, the paper demonstrates the 
successful establishment of a mouse line expressing, at least on the mRNA level, human 
CEL carrying a disease-associated mutation; but the mice lacked a clear phenotype. This 
indicates that further manipulation of genetic or environmental factors should be explored in 
the attempt to create a transgenic mouse model for human CEL-MODY.
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4.  GENERAL DISCUSSION 
Exocrine and endocrine pancreatic disease is often observed to occur together. The close co-
localization of the two distinct tissues within one organ, as well as their common 
embryological ancestry, has given rise to hypotheses concerning the pathogenesis of 
pancreatic diseases. However, in many cases the molecular pathways are not fully 
understood, and two questions remain: Which cell type is the origin of the disease? And 
what is the most fundamental pathological process?  
Principally, there are three possible sites of action in combined exocrine and endocrine 
pancreatic disease: The exocrine cells, the endocrine cells, or the common progenitor cells 
(Figure 7). In order to investigate the association between exocrine function and diabetes 
further, we have studied exocrine and endocrine function as well as pancreatic structure in 
three different contexts: HNF1A-MODY, HNF1B-MODY and CEL-MODY.
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Figure 7. The schematic illustrates our current perception of the associations between 
diabetes and pancreatic exocrine dysfunction. The three principal sites of origin of disease 
are the exocrine cells, the endocrine cells or the common progenitor cells. Various causes of 
combined exocrine and endocrine disease are attributed to each of these tissues. 
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4.1 HNF1B-MODY: Developmental disorder and pancreas 
malformation (Paper III).
Considering the striking association with pancreatic atrophy reported in HNF1B mutation 
carriers based on MRI or CT imaging (50; 51; 131) and reports of exocrine dysfunction (50; 
51; 333), we wanted to investigate pancreatic structure and exocrine pancreatic dysfunction 
in subjects with HNF1B-MODY. In Paper III, we describe the absence of tissue 
corresponding to the pancreatic body and tail as evaluated by CT and MRCP in five 
individuals from two families with different mutations in HNF1B. All of the subjects had 
exocrine dysfunction as assessed by fecal elastase analysis. Although our description of 
agenesis of the dorsal pancreas differed from the pancreatic atrophy described in previous 
studies, this difference might be due to alternative interpretation rather than a true variation 
in the structural changes. The distinction is important, however, for the understanding of the 
underlying pathogenetic mechanisms. Whereas agenesis and hypoplasia signify the abscent 
or incomplete development of a tissue or organ, atrophy implies the partial or complete 
wasting away of an organ. Causes of atrophy include poor nurishment, poor circulation, loss 
of neural or hormonal stimulation of the target organ, or disease intrinsic to the tissue itself.  
Mouse studies have revealed that Hnf1b has an essential function in the first steps of the 
pancreatic development as a critical regulator of a transcriptional network that controls the 
specification, growth, and differentiation of the embryonic pancreas (334; 335). Embryos 
completely deficient of Hnf1b exhibited a rudimentary dorsal pancreatic bud, which was 
only transiently present, and a ventral part of the pancreas which was not specified (130). In 
humans, severe hypoplasia of the pancreatic body and tail, resulting mainly from 
underdeveloped acini, was observed during autopsy of two fetuses carrying heterozygous 
mutations in exon 2 and 7 of HNF1B, respectively (336). Moreover, the fetuses exhibited 
absence of ventral pancreatic-derived tissue recognized from histological and 
immunohistochemical analyses, indicating ventral pancreatic agenesis in addition to dorsal 
pancreatic hypoplasia (336). The results of these studies seem to support a developmental 
defect as the cause of disease.
The findings of hypoplasia of the pancreatic head and agensis of the body and tail in children 
and adult HNF1B mutation carriers in Paper III, are complementary with the mouse and 
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human fetal studies. The stronger severity of the phenotype we observed compared to that in 
the human fetuses, suggests that either different mutations are associated with different 
severity (hypoplasia vs. aplasia), paralleling observations of genotype-phenotype 
associations in HNF1A–MODY (118), but in contrast to previous reports on lacking 
association between genotypes and pheotypes in HNF1B mutation carriers (126; 131). More 
likely, perhaps, the pancreatic abnormalities may have a degenerative component in addition 
to a congenital malformation. Studies have shown that surgical pancreatectomy or 
autoimmune destruction of the pancreatic beta cells must remove more than 90 % of the 
insulin secretory capacity before resulting in diabetes (337; 338). However, others have 
reported an average beta cell area of 65 % in patients with overt type 2 diabetes (339). As 
the pancreatic volume was 24-43 % of normal in our cases, the HNF1B mutations could 
have had a direct effect on beta cell mass or insulin secretion in addition to the loss of beta 
cells as a result of pancreatic agenesis, in order to yield diabetes, given a relatively even 
distribution of beta cells within the pancreas. Interestingly, the two children in the study had 
not developed diabetes, although the elder child had IGT. Taken together, our observations 
strengthen the evidence for a critical role of HNF1B in the normal development and 
differentiation of the pancreas and support the notion that HNF1B mutations cause diabetes 
and exocrine dysfunction based on congenital malformation with a possible additional 
degenerative component. 
Other examples of mutations in genes expressed in the progenitor cells associated with both 
exocrine and endocrine pancreatic disorder, include mutations in IPF1(93), PTF1A (201), 
and EIF2AK3. For all of them, pancreatic hypoplasia, atrophy or agenesis has been reported 
in mutation carriers in addition to either MODY-type diabetes (IPF1) or PNDM (IPF , 
PTF1A, EIF2AK3) (92; 93; 201; 212). Studies have shown that targeted disruption of Ipf1 or 
Ptf1a in transgenic mice results in a failure of the pancreas to devlop, i.e. pancreatic 
agenesis; and in addition the Ptf1a-/- null phenotype is postnatally lethal, although low 
insulin levels may still be detectable due to production in beta cells misallocated to splenic 
mesenchyme (28; 37; 271; 287). These data suggest that mutation in IPF1 and PTF1A affect 
pancreas development, causing pancreatic agenesis leading to both diabetes and exocrine 
deficiency.
The loss of expression of EIF2AK3 (eIF2a kinase 3, PERK) was recently identified as a new 
form of permanent neonatal diabetes associated with the human Wolcott-Rallison syndrome 
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(212). PERK KO mice have normal pancreata at birth, but develop diabetes and exocrine 
deficiency due to decreased beta cell proliferation and differentiation, and massive apoptosis 
of the exocrine tissue (260; 261; 340). PERK KO mice exhibit distended ER due to 
accumulation of proinsulin and GLUT2, and it was speculated that ER stress was the 
pathogenetic mechanism leading to diabetes (260). However, a later study did not detect 
increased ER stress markers, and a developmental defect is now considered the main cause 
of diabetes (340). It is still possible that ER stress leading to apoptosis of acinar tissue is the 
main cause of the exocrine deficiency in EIF2AK3 mutation carriers (260). 
4.2 HNF1A-MODY: Exocrine dysfunction and small 
pancreas secondary to diabetes (Papers I and II). 
For HNF1A-MODY, information about pancreatic structure or exocrine function was, before 
our study started,  lacking. As HNF1A encodes a transcription factor that is closely related to 
HNF1B, it was conceivable that a mutation in this gene could yield a similar phenotype for 
pancreas structure as seen in HNF1B-MODY. HNF1A is also expressed in the exocrine 
pancreas and might be directly associated with a defect in pancreatic exocrine function 
(341). In addition, exocrine dysfunction has been observed in 10-30 % of patients with type 
1 or 2 diabetes (218-222), and reduced pancreatic volume as estimated by radiological 
imaging or autopsy studies, has been reported for type 1 diabetes patients and to some 
degree in type 2 diabetes in a number of papers (45-47; 342-344). Thus, if exocrine 
dysfunction was associated with diabetes in HNF1A mutation carriers, a primary process in 
the endocrine or exocrine tissue, or at the progenitor level, seemed possible. In Paper I we 
describe for the first time the prevalence of pancreatic exocrine dysfunction in a cohort of 
patients with HNF1A-MODY. Exocrine dysfunction was expressed by fecal elastase 
deficiency, defined by a fecal elastase level less than 200 ȝg/g. The data in Paper I indicated 
that 13 % of adult HNF1A-MODY patients had exocrine dysfunction. This was similar to 
results from the type 1 control group included in the study (19 %) and in line with previous 
findings in type 1 and 2 diabetic patients, but three times higher than that in nondiabetic 
controls (4 %). The strong association observed in HNF1B-MODY was not paralleled in 
HNF1A-MODY. Fecal elastase deficiency was not restricted to any particular HNF1A
mutation, as it was observed in association with six different mutations. 
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In Paper II, we pursued the investigation of these patients further, and our data showed for 
the first time that the HNF1A-MODY patients had significantly reduced pancreatic volume 
compared to non-diabetic controls, but the reduction in pancreatic volume was less than in 
type 1 diabetes. We found that in both HNF1A mutation carriers and type 1 diabetes 
subjects, reduced pancreatic volume index was inversely associated with diabetes duration in 
agreement with some (47) but not all (45; 46) previous studies. Although reduced pancreatic 
volume adjusted for body surface area was associated with low fecal elastase levels, in line 
with a previous report observing an association of pancreatic volume and serum 
immunoactive trypsin (45), exocrine dysfunction did not explain the reduction of pancreatic 
volume or the differences between pancreatic volumes in diabetes subtypes in our study.  
Pronounced atrophy of the pancreas as previously reported for HNF1B mutation carriers, or 
dorsal agenesis of the pancreas as described in Paper III, was not observed. Although 
HNF1A and HNF1B are closely related and interact in the same transcriptorial network, 
HNF1A appears to have less pronounced effect on pancreas volume and structure than 
HNF1B (50; 126). This is agreement with findings in mouse studies delineating Hnf1b as an 
important regulator of pancreas organogenesis and differentiation, whereas Hnf1a primarily 
regulates the growth and function of beta cells (reviewed in (335)). Primary exocrine disease 
can also affect pancreatic volume, as demonstrated by a recent study showing a 21 % 
reduction of pancreatic volume in patients with chronic pacreatitis, accompanied by a 29 % 
deficit in beta cell area (44). Recently, it was argued that type 3c diabetes, i.e. diabetes 
caused by chronic pancreatitis, is much more common than generally believed, as pancreatic 
morphological changes are present in about 35 % of type 2 diabetes cases and in up to 50 % 
of type 1 diabetes subjects (345; 346). In Paper II, we found a prevalence of 19 % for fecal 
elastase deficiency in subjects with type 1 diabetes. The appearant discrepancy between our 
findings and that of some others may be due to differences in the diagnostics; most studies 
rely on results from one fecal elastase analysis, whereas we defined fecal elastase deficiency 
as fecal elastase below 200 μg/g in two consecutive tests. Observations in subjects with 
diabetes include changes of the pancreatic duct system characteristic for chronic pancreatitis 
(347; 348). However, the structural changes characteristic of chronic pancreatitis (Table 7) 
were not detected in our HNF1A mutation carriers. Pancreatic lipomatosis has been 
identified as an early structural marker of pancreatic exocrine disease in CEL mutation 
carriers (52; 53), and fatty replacement has also been observed in other causes of monogenic 
diabetes with primary affection of the exocrine pancreas (209; 349). A negative correlation 
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between pancreatic fat content and beta cell function has been observed by some (350) but 
not by others (342). However, pancreatic x-ray attenuation was not associated with fecal 
elastase levels in HNF1A-MODY patients, and pancreatic lipomatois was not observed. 
Table 7  Exocrine function and radiological findings in some pancreatic disorders 
Characteristics T1D T2D HNF1A-
MODY
HNF1B-
MODY
CEL-
MODY
Chronic
pancreatitis
Diabetes (%) 100 100 100 50? 100? 22** 
FED (%) 19 10-35 13 100 100  
Steatorrhea (%) 70 33 100 NI 78 7** 
Radiological findings     
Pancreatic volume 
index reduction (%) 
53 NS 25 Striking  21 
Pancreatic fibrosis/ 
lipomatosis 
No No No No Lipomatosis Fibrosis 
Duct abnormalities No 
*(Yes)
No
*(Yes)
No No No Strictures, 
widening,
irregularities
Cavities No No No No No Yes 
Calcifications No No No Yes/No  Yes 
Pancreatic
malformation 
No No No Dorsal 
agenesis
No No 
T1D, type 1 diabetes; T2D, type 2 diabetes; CEL, carboxyl-ester lipase; FED, fecal elastase 
deficiency, i.e. fecal elastase levels < 200 μg/g in two consecutive tests. The table is mainly based on 
findings in Papers I-IV, and on (44; 45; 52; 53). *Pancreatic duct changes classified as chronic 
pancreatitis were observed retrospectively in ERCPs in 77 % out of 156 patients with diabetes (38 
subjects with IDDM) (347). **From (351). 
Taken together, the findings in Papers I and II indicate that the prevalence of exocrine 
dysfunction as well as the structural changes of the pancreas in HNF1A-MODY are similar 
to that observed in type 1 diabetes, and different from that characterizing HNF1B-MODY or 
CEL-MODY (Table 7). Diabetes has traditionally been regarded as the primary process in 
type 1 and type 2 diabetes, leading to secondary exocrine dysfunction. The prevailing 
paradigm postulates that insulinopenia, resulting in deficient trophic action of insulin on 
acinar cells, is the main cause of impaired pancreatic exocrine function (352). In line with 
this, the more severe insulin deficiency seen in type 1 diabetes could explain the greater 
pancreatic volume reduction compared with HNF1A-MODY. However, alternative 
hypotheses for the causes of pancreatic volume reduction exist, including: 1) diabetic 
microangiopathy, causing pancreatic fibrosis; 2) diabetic autonomic neuropathy, leading to 
impaired enteropancreatic reflexes (reduced incretin effect); 3) hormone suppression caused 
by high levels of circulating glucagon (353) or other gut hormones such as somatostatin or 
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pancreatic polypeptide (354). Recently, it was suggested that pancreatic atrophy may result 
from the chronic inflammation associated with ongoing beta cell destruction (355). 
Simultaneous damage of endocrine and exocrine pancreas by a common autoimmune 
process has also been suggested (344; 356). 
A recent review of studies reporting loss of the normally continuous interstitial matrix 
connection between endocrine and exocrine cells of the pancreas at the ultrastructural level 
in rodent models and humans with type 2 diabetes, attempts to unite several of these 
theories. Perivascular-periductal interstitial fibrosis is suggested to be the common 
denominator (357). The authors argue that A) pericapillary fibrosis in the islet capillaries 
and efferent islet venules might impair delivery of insulin and result in a delay of 1st phase 
insulin secretion; and B) exocrine pancreatic periductal fibrosis could interfere with the 
delivery of pancreatic enzymes to the gut, reducing digestion of nutrients, resulting in 
decreased stimulation of incretin secretion and a diminished incretin effect on insulin 
secretion; and C) islet-acinar cell-cell communication is lost, leading to defective paracrine 
signalling and impairing insulin’s trophic effect on the acinar cells. Any of the potential 
mechanisms discussed above might apply to HNF1A-MODY as well as to type 1 and 2 
diabetes. Furthermore, the possibility that primary exocrine disease is involved in the 
pancreatic volume reduction and exocrine dysfunction cannot be ruled out by our studies. 
4.3  Clinical implications of fecal elastase deficiency in 
diabetes.
The fact that severe dysfunction of the exocrine pancreas is reported to be present in as many 
as 10-30 % of patients with type 1 and type 2 diabetes (218-222) compared to ~4 % among 
nondiabetic subjects, seems to have drawn little attention in clinical practice. Some even 
question the clinical relevance of pancreatic exocrine dysfunction as expressed by fecal 
elastase deficiency in subjects with diabetes, based on claims that it is moderate and 
nonprogressive (230; 231). This is contradicted by our finding of pathologically high fat 
excretion in all of the available six patients (100 %) with fecal elastase deficiency and 
HNF1A-MODY, 16 out of 23 adult type 1 diabetes subjects (70 %), four out of six children 
with type 1 diabetes (33 %) and one of three available type 2 diabetes subjects (33 %; Papers 
I and II and unpublished); as well as in seven out of nine subjects with CEL-MODY (78 %; 
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Paper IV). Our results support previous reports of a high prevalence of steatorrhea in 
subjects with diabetes and fecal elastase deficiency. In one large multicenter study, as many 
as 60 % of patients with type 1 or 2 diabetes and fecal elastase deficiency had pathologically 
increased fecal fat excretion (229), and in another study, 35 % of obese diabetic patients 
with low fecal elastase exhibited steathorrea (222). The overall prevalence of about 42 % for 
impaired exocrine dysfunction as assessed by fecal elastase in subjects with diabetes, agrees 
with previous reports of exocrine dysfunction in diabetes patients using direct tests of 
pancreatic function; underscoring that fecal elastase deficiency most probably represents 
decreased secretion of exocrine enzymes (162; 164; 168). Moreover, an independent 
correlation between fecal elastase levels and, respectively, glycemic control and residual 
beta cell function has been observed (223). 
The apparent lack of clinical symptoms of exocrine dysfunction has been used as an 
argument to disclaim its importance in diabetes (231). None of the subjects identified with 
pathologically increased fecal fat excretion in any of our studies (Papers I-IV) had 
spontaneously complained of abdominal symptoms to their physicians. Interestingly, on 
direct questioning either in a clinical interview or a questionnaire, several but not all 
reported symptoms such as loose stools, foul-smelling flatulence or abdominal pain. 
However, none of the symptoms commonly agreed to be associated with steatorrhea 
discriminated between subjects with and without exocrine dysfunction as they were also 
frequently observed in individuals with normal fecal elastase levels (Raeder and Vesterhus, 
unpublished). The CEL-MODY patients (Paper IV) in particular reported that the abdominal 
symptoms affected their quality of life on a daily basis. Most of them had substantially 
elevated fecal fat excretion with a median of 25 g/day at baseline (range 3-43). Seven out of 
nine patients reported immediate improvement of their abdominal symptoms with pancreatic 
enzyme supplement treatment (PEST). 
Oral PEST constitutes the main treatment of maldigestion due to pancreatic exocrine 
insufficiency (for a recent review, see (358)). In Paper IV, we found a statistically 
significantly decreased, although still high fat excretion in the four patients who delivered 
stool samples at 30 months. The patients in the present study were instructed to take the 
capsules immediately after the beginning of the meal for maximal effect according to 
previous recommendations (234). It is well recognized that fat excretion is rarely normalized 
by PEST (358). The initial dosage of enzyme supplements of 10-20 000 IU of lipase per 
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meal may have been modest, as some reports indicate that a minimal dose of 25 000-50 000 
IU of lipase per meal is required (232).  
The effect of PEST on glycemic control in the presence of combined diabetes and pancreatic 
exocrine disease has been claimed to be adverse or indifferent by some and reported to 
improve HbA1c by others (237; 359; 360). PEST could improve glucose homeostasis 
through its effect on increased incretin secretion, as it has been demonstrated that GIP 
secretion is reduced in steatorrhea due to alcoholic pancreatitis and can be normalized by 
PEST (361). We found no effect on glycemic control in CEL-MODY patients, confirming 
recent results from a study examining enzyme replacement in type 1 diabetes subjects with 
exocrine dysfunction (227). Problems with compliance, particularly over time, complicate 
the evaluation of the true effect of the treatment. In addition, the motivation to collect 72-h 
stool samples for the assessment of the effect on steatorrhea declines, as demonstrated in our 
study.
The treatment of exocrine dysfunction is important because of the risk of malnutrition 
including deficiency of fat-soluble vitamins. A high rate of pancreatic exocrine dysfunction 
was reported in patients with osteoporosis and vitamin D deficiency in one study (362). 
Others observed normal levels of fat-soluble vitamins during a 16-week follow-up in both 
enzyme replacement and placebo groups of patients with diabetes and fecal elastase 
deficiency (227). We found pathologically reduced levels of vitamin E in all our CEL-
MODY patients; but vitamin E increased in all patients with enzyme replacement and was 
restored to within normal cut-off values in five of seven patients at 12 months (Paper IV). 
The observed vitamin E deficiency might have contributed to the neurological manifestation 
of demyelinating neuropathy that was identified in a majority of the patients (363; 364). 
Levels of vitamins D and A were in the lower normal range in these patients, but vitamin A 
increased with treatment. Furthermore, osteoporosis was diagnosed in three subjects and 
osteopenia in two at baseline; possibly secondary to exocrine dysfunction. In HNF1B-
MODY, we also observed pathologically reduced vitamin E and vitamin D levels in two 
subjects but neurological examination or bone mass density measurements were not 
performed (Paper III). 
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4.4  CEL-MODY: Diabetes secondary to pancreatic 
exocrine disorder? The search for pathogenetic processes 
in two mouse models (Papers V and VI). 
CEL-MODY is a syndrome of combined diabetes and exocrine dysfunction due to mutations 
in CEL (52). However, the molecular mechanisms linking genetic defects in a gene 
expressed in the exocrine tissue but not in islet cells, to diabetes, are unclear. Both known 
disease-associated alleles were predicted by in silico studies to lead to truncated proteins 
with an altered C-terminal and loss of the PEST sequence and several glycosylation sites, 
and to encode new C-terminal protein segments of more than 100 amino acids. Enzyme 
activity assays using stably transfected CHO cells revealed reduced protein stability and 
secretion rate of the mutant protein although enzyme activity was unaffected (52), and 
reduced stability of the mutant protein was confirmed in preliminary in vitro experiments 
using a rabbit reticulocyte lysate system (Vesterhus, unpublished). This could support the 
theory of a loss-of-function mechanism leading to disease. Alternatively, the aberrant protein 
could alter cellular function and trigger mechanisms that are detrimental to the tissues, such 
as autoimmunity or ER stress. 
Mouse studies have previously proved important in the demonstration of the pathogenicity 
of putative disease-related alleles and the study of the associated pancreatic 
pathophysiology; e.g. mouse models for MODY subgroups, Johanson-Blizzard syndrome 
and Wolcott-Rallison syndrome (130; 209; 256; 260; 265; 271; 279; 365). Accordingly, we 
wanted to recapitulate the phenotype of CEL-MODY in an in vivo model with disruption of 
the CEL gene. We aimed at studying an existing global knockout mouse model (CELKO) in 
order to explore a loss-of-function effect; and to create and subsequently study a transgenic 
mouse line expressing a disease-associated human CEL allele (TgCEL) to investigate the 
possibility of an altered cellular function. 
CELKO
Paper V describes the study of the pancreatic exocrine and endocrine function in CELKO 
mice. Phenotypes described in CELKO mice to date are listed in Table 8. The few 
observations that were made of differences between CELKO mice and controls in Paper V 
were made in females only and were compatible with mild glucose intolerance: A non-
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significant tendency to reduced glucose tolerance; increased random fed blood glucose after 
12 weeks on a 60 % high fat diet (P = 0.002); and increased islet area on 60 % high fat diet
Table 8  Phenotypes observed in CELKO mice 
Phenotype References 
Independent of a low fat or high fat/high cholesterol diet: 
- Increased fecal excretion cholesteryl ester 
- Decreased serum levels of cholesteryl ester 
- No difference in free cholesterol absorption or serum cholesterol levels 
(366)
- 50 % reduction in cholesteryl ester absorption 
- No difference in the absorption of free cholesterol, triglycerides or retinyl ester, or 
in plasma lipid or lipoprotein profiles 
- Normal growth and development 
(367)
No affection of absorption of retinyl ester, chylomicron-retinyl ester, or hepatic 
retinoid metabolism 
(368)
- Absent cholesteryl ester hydrolase activity 
- Normal retinyl ester hydrolase activity 
(369)
- Normal weight gain on a high fat/high cholesterol diet 
- Protection against diet-induced obesity in PTL-/-,CEL-/- double KO mice 
compared to PTL-/- mice 
- Enhanced reduction in absorption of triacylglycerol and retinyl palmitate, but not 
cholesterol, in PTL-/-,CEL-/- double KO mice compared to PTL-/- mice 
(305)
- Increased random fed blood glucose, tendency to reduced glucose tolerance and 
islet hyperplasia in female mice on a 60 % high fat diet 
- No disturbances of exocrine pancreatic function or morphology was noted 
- Increased liver steatosis 
Paper V 
PTL, pancreatic triglyceride lipase. 
(P = 0.03) that could be a compensatory effect of increased insulin resistance. The 
demonstration of a phenotype in female mice only would not be surprising even if the human 
syndrome seems to affect men and women alike, as restriction of the expression of diabetes 
to one gender is a frequent finding in rodent models (247; 370). However, an insulin 
secretory deficiency is the characteristic defect in CEL mutation carriers whereas insulin 
resistance is not part of the syndrome, although not formally tested; thus, the endocrine 
phenotype of CEL-MODY does not seem to be recapitulated in the CELKO model. The 
dietary challenge with a 60 % high fat diet, containing three times the fat in percent of 
calories compared to normal chow, induced changes consistent with metabolic changes 
promoting a diabetic phenotype, but did not provoke a full-blown CEL-MODY phenotype. 
Pancreatic exocrine dysfunction was not detected and exocrine pancreas morphology 
appeared normal.  
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Interestingly, there was a predominance of liver steatosis in female CELKO mice on a high 
fat diet and in male CELKO mice irrespective of diet compared to controls. Recently, liver 
steatosis was reported to be associated with reduced glucose tolerance and increased 
postprandial glucose levels, but not impaired fasting glucose, in subjects with the non-
alcoholic fatty liver syndrome (371). CEL is expressed both at the mRNA and protein level 
in human liver (323). However, liver steatosis is not observed in human mutation carriers.  
Instead, lipomatosis of the pancreas is an early structural marker of disease in prediabetic 
subjects with CEL-mutation (53). Recently, histopathological examinations of tumour-free 
pancreatic sections from a deceased CEL-MODY patient with mammary and pancreatic 
cancer, revealed insulin-staining islets, and some acini surrounded by lymphocytes, 
submerged in intrapancreatic fat and fibrous tissue (Immervoll, Hoem, Raeder; unpublished). 
These findings could implicate fat infiltration and inflammation in the pathogenesis of CEL-
MODY. Fatty replacement of the pancreas has also been observed in cystic fibrosis, 
Shwachman-Diamond syndrome and Johanson-Blizzard syndrome, which are monogenic 
conditions with primary affection of the exocrine pancreas and frequent development of 
secondary diabetes (209; 349; 372). Pancreatic steatosis was recently reported to be 
associated with the dissemination and lethality of pancreatic cancer, supporting a role for 
pancreatic fat in disease development (373). No striking difference in pancreatic fatty tissue 
was observed between CELKO and control mice on examination of histological sections, but 
the differentiation of fat within or surrounding the pancreatic tissue was complicated by the 
less clear demarcation of the organ in mice compared to humans. 
TgCEL
Paper VI describes the establishment of a mouse line exhibiting pancreas-specific expression 
of the human disease-associated Del1 CEL allele. It is worth noticing that bitransgenic 
TgCEL+/-_Cre+/- mice had a birth rate of only 11 % compared to 25 % as predicted from 
Mendelian laws, suggesting a certain lethality in utero. However, no particular pancreatic 
endocrine pathology was detected clinically, morphologically or at the molecular level in 
TgCEL mice fed normal chow or a 60 % by calorie high fat diet. Pancreatic exocrine 
dysfunction was also not detected. Principally, this could be due to either a truly normal 
pancreas function or a lack of sensitivity of the diagnostic methods employed. It should be 
noted that a stimulated insulin secretion test examining first phase insulin secretion was not 
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performed in mice fed the high fat diet, and histopathological examination of pancreatic 
sections from high fat diet mice is also pending. Therefore, a subclinical pancreatic 
endocrine pathology cannot yet be excluded in the high fat diet-TgCEL mice. It is also 
possible that an additional challenge to the pancreatic endocrine tissue such as streptozin 
injections would reveal a predisposition towards diabetes in TgCEL mice. We studied 
exocrine function in the mice by indirect methods; primarily serum amylase and fecal 
elastase, accompanied by investigations of fecal chymotrypsin, fat absorption and Oil Red O 
staining of fat in stool in some of the mice. All of the methods are previously published used 
in mouse studies of pancreatic exocrine function (209; 260; 374). Direct function tests are 
considered the gold standard in humans. It is possible that a challenge to the exocrine tissue 
either by in vivo induction of pancreatitis by cerulein injections or by cholecystokinin-
stimulated amylase secretion in freshly isolated acini would unmask latent exocrine 
dysfunction as demonstrated for Ubr1-/- mice (209). 
Interestigly, a few discrete areas of abnormal exocrine tissue were observed by light 
microscopy of pancreatic sections from two male mice carrying the human CEL transgene. 
One of the mice was a TgCEL mouse, whereas the other was genotyped to lack the EL CRE 
transgene and thus was classified as a control mouse carrying dormant human CEL.
However, qRT-PCR suggested some expression of human CEL in the pancreas of this 
mouse, resulting in ambiguity concerning its true genotype. The nature of the abnormality 
was not extensively investigated, but preliminary examination by a pathologist identified 
probable inclusion bodies. The implications of this are unclear. However, it is of interest that 
inclusion bodies were also detected during histopathological examination of pancreatic 
sections from a recently deceased CEL mutation carrier (Immervoll, Hoem, Raeder, 
unpublished). Further investigations are warranted, the genotype of the second mouse should 
be firmly established, and the finding should be replicated in a larger group of mice. 
One hypothesis is that aggregation of mutant CEL protein causes pathology via ER stress-
related mechanisms. Previous mouse studies have reported dilated ER cisternae as a 
manifestation of accumulation of aberrant proteins that could result in ER stress (260; 375). 
Accordingly, we examined electron micrographs of acinar and beta cells of chow-fed 
TgCEL and control mice of both genders, but no consistent differences in ER structure were 
observed (Vesterhus, unpublished). 
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Why did the TgCEL mouse line fail to develop a CEL-MODY phenotype? Given that the 
hypothesis is correct, there are at least four principal explanations: 
1. The phenotype was present, but we failed to recognize it because 
a. we did not do the right tests (discussed above) 
b. the symptoms were mild and larger groups of mice would have been needed 
to prove a difference 
2. The phenotype was latent, but did not develop because 
a. we did not apply the right challenges (discussed above) 
b. we did not follow the mice long enough to reveal an age-dependent 
phenotype
3.  The design of the mouse line was not optimal, and problems could be associated 
with:
a. gene integration in the genome – yielding low or no protein expression 
b. the elastase promoter – not ideal time- or tissue-specificity of induction of 
expression
c. the genetic background of the mouse strain – obscuring phenotype expression 
4. Mice have a different metabolic system from man and might not be a suitable model 
system 
Expression of human CEL was verified by qRT-PCR, and sequencing of all TgCEL mice 
subject to investigation confirmed the presence of the disease-associated Del1 mutation. 
However, expression at the protein level should also be ascertained and quantified. Lacking 
or low expression at the protein level could explain the lacking phenotype. Only recently did 
we obtain an antibody that recognizes the mutant CEL protein, and we are in the process of 
confirming protein expression by western blot and immunohistochemical staining of 
pancreas sections from TgCEL mice. Pancreas-specific expression was demonstrated by 
beta-gal staining and immunological staining for LacZ in the offspring of EL CRE and 
Rosa26 mice. The elastase promoter controlling expression of the Cre recombinase results in 
transgene expression in the mature pancreas, whereas CEL is an early marker of exocrine 
cell differentiation (38). Thus, it is possible that CEL has as yet unknown functions during 
embryogenesis and that a different promoter, e.g. PDX1, inducing transgene expression at an 
earlier stage, would be better suited to promote the pathology associated with CEL-MODY.
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A striking difference in phenotype penetrance has been demonstrated in various mouse 
strains based on different genetic backgrounds (247; 253; 254). Some problems associated 
with the interpretation of results of studies using gene targeted and transgenic mice, 
particularly in relationship to genetic background, are reviewed in (376). The susceptibility 
to impaired insulin secretion or insulin resistance varies between mouse strains as discussed 
in chapter 1.3. We cannot reject the possibility that the lacking phenotype might be 
connected to the C57BL/6-FVB genetic background of the mice, such that knock-in of the 
disease-associated CEL allele in another strain might yield other results as has been seen in 
mice with targeted deletions of the insulin receptor or insulin receptor substrate genes (253). 
Creating the TgCEL on different inbred strains (e.g. C57Bl/6, 129Sv etc) would unmask a 
phenotype that is influenced by one or more modifier genes close to the target locus.  
The loss-of-function hypothesis versus the altered cellular function 
hypothesis
The evidence in favour of a loss-of-function mechanism in the pathogenesis of CEL-MODY
relies on some previous experiments showing reduced stability of mutant CEL as assessed 
by enzyme activity assays in CHO cells or a stability assay with radioactively labelled 
protein using a rabbit reticulocyte lysate system for protein expression, as previously 
explained ((52), and Vesterhus, unpublished). However, the specific activity of mutant CEL 
could not be calculated because of the lack of an appropriate antibody, thus the results of the 
enzyme activity assay were uncertain. Others have reported reduced secretion rate and 
subsequent degradation of CEL synthesized in CHO ldlD cels under conditions preventing 
propoer O-glycosylation (319). In contrast, recent studies in our group indicated that 
transfected HEK293 cells secreted both wildtype and Del1 mutant protein variants into the 
growth medium at high levels and at similar rates  (B. Johansson, unpublished). Previous 
papers have reported that C-terminal deletions in CEL removing PEST sequences and 
glycosylation sites do not interfere with the catalytic activity of the enzyme in vitro (316).
Furthermore, a variant VNTR with only 3 repeats, i.e. approximately the same length of 
normal protein as the Del4 disease-associated allele, was observed in a Danish MODY 
family but is not associated with fecal elastase deficiency, although it segregates with 
diabetes (Torsvik et al., manuscript submitted). In line with this, CELKO mice did not 
recapitulate the characteristics of CEL-MODY and the results described in Paper V do not 
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present new evidence in support of loss-of-function as the pathogenic mechanism in CEL-
MODY.
Three lines of evidence suggest that the single-base deletions lead to pathology through an 
altered cellular function. First, the nature of inheritance: CEL-MODY is autosomal 
dominantly inherited, i.e. the syndrome appears in heterozygote mutation carriers. This is in 
contrast to the usually recessive nature of metabolic diseases based on enzyme defects (377). 
Second, the lack of a convincing phenotype in the knockout mouse model. CELKO mice, 
which should constitute the equivalent of homozygous mutation carriers, would be expected 
to have a stronger phenotype if the hypothesis were correct. 
Third, single-base insertions leading to frameshift and premature truncation occur in CEL as 
common variants and may be associated with an increased risk of exocrine dysfunction in 
subjects with diabetes. Importantly, the observed Ins4 is not associated with diabetes despite 
yielding the same length of normal protein as the disease-associated Del4 mutation, although 
a person with Ins4 and Ins11 combined did have FED (52). The main difference between the 
Ins4 and the Del4 protein is the longer strand of altered protein downstream to the deletion
versus the insertion (predicted to about 100 compared to 5 amino acids), strongly indicating 
that the new protein terminus is implicated in the pathogenesis. The same argument holds 
true for the MODY family without exocrine dysfunction carrying the variant VNTR with 
only 3 repeats mentioned above. The novel protein ending may include glycosylation sites 
that lead to aberrant glycosylation and subsequently capture of the altered protein in the 
quality control machinery of the cell. Previous studies have indicated that aberrant CEL is 
rapidly degraded via the ubiquitin-proteasome pathway (320). Alternatively, defective 
protein could accumulate or aggregate within the acinar cells, thus eliciting a cellular 
unfolded protein response that could trigger ER stress (320). ER stress has been previously 
linked to diabetes (375). In support of this hypothesis, preliminary data from our group 
indicate altered glycosylation in mutant compared to wildtype CEL resulting in a shift in the 
ratio of a low-molecular to a high-molecular band (B. Johansson, unpublished). Further 
preliminary data from immunohistochemistry studies show a changed subcellular 
localization from the ER and Golgi for wildtype human CEL to a more widespread, punctual 
localization to an unidentified organelle for mutant CEL (J. Torsvik, unpublished). Also, 
cells expressing mutant CEL display increased stress markers such as phosphorylated eIF2A 
(J. Torsvik, unpublished). 
64
4.5  Conclusions and future directions 
Papers I and II show that HNF1A-MODY is associated with fecal elastase deficiency and 
pancreatic volume reduction in line with findings in type 1 diabetes, but with less 
pronounced pancreatic atrophy and a less striking association with exocrine dysfunction than 
in HNF1B-MODY. We describe dorsal agenesis of the pancreas with associated fecal 
elastase deficiency to be a phenotype of HNF1B-MODY, supporting a developmental role 
for HNF1B (Paper III). Exocrine dysfunction seems to result from structural abnormality in 
HNF1B-MODY, whereas in HNF1A-MODY it is suggested to arise secondary to diabetes 
(Papers I-III). This underscores the heterogeneous nature of  the interactions between the 
endocrine and exocrine pancreatic tissues that can lead to similar phenotypes of combined 
diabetes and exocrine dysfunction. Furthermore, our data support previous findings that 
fecal elastase deficiency is a relevant marker of clinically important exocrine dysfunction in 
diabetes as steatorrhea and deficiencies in fat soluble vitamins, particularly vitamin E, were 
observed in a high percentage of subjects with diabetes and fecal elastase deficiency (Papers 
I-IV). Based on the evidence discussed above, we suggest that whether exocrine function 
should be tested in all patients with diabetes, and what constitutes the criteria for enzyme 
substitution treatment, should be discussed as there is a distinctive risk that treatable 
malabsorption is currently undiagnosed in patients with diabetes. 
CEL-MODY is hypothesized to be an example of monogenic diabetes arising secondary to 
pancreatic exocrine dysfunction. We studied the global knockout model (CELKO) and 
created and studied the TgCEL mouse line expressing the Del1 disease-associated human 
CEL allele in order to investigate two opposing hypotheses on the molecular mechanisms 
involved in the pathogenesis of the syndrome; namely loss-of-function or an altered cellular 
function of the mutant protein, respectively (Papers V and VI). However, no clear phenotype 
resemblant of CEL-MODY was demonstrated in either CELKO or TgCEL mice. Further 
studies remain to be done particularly to explore the effects of mutant human CEL in a 
transgenic mouse line. Based on our current knowledge, including unpublished data, 
haploinsufficiency at the genetic level is a much less likely hypothesis than an altered 
function of the mutant protein, although it cannot be excluded. 
Briefly summarized, the present work has contributed to the increasing pile of evidence 
concerning the nature of the association between pancreatic exocrine dysfunction and 
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diabetes. Future studies should investigate the pancreatic exocrine function in nondiabetic 
HNF1A mutation carriers in order to evaluate whether diabetes is in fact the primary event in 
exocrine dysfunction associated with HNF1A-MODY, or whether the exocrine pancreas has 
a primary role after all. Follow-up data should be collected to assess the possible 
development or progression of malabsorption and vitamin deficiencies and their secondary 
sequelae in subjects with fecal elastase deficiency and HNF1A-MODY, HNF1B-MODY,
CEL-MODY or type 1 and type 2 diabetes. This would yield important information for the 
decision of whom to treat. 
Future studies of CEL-MODY should focus on further characterization of the pancreatic 
exocrine dysfunction in CEL mutation carriers, including investigations of the incretin 
response and direct tests of exocrine function to differentiate between acinar and ductal 
damage, such as used to define the acinar pathology in Johanson-Blizzard syndrome and the 
ductal defects in cystic fibrosis (378; 379). Although an acinar defect is most likely, given 
the adult expression of CEL in acinar tissue and not in ductal or beta cells, embryonic 
expression of CEL might differ and affect function in adult life (323). Expanding the clinical 
spectrum and screening for HNF1B mutations in a renal registry greatly increased the 
prevalence of HNF1B-MODY (126). Likewise, screening for CEL mutations in materials of 
families with a monogenic pattern of pancreatic exocrine dysfunction as the primary clinical 
manifestation, as well as in MODY-X families with fecal elastase deficiency, should be 
done. Furthermore, sophisticated radiological modalities should be applied in an effort to 
further explore the morphological changes of the pancreas in CEL-MODY. We are currently 
in the process of planning such studies of both the incretin response, imaging of pancreatic 
morphology and function, and direct tests of exocrine function in prediabetic mutation 
carriers and patients with the full-blown syndrome. 
Due to the polymorphic nature of the gene, sequencing of CEL has proved difficult. It would 
be of interest to develop a simple and robust method to detect insertions and deletions in the 
gene. The effect of gene variants as risk factors for type 1 diabetes should be further 
explored, and such studies are currently being pursued by our research group. Furthermore, 
the association of CEL repeat length variants with serum cholesterol levels reported by 
others should be confirmed (297). It would also be interesting to investigate whether CEL
insertions are related to dyslipidemia or cardiovascular disease. Moreover, the region 
surrounding the gene should be studied in detail, as its highly repetitive nature provides a 
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reason to speculate that there might be rearrangements in the region. If so, it would be of 
interest to study those and to investigate whether  they would be associated with disease. 
The post-translational processing of mutant CEL, including ubiquitination and degradation, 
warrants further study to improve our understanding of the pathogenesis of CEL-MODY.
Pursuing studies of the CELKO mice seems unlikely to yield further information, and we 
consider these studies finished. The TgCEL mouse line, however, should be more 
exhaustively studied. In particular studies in older mice and larger groups should be carried 
out, and a cerulein challenge to the exocrine function should be assayed. Breedings are 
ongoing in order to produce mice for these experiments. We are currently controlling the 
presence of transgene expression at the protein level by western blot and 
immunohistochemical analysis. As a next step, a new strategy, such as modifying the mouse 
model by substituting the elastase promoter with for instance a PDX1 promoter for early 
fetal expression of transgenic mutant CEL, as well as backcrossing the transgenic allele onto 
other mouse strains, should be considered. In parallel with the mouse studies, investigations 
in cell lines should be continued in the attempt to unravel the molecular mechanisms 
connected to the synthesis, processing and secretion of mutant CEL. Such studies are being 
pursued by other members of our laboratory. The establishment of an in vivo model that 
truly recapitulates the syndrome of CEL-MODY would be of utmost importance for the 
demonstration of the processes leading to disease, and to finally settle the question of which 
tissue is the origin of the syndrome. Ultimately, this could yield insights that would be useful 
for the understanding of other forms of diabetes.
67
References
1. Henderson JR: Why are the islets of Langerhans? Lancet 2:469-470, 1969 
2. Feldman M, Friedman LS, Sleisenger MH: Sleisenger & Fordtran's 
Gastrointestinal and Liver Diseases. Pathophysiology/Diagnosis/Management; 7th 
Edition, Saunders, 2002 
3. Ermak TH, Rothman SS: Zymogen granules of pancreas decrease in size in 
response to feeding. Cell Tissue Res 214:51-66, 1981 
4. Greene LJ, Hirs CH, Palade GE: On the protein composition of bovine pancreatic 
zymogen granules. J Biol Chem 238:2054-2070, 1963 
5. Tartakoff A, Greene LJ, Palade GE: Studies on the guinea pig pancreas. 
Fractionation and partial characterization of exocrine proteins. J Biol Chem
249:7420-7431, 1974 
6. Mroz EA, Lechene C: Pancreatic zymogen granules differ markedly in protein 
composition. Science 232:871-873, 1986 
7. Keller J, Layer P: Human pancreatic exocrine response to nutrients in health and 
disease. Gut 54 Suppl 6:vi1-28, 2005 
8. Li Y, Hao Y, Owyang C: High-affinity CCK-A receptors on the vagus nerve 
mediate CCK-stimulated pancreatic secretion in rats. Am J Physiol 273:G679-685, 
1997
9. Chey WY, Kim MS, Lee KY, Chang TM: Effect of rabbit antisecretin serum on 
postprandial pancreatic secretion in dogs. Gastroenterology 77:1268-1275, 1979 
10. Kulkarni RN: The islet beta-cell. Int J Biochem Cell Biol 36:365-371, 2004 
11. Junqueira LC, Carneiro J, Kelley RO: Basic histology. London, Prentice-Hall 
International, 1995 
12. Orci L: The insulin factory: a tour of the plant surroundings and a visit to the 
assembly line. The Minkowski lecture 1973 revisited. Diabetologia 28:528-546, 1985 
13. Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical 
pathophysiology of maturity-onset diabetes of the young. N Engl J Med 345:971-980, 
2001
14. Boden G, Chen X: Effects of fatty acids and ketone bodies on basal insulin 
secretion in type 2 diabetes. Diabetes 48:577-583, 1999 
15. Ahren B, Holst JJ: The cephalic insulin response to meal ingestion in humans is 
dependent on both cholinergic and noncholinergic mechanisms and is important for 
postprandial glycemia. Diabetes 50:1030-1038, 2001 
16. Seufert J: Leptin effects on pancreatic beta-cell gene expression and function. 
Diabetes 53 Suppl 1:S152-158, 2004 
17. Edlund H: Pancreatic organogenesis--developmental mechanisms and 
implications for therapy. Nat Rev Genet 3:524-532, 2002 
18. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A: The 
unique cytoarchitecture of human pancreatic islets has implications for islet cell 
function. Proc Natl Acad Sci U S A 103:2334-2339, 2006 
19. Orci L, Unger RH: Functional subdivision of islets of Langerhans and possible 
role of D cells. Lancet 2:1243-1244, 1975 
68
20. Drucker DJ: The biology of incretin hormones. Cell Metab 3:153-165, 2006 
21. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 
2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52, 1986 
22. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, Holst JJ, 
Krarup T: Reduced incretin effect in type 2 diabetes: cause or consequence of the 
diabetic state? Diabetes 56:1951-1959, 2007 
23. Chia CW, Egan JM: Incretin-based therapies in type 2 diabetes mellitus. J Clin 
Endocrinol Metab 93:3703-3716, 2008 
24. Ganong WF: Review of medical physiology. New York, Lange Medical 
Books/McGraw-Hill, 2005 
25. Cano DA, Hebrok M, Zenker M: Pancreatic development and disease. 
Gastroenterology 132:745-762, 2007 
26. Slack JM: Developmental biology of the pancreas. Development 121:1569-1580, 
1995
27. Hebrok M, Kim SK, Melton DA: Notochord repression of endodermal Sonic 
hedgehog permits pancreas development. Genes Dev 12:1705-1713, 1998 
28. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan 
BL, Wright CV: PDX-1 is required for pancreatic outgrowth and differentiation of 
the rostral duodenum. Development 122:983-995, 1996 
29. Hale MA, Kagami H, Shi L, Holland AM, Elsasser HP, Hammer RE, MacDonald 
RJ: The homeodomain protein PDX1 is required at mid-pancreatic development for 
the formation of the exocrine pancreas. Dev Biol 286:225-237, 2005 
30. Stanger BZ, Tanaka AJ, Melton DA: Organ size is limited by the number of 
embryonic progenitor cells in the pancreas but not the liver. Nature 445:886-891, 
2007
31. Golosow N, Grobstein C: Epitheliomesenchymal interaction in pancreatic 
morphogenesis. Dev Biol 4:242-255, 1962 
32. Gittes GK, Galante PE, Hanahan D, Rutter WJ, Debase HT: Lineage-specific 
morphogenesis in the developing pancreas: role of mesenchymal factors. 
Development 122:439-447, 1996 
33. Murtaugh LC, Melton DA: Genes, signals, and lineages in pancreas development. 
Annu Rev Cell Dev Biol 19:71-89, 2003 
34. Sarkar SA, Kobberup S, Wong R, Lopez AD, Quayum N, Still T, Kutchma A, 
Jensen JN, Gianani R, Beattie GM, Jensen J, Hayek A, Hutton JC: Global gene 
expression profiling and histochemical analysis of the developing human fetal 
pancreas. Diabetologia 51:285-297, 2008 
35. Gradwohl G, Dierich A, LeMeur M, Guillemot F: neurogenin3 is required for the 
development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci 
U S A 97:1607-1611, 2000 
36. Jensen J, Heller RS, Funder-Nielsen T, Pedersen EE, Lindsell C, Weinmaster G, 
Madsen OD, Serup P: Independent development of pancreatic alpha- and beta-cells 
from neurogenin3-expressing precursors: a role for the notch pathway in repression 
of premature differentiation. Diabetes 49:163-176, 2000 
37. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV: The 
role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic 
progenitors. Nat Genet 32:128-134, 2002 
69
38. Albers GH, Escribano MJ, Gonzalez M, Mulliez N, Nap M: Fetoacinar pancreatic 
protein in the developing human pancreas. Differentiation 34:210-215, 1987 
39. Pungpapong S, Wallace MB, Woodward TA, Noh KW, Raimondo M: Accuracy 
of endoscopic ultrasonography and magnetic resonance cholangiopancreatography
for the diagnosis of chronic pancreatitis: a prospective comparison study. J Clin 
Gastroenterol 41:88-93, 2007 
40. Tamura R, Ishibashi T, Takahashi S: Chronic pancreatitis: MRCP versus ERCP 
for quantitative caliber measurement and qualitative evaluation. Radiology 238:920-
928, 2006 
41. Catalano MF, Lahoti S, Geenen JE, Hogan WJ: Prospective evaluation of 
endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin 
test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 48:11-17, 1998 
42. Bozkurt T, Braun U, Leferink S, Gilly G, Lux G: Comparison of pancreatic 
morphology and exocrine functional impairment in patients with chronic pancreatitis. 
Gut 35:1132-1136, 1994 
43. Balci NC, Alkaade S, Akduman IE, Bilgin M, Murdock CP, Burton FR: Serial 
contrast-enhanced MRI of the pancreas: correlation with secretin-stimulated 
endoscopic pancreatic function test. Acad Radiol 13:1367-1372, 2006 
44. Schrader H, Menge BA, Schneider S, Belyaev O, Tannapfel A, Uhl W, Schmidt 
WE, Meier JJ: Reduced pancreatic volume and beta-cell area in patients with chronic 
pancreatitis. Gastroenterology 136:513-522, 2009 
45. Goda K, Sasaki E, Nagata K, Fukai M, Ohsawa N, Hahafusa T: Pancreatic 
volume in type 1 and type 2 diabetes mellitus. Acta Diabetol 38:145-149, 2001 
46. Alzaid A, Aideyan O, Nawaz S: The size of the pancreas in diabetes mellitus. 
Diabet Med 10:759-763, 1993 
47. Gilbeau JP, Poncelet V, Libon E, Derue G, Heller FR: The density, contour, and 
thickness of the pancreas in diabetics: CT findings in 57 patients. AJR Am J 
Roentgenol 159:527-531, 1992 
48. Williams JA, Goldfine ID: The insulin-pancreatic acinar axis. Diabetes 34:980-
986, 1985 
49. Korc M, Owerbach D, Quinto C, Rutter WJ: Pancreatic islet-acinar cell 
interaction: amylase messenger RNA levels ar determined by insulin. Science
213:351-353, 1981 
50. Bellanne-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, 
Beaufils S, Wilhelm JM, Boitard C, Noel LH, Velho G, Timsit J: Clinical spectrum 
associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 140:510-
517, 2004 
51. Edghill EL, Bingham C, Slingerland AS, Minton JA, Noordam C, Ellard S, 
Hattersley AT: Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes 
and intrauterine growth retardation: support for a critical role of HNF-1beta in human 
pancreatic development. Diabet Med 23:1301-1306, 2006 
52. Ræder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, Nermoen I, 
Eide SA, Grevle L, Bjørkhaug L, Sagen JV, Aksnes L, Søvik O, Lombardo D, 
Molven A, Njølstad PR: Mutations in the CEL VNTR cause a syndrome of diabetes 
and exocrine dysfunction. Nat Genet 38:54-62, 2006 
70
53. Ræder H, Haldorsen IS, Ersland L, Gruner R, Taxt T, Søvik O, Molven A, 
Njølstad PR: Pancreatic lipomatosis is a structural marker in nondiabetic children 
with mutations in carboxyl-ester lipase. Diabetes 56:444-449, 2007 
54. Balakrishnan V, Narayanan VA, Siyad I, Radhakrishnan L, Nair P: Agenesis of 
the dorsal pancreas with chronic calcific pancreatitis. case report, review of the 
literature and genetic basis. JOP 7:651-659, 2006 
55. Klein WA, Dabezies MA, Friedman AC, Caroline DF, Boden GH, Cohen S: 
Agenesis of dorsal pancreas in a patient with weight loss and diabetes mellitus. Dig
Dis Sci 39:1708-1713, 1994 
56. Uygur-Bayramicli O, Dabak R, Kilicoglu G, Dolapcioglu C, Oztas D: Dorsal 
pancreatic agenesis. JOP 8:450-452, 2007 
57. Fukuoka K, Ajiki T, Yamamoto M, Fujiwara H, Onoyama H, Fujita T, Katayama 
N, Mizuguchi K, Ikuta H, Kuroda Y, Hanioka K: Complete agenesis of the dorsal 
pancreas. J Hepatobiliary Pancreat Surg 6:94-97, 1999 
58. Gold RP: Agenesis and pseudo-agenesis of the dorsal pancreas. Abdom Imaging
18:141-144, 1993 
59. Schnedl WJ, Reisinger EC, Schreiber F, Pieber TR, Lipp RW, Krejs GJ: 
Complete and partial agenesis of the dorsal pancreas within one family. Gastrointest
Endosc 42:485-487, 1995 
60. Kinney TP, Freeman ML: Recent advances and novel methods in pancreatic 
imaging. Minerva Gastroenterol Dietol 54:85-95, 2008 
61. Kwon RS, Scheiman JM: New advances in pancreatic imaging. Curr Opin 
Gastroenterol 22:512-519, 2006 
62. Association AD: Diagnosis and classification of diabetes mellitus. Diabetes Care
27:5-10, 2005 
63. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med 15:539-553, 1998 
64. Diagnosis and classification of diabetes mellitus. Diabetes Care 31:6, 2008 
65. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease 
pathogenesis and treatment. Lancet 358:221-229, 2001 
66. Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the US in 2002. 
Diabetes Care 26:917-932, 2003 
67. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, 
Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired 
fasting glucose in adults in the U.S. population: National Health And Nutrition 
Examination Survey 1999-2002. Diabetes Care 29:1263-1268, 2006 
68. Krolewski AS, Warram JH: Epidemiology of late complications of diabetes: A 
basis for the development and evaluation of preventive program. In Joslin’s Diabetes 
Mellitus Kahn CR, Weir GC, King GL, Moses AC, Smith RJ, Jacobson AM, Eds. 
New York, Lippincott, Williams & Wilkins, 2005 
69. Stene LC, Midthjell K, Jenum AK, Skeie S, Birkeland KI, Lund E, Joner G, Tell 
GS, Schirmer H: [Prevalence of diabetes mellitus in Norway]. Tidsskr Nor 
Laegeforen 124:1511-1514, 2004 
70. Skyler JS, Oddo C: Diabetes trends in the USA. Diabetes Metab Res Rev 18 
Suppl 3:S21-26, 2002 
71
71. Kahn CR: Banting Lecture. Insulin action, diabetogenes, and the cause of type II 
diabetes. Diabetes 43:1066-1084, 1994 
72. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR: 
Role of glucose and insulin resistance in development of type 2 diabetes mellitus: 
results of a 25-year follow-up study. Lancet 340:925-929, 1992 
73. Doria A, Patti ME, Kahn CR: The emerging genetic architecture of type 2 
diabetes. Cell Metab 8:186-200, 2008 
74. McCarthy MI, Hattersley AT: Learning from molecular genetics: novel insights 
arising from the definition of genes for monogenic and type 2 diabetes. Diabetes
57:2889-2898, 2008 
75. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, 
Altshuler D, Nilsson P, Groop L: Clinical risk factors, DNA variants, and the 
development of type 2 diabetes. N Engl J Med 359:2220-2232, 2008 
76. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, 
Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, 
Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, 
Walker M, Hitman GA, Morris AD, Doney AS, McCarthy MI, Hattersley AT: 
Replication of genome-wide association signals in UK samples reveals risk loci for 
type 2 diabetes. Science 316:1336-1341, 2007 
77. Eide SA, Raeder H, Johansson S, Midthjell K, Sovik O, Njolstad PR, Molven A: 
Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 
Study). Diabet Med 25:775-781, 2008 
78. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M: A 
new subtype of autosomal dominant diabetes attributable to a mutation in the gene for 
sulfonylurea receptor 1. Lancet 361:301-307, 2003 
79. Glaser B: Dominant SUR1 mutation causing autosomal dominant type 2 diabetes. 
Lancet 361:272-273, 2003 
80. Murphy R, Ellard S, Hattersley AT: Clinical implications of a molecular genetic 
classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab,
2008
81. Sagen JV, Bjorkhaug L, Molnes J, Raeder H, Grevle L, Sovik O, Molven A, 
Njolstad PR: Diagnostic screening of MODY2/GCK mutations in the Norwegian 
MODY Registry. Pediatr Diabetes 9:442-449, 2008 
82. Ledermann HM: Is maturity onset diabetes at young age (MODY) more common 
in Europe than previously assumed? Lancet 345:648, 1995 
83. Frayling TM, Evans JC, Bulman MP, Pearson E, Allen L, Owen K, Bingham C, 
Hannemann M, Shepherd M, Ellard S, Hattersley AT: beta-cell genes and diabetes: 
molecular and clinical characterization of mutations in transcription factors. Diabetes
50 Suppl 1:S94-100, 2001 
84. Lehto M, Wipemo C, Ivarsson SA, Lindgren C, Lipsanen-Nyman M, Weng J, 
Wibell L, Widen E, Tuomi T, Groop L: High frequency of mutations in MODY and 
mitochondrial genes in Scandinavian patients with familial early-onset diabetes. 
Diabetologia 42:1131-1137, 1999 
85. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel 
M, Takeda J, Passa P, et al.: Familial hyperglycemia due to mutations in glucokinase. 
Definition of a subtype of diabetes mellitus. N Engl J Med 328:697-702, 1993 
72
86. Massa O, Meschi F, Cuesta-Munoz A, Caumo A, Cerutti F, Toni S, Cherubini V, 
Guazzarotti L, Sulli N, Matschinsky FM, Lorini R, Iafusco D, Barbetti F: High 
prevalence of glucokinase mutations in Italian children with MODY. Influence on 
glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes 
Study Group of the Italian Society of Paediatric Endocrinology and Diabetes 
(SIEDP). Diabetologia 44:898-905, 2001 
87. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, 
Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha 
gene in maturity-onset diabetes of the young (MODY1). Nature 384:458-460, 1996 
88. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, Lesage S, Vionnet 
N, Clement K, Fougerousse F, et al.: Close linkage of glucokinase locus on 
chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature
356:162-164, 1992 
89. Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, 
O'Rahilly S, Watkins PJ, Wainscoat JS: Linkage of type 2 diabetes to the glucokinase 
gene. Lancet 339:1307-1310, 1992 
90. Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, 
Undlien DE, Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI: 
Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med
344:1588-1592, 2001 
91. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, 
Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, 
Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, 
Pedersen O, Polonsky KS, Bell GI, et al.: Mutations in the hepatocyte nuclear factor-
1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384:455-458, 
1996
92. Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset type-II diabetes 
mellitus (MODY4) linked to IPF1. Nat Genet 17:138-139, 1997 
93. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic 
agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding 
sequence. Nat Genet 15:106-110, 1997 
94. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, 
Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI: 
Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. 
Nat Genet 17:384-385, 1997 
95. Malecki MT, Jhala US, Antonellis A, Fields L, Doria A, Orban T, Saad M, 
Warram JH, Montminy M, Krolewski AS: Mutations in NEUROD1 are associated 
with the development of type 2 diabetes mellitus. Nat Genet 23:323-328, 1999 
96. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly 
E, Vaillant E, Benmezroua Y, Durand E, Bakaher N, Delannoy V, Vaxillaire M, 
Cook T, Dallinga-Thie GM, Jansen H, Charles MA, Clement K, Galan P, Hercberg S, 
Helbecque N, Charpentier G, Prentki M, Hansen T, Pedersen O, Urrutia R, Melloul 
D, Froguel P: Role of transcription factor KLF11 and its diabetes-associated gene 
variants in pancreatic beta cell function. Proc Natl Acad Sci U S A, 2005 
97. Ræder H JS, Holm PI, Haldorsen IS, Mas E, Sbarra V, Nermoen I, Eide SA, 
Grevle L, Bjørkhaug L, Sagen JV, Aksnes L, Søvik O, Lombardo D, Molven A, 
73
Njølstad PR Mutations in the CEL VNTR cause a syndrome of diabetes and exocrine 
dysfunction. Nat Genet 38:54-62, 2006 
98. Raeder H, Haldorsen IS, Ersland L, Gruner R, Taxt T, Sovik O, Molven A, 
Njolstad PR: Pancreatic lipomatosis is a structural marker in nondiabetic children 
with mutations in carboxyl-ester lipase. Diabetes 56:444-449, 2007 
99. Molven A, Ringdal M, Nordbo AM, Raeder H, Stoy J, Lipkind GM, Steiner DF, 
Philipson LH, Bergmann I, Aarskog D, Undlien DE, Joner G, Sovik O, Bell GI, 
Njolstad PR: Mutations in the insulin gene can cause MODY and autoantibody-
negative type 1 diabetes. Diabetes 57:1131-1135, 2008 
100. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, 
Shepherd MH, Hussain K, Kapoor RR, Malecki M, MacDonald MJ, Stoy J, Steiner 
DF, Philipson LH, Bell GI, Hattersley AT, Ellard S: Insulin mutation screening in 
1,044 patients with diabetes: mutations in the INS gene are a common cause of 
neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. 
Diabetes 57:1034-1042, 2008 
101. Stoy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, 
Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, 
Steiner DF, Hattersley AT, Philipson LH, Bell GI: Insulin gene mutations as a cause 
of permanent neonatal diabetes. Proc Natl Acad Sci U S A 104:15040-15044, 2007 
102. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan 
J, Aguilar-Bryan L, Vaxillaire M, Froguel P: Activating mutations in the ABCC8 
gene in neonatal diabetes mellitus. N Engl J Med 355:456-466, 2006 
103. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill 
EL, Mackay DJ, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JP, 
Hattersley AT, Ashcroft FM: Permanent neonatal diabetes caused by dominant, 
recessive, or compound heterozygous SUR1 mutations with opposite functional 
effects. Am J Hum Genet 81:375-382, 2007 
104. Stoffel M, Duncan SA: The maturity-onset diabetes of the young (MODY1) 
transcription factor HNF4alpha regulates expression of genes required for glucose 
transport and metabolism. Proc Natl Acad Sci U S A 94:13209-13214, 1997 
105. Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB: Hepatocyte 
nuclear factor 4alpha regulates the expression of pancreatic beta -cell genes 
implicated in glucose metabolism and nutrient-induced insulin secretion. J Biol Chem
275:35953-35959, 2000 
106. Herman WH, Fajans SS, Ortiz FJ, Smith MJ, Sturis J, Bell GI, Polonsky KS, 
Halter JB: Abnormal insulin secretion, not insulin resistance, is the genetic or primary 
defect of MODY in the RW pedigree. Diabetes 43:40-46, 1994 
107. Byrne MM, Sturis J, Menzel S, Yamagata K, Fajans SS, Dronsfield MJ, Bain 
SC, Hattersley AT, Velho G, Froguel P, Bell GI, Polonsky KS: Altered insulin 
secretory responses to glucose in diabetic and nondiabetic subjects with mutations in 
the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes 45:1503-1510, 
1996
108. Lehto M, Tuomi T, Mahtani MM, Widen E, Forsblom C, Sarelin L, Gullstrom 
M, Isomaa B, Lehtovirta M, Hyrkko A, Kanninen T, Orho M, Manley S, Turner RC, 
Brettin T, Kirby A, Thomas J, Duyk G, Lander E, Taskinen MR, Groop L: 
74
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin 
secretion defect. J Clin Invest 99:582-591, 1997 
109. Boj SF, Parrizas M, Maestro MA, Ferrer J: A transcription factor regulatory 
circuit in differentiated pancreatic cells. Proc Natl Acad Sci U S A 98:14481-14486, 
2001
110. Thomas H, Jaschkowitz K, Bulman M, Frayling TM, Mitchell SM, Roosen S, 
Lingott-Frieg A, Tack CJ, Ellard S, Ryffel GU, Hattersley AT: A distant upstream 
promoter of the HNF-4alpha gene connects the transcription factors involved in 
maturity-onset diabetes of the young. Hum Mol Genet 10:2089-2097, 2001 
111. Thomas H, Senkel S, Erdmann S, Arndt T, Turan G, Klein-Hitpass L, Ryffel 
GU: Pattern of genes influenced by conditional expression of the transcription factors 
HNF6, HNF4alpha and HNF1beta in a pancreatic beta-cell line. Nucleic Acids Res
32:e150, 2004 
112. Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, 
Hattersley AT: Beta-cell dysfunction, insulin sensitivity, and glycosuria precede 
diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care
28:1751-1756, 2005 
113. Shepherd M, Ellis I, Ahmad AM, Todd PJ, Bowen-Jones D, Mannion G, Ellard 
S, Sparkes AC, Hattersley AT: Predictive genetic testing in maturity-onset diabetes of 
the young (MODY). Diabet Med 18:417-421, 2001 
114. Fajans SS, Bell GI: Phenotypic heterogeneity between different mutations of 
MODY subtypes and within MODY pedigrees. Diabetologia 49:1106-1108, 2006 
115. Hattersley AT: Maturity-onset diabetes of the young: clinical heterogeneity 
explained by genetic heterogeneity. Diabet Med 15:15-24, 1998 
116. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, Costa A, 
Conget I, Pedersen O, Sovik O, Lorini R, Groop L, Froguel P, Hattersley AT: The 
genetic abnormality in the beta cell determines the response to an oral glucose load. 
Diabetologia 45:427-435, 2002 
117. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT: Isomers of the 
TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression 
in the pancreas and define the relationship between mutation position and clinical 
phenotype in monogenic diabetes. Hum Mol Genet 15:2216-2224, 2006 
118. Bellanne-Chantelot C, Carette C, Riveline JP, Valero R, Gautier JF, Larger E, 
Reznik Y, Ducluzeau PH, Sola A, Hartemann-Heurtier A, Lecomte P, Chaillous L, 
Laloi-Michelin M, Wilhem JM, Cuny P, Duron F, Guerci B, Jeandidier N, Mosnier-
Pudar H, Assayag M, Dubois-Laforgue D, Velho G, Timsit J: The type and the 
position of HNF1A mutation modulate age at diagnosis of diabetes in patients with 
maturity-onset diabetes of the young (MODY)-3. Diabetes 57:503-508, 2008 
119. Stride A, Shepherd M, Frayling TM, Bulman MP, Ellard S, Hattersley AT: 
Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-
1alpha gene mutation carriers. Diabetes Care 25:2287-2291, 2002 
120. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT: 
Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet
362:1275-1281, 2003 
121. Sovik O, Njolstad P, Folling I, Sagen J, Cockburn BN, Bell GI: 
Hyperexcitability to sulphonylurea in MODY3. Diabetologia 41:607-608, 1998 
75
122. Hansen T, Eiberg H, Rouard M, Vaxillaire M, Moller AM, Rasmussen SK, 
Fridberg M, Urhammer SA, Holst JJ, Almind K, Echwald SM, Hansen L, Bell GI, 
Pedersen O: Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: 
evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues 
in a glucose-tolerant carrier of a P447L mutation. Diabetes 46:726-730, 1997 
123. Hathout EH, Cockburn BN, Mace JW, Sharkey J, Chen-Daniel J, Bell GI: A 
case of hepatocyte nuclear factor-1 alpha diabetes/MODY3 masquerading as type 1 
diabetes in a Mexican-American adolescent and responsive to a low dose of 
sulfonylurea. Diabetes Care 22:867-868, 1999 
124. Ellard S, Bellanne-Chantelot C, Hattersley AT: Best practice guidelines for the 
molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia,
2008
125. Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L, 
Haggblom M, Groop L: Chronic diabetic complications in patients with MODY3 
diabetes. Diabetologia 41:467-473, 1998 
126. Edghill EL, Bingham C, Ellard S, Hattersley AT: Mutations in hepatocyte 
nuclear factor-1beta and their related phenotypes. J Med Genet 43:84-90, 2006 
127. Bingham C, Hattersley AT: Renal cysts and diabetes syndrome resulting from 
mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant 19:2703-2708, 
2004
128. Stride A, Hattersley AT: Different genes, different diabetes: lessons from 
maturity-onset diabetes of the young. Ann Med 34:207-216, 2002 
129. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O: A novel 
syndrome of diabetes mellitus, renal dysfunction and genital malformation associated 
with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. 
Hum Mol Genet 8:2001-2008, 1999 
130. Haumaitre C, Barbacci E, Jenny M, Ott MO, Gradwohl G, Cereghini S: Lack of 
TCF2/vHNF1 in mice leads to pancreas agenesis. Proc Natl Acad Sci U S A
102:1490-1495, 2005 
131. Edghill EL, Oram RA, Owens M, Stals KL, Harries LW, Hattersley AT, Ellard 
S, Bingham C: Hepatocyte nuclear factor-1{beta} gene deletions--a common cause of 
renal disease. Nephrol Dial Transplant 23:627-635, 2008 
132. Pearson ER, Badman MK, Lockwood CR, Clark PM, Ellard S, Bingham C, 
Hattersley AT: Contrasting diabetes phenotypes associated with hepatocyte nuclear 
factor-1alpha and -1beta mutations. Diabetes Care 27:1102-1107, 2004 
133. Bellanne-Chantelot C, Clauin S, Chauveau D, Collin P, Daumont M, Douillard 
C, Dubois-Laforgue D, Dusselier L, Gautier JF, Jadoul M, Laloi-Michelin M, 
Jacquesson L, Larger E, Louis J, Nicolino M, Subra JF, Wilhem JM, Young J, Velho 
G, Timsit J: Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-
1{beta} (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of 
the Young Type 5. Diabetes 54:3126-3132, 2005 
134. Ulinski T, Lescure S, Beaufils S, Guigonis V, Decramer S, Morin D, Clauin S, 
Deschenes G, Bouissou F, Bensman A, Bellanne-Chantelot C: Renal phenotypes 
related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J
Am Soc Nephrol 17:497-503, 2006 
76
135. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, 
Shield JP, Temple K, Ellard S, Hattersley AT: Mutations in ATP-sensitive K+ 
channel genes cause transient neonatal diabetes and permanent diabetes in childhood 
or adulthood. Diabetes 56:1930-1937, 2007 
136. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, 
Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, 
Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, 
Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating 
mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 
and permanent neonatal diabetes. N Engl J Med 350:1838-1849, 2004 
137. Sagen JV, Ræder H, Hathout E, Shehadeh N, Gudmundsson K, Bævre H, 
Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, 
Søvik O, Njølstad PR: Permanent neonatal diabetes due to mutations in KCNJ11 
encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. 
Diabetes 53:2713-2718, 2004 
138. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, 
Czernichow P, Froguel P, Polak M: Kir6.2 mutations are a common cause of 
permanent neonatal diabetes in a large cohort of French patients. Diabetes 53:2719-
2722, 2004 
139. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT: Mutations in 
KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the 
first 6 months of life, with the phenotype determined by genotype. Diabetologia
49:1190-1197, 2006 
140. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, 
Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, 
Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT: Switching from 
insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl 
J Med 355:467-477, 2006 
141. Murphy R, Turnbull DM, Walker M, Hattersley AT: Clinical features, diagnosis 
and management of maternally inherited diabetes and deafness (MIDD) associated 
with the 3243A>G mitochondrial point mutation. Diabet Med, 2008 
142. DiMagno EP, Go VL, Summerskill WH: Relations between pancreatic enzyme 
ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 288:813-
815, 1973 
143. Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W: Functional reserve 
capacity of the exocrine pancreas. Digestion 35:175-181, 1986 
144. Carriere F, Grandval P, Gregory PC, Renou C, Henniges F, Sander-Struckmeier 
S, Laugier R: Does the pancreas really produce much more lipase than required for 
fat digestion? Jop 6:206-215, 2005 
145. Van De Kamer JH, Ten Bokkel Huinink H, Weyers HA: Rapid method for the 
determination of fat in feces. J Biol Chem 177:347-355, 1949 
146. Benini L, Caliari S, Guidi GC, Vaona B, Talamini G, Vantini I, Scuro LA: Near 
infrared spectrometry for faecal fat measurement: comparison with conventional 
gravimetric and titrimetric methods. Gut 30:1344-1347, 1989 
77
147. Fomon SJ, Ziegler EE, Thomas LN, Jensen RL, Filer LJ, Jr.: Excretion of fat by 
normal full-term infants fed various milks and formulas. Am J Clin Nutr 23:1299-
1313, 1970 
148. Chowdhury RS, Forsmark CE: Review article: Pancreatic function testing. 
Aliment Pharmacol Ther 17:733-750, 2003 
149. Dominici R, Franzini C: Fecal elastase-1 as a test for pancreatic function: a 
review. Clin Chem Lab Med 40:325-332, 2002 
150. Schneider A, Funk B, Caspary W, Stein J: Monoclonal versus polyclonal ELISA 
for assessment of fecal elastase concentration: pitfalls of a new assay. Clin Chem
51:1052-1054, 2005 
151. Fischer B, Hoh S, Wehler M, Hahn EG, Schneider HT: Faecal elastase-1: 
lyophilization of stool samples prevents false low results in diarrhoea. Scand J 
Gastroenterol 36:771-774, 2001 
152. Lankisch PG: Now that fecal elastase is available in the United States, should 
clinicians start using it? Curr Gastroenterol Rep 6:126-131, 2004 
153. Loser C, Mollgaard A, Folsch UR: Faecal elastase 1: a novel, highly sensitive, 
and specific tubeless pancreatic function test. Gut 39:580-586, 1996 
154. Lyubimova NV, Kosyrev VY, Patyutko YI, Kushlinskii NE: Analysis of 
elastase 1 for evaluation of excretory function of the pancreas after 
gastropancreatoduodenal resection. Bull Exp Biol Med 135:34-36, 2003 
155. Masoero G, Zaffino C, Laudi C, Lombardo L, Rocca R, Gallo L, Della Monica 
P, Pera A: Fecal pancreatic elastase 1 in the work up of patients with chronic 
diarrhea. Int J Pancreatol 28:175-179, 2000 
156. Nissler K, Von Katte I, Huebner A, Henker J: Pancreatic elastase 1 in feces of 
preterm and term infants. J Pediatr Gastroenterol Nutr 33:28-31, 2001 
157. Jones CM: Pancreatic and hepatic activity in diabetes mellitus. Arch Intern Med
35:315-336, 1925 
158. Domschke W, Tympner F, Domschke S, Demling L: Exocrine pancreatic 
function in juvenile diabetics. Am J Dig Dis 20:309-312, 1975 
159. Adrian TE, Barnes AJ, Bloom SR: Hypotrypsinaemia in diabetes mellitus. Clin
Chim Acta 97:213-216, 1979 
160. Frier BM, Saunders JH, Wormsley KG, Bouchier IA: Exocrine pancreatic 
function in juvenile-onset diabetes mellitus. Gut 17:685-691, 1976 
161. Harano Y, Kim CI, Kang M, Shichiri M, Shimizu Y, Li H, Yoshida M, Shigeta 
Y, Abe H: External pancreatic dysfunction associated with diabetes mellitus. J Lab 
Clin Med 91:780-790, 1978 
162. Lankisch PG, Manthey G, Otto J, Koop H, Talaulicar M, Willms B, Creutzfeldt 
W: Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion
25:211-216, 1982 
163. Bargen JA: The "diarrhea of diabetes" and steathorrea of pancreatic 
insufficiency. Mayo Clin Proc 11:737-742, 1936 
164. Chey WY, Shay H, Shuman CR: External Pancreatic Secretion In Diabetes 
Mellitus. Ann Intern Med 59:812-821, 1963 
165. Pollard H: The external secretion nof the pancreas and diabetes mellitus. Am J 
Dig Dis 10:20-23, 1943 
78
166. Diamond JS: The secretin test in the diagnosis of pancreatic diseases with a 
report of one hundred thirty tests. Am J Dig Dis 7:435-442, 1940 
167. Aktan HS, Klotz AP: Fat absorption and pancreatic function in diabetes mellitus. 
Ann Intern Med 49:820-828, 1958 
168. Vacca JB, Henke WJ, Knight WA, Jr.: The Exocrine Pancreas In Diabetes 
Mellitus. Ann Intern Med 61:242-247, 1964 
169. Dandona P, Freedman DB, Foo Y, Perkins J, Katrak A, Mikhailidis DP, Rosalki 
SB, Beckett AG: Exocrine pancreatic function in diabetes mellitus. J Clin Pathol
37:302-306, 1984 
170. Kawamori R, Katsura M, Ishida S, Yamasaki Y, Tujii M, Kawano S, Kamada T: 
Subclinical exocrine pancreatic derangement in human diabetic patients evaluated 
from pure pancreatic juice. J Diabetes Complications 9:69-73, 1995 
171. Hitanant S, Vannasaeng S, Tan-ngarm-trong D, Plengvanit U, Viranuvatti V: 
Exocrine pancreatic function among diabetic patients in Thailand. Am J 
Gastroenterol 81:559-561, 1986 
172. Sato M, Yamamoto K, Mayama H, Yamashiro Y: Exocrine pancreatic function 
in diabetic children. J Pediatr Gastroenterol Nutr 3:415-420, 1984 
173. Lorini R, Cortona L, Scotta MS, Melzi d'Eril GV, Severi F: Exocrine pancreatic 
function in children and adolescents with insulin-dependent diabetes mellitus. 
Diabetes Res Clin Pract 8:263-267, 1990 
174. Holmes GK: Screening for coeliac disease in type 1 diabetes. Arch Dis Child
87:495-498, 2002 
175. Mahmud FH, Murray JA, Kudva YC, Zinsmeister AR, Dierkhising RA, Lahr 
BD, Dyck PJ, Kyle RA, El-Youssef M, Burgart LJ, Van Dyke CT, Brogan DL, 
Melton LJ, 3rd: Celiac disease in type 1 diabetes mellitus in a North American 
community: prevalence, serologic screening, and clinical features. Mayo Clin Proc
80:1429-1434, 2005 
176. Sabbatella L, Di Tola M, Picarelli A: The high frequency of coeliac disease and 
other autoimmune diseases in subjects affected by Type I (insulin-dependent) 
diabetes mellitus and in their first-degree relatives. Diabetologia 45:748, 2002 
177. Poulain C, Johanet C, Delcroix C, Levy-Marchal C, Tubiana-Rufi N: Prevalence 
and clinical features of celiac disease in 950 children with type 1 diabetes in France. 
Diabetes Metab, 2007 
178. Carroccio A, Iacono G, Montalto G, Cavataio F, Di Marco C, Balsamo V, 
Notarbartolo A: Exocrine pancreatic function in children with coeliac disease before 
and after a gluten free diet. Gut 32:796-799, 1991 
179. Maton PN, Selden AC, Fitzpatrick ML, Chadwick VS: Defective gallbladder 
emptying and cholecystokinin release in celiac disease. Reversal by gluten-free diet. 
Gastroenterology 88:391-396, 1985 
180. Rhodes RA, Tai HH, Chey WY: Impairment of secretin release in celiac sprue. 
Am J Dig Dis 23:833-839, 1978 
181. Wang F, Herrington M, Larsson J, Permert J: The relationship between diabetes 
and pancreatic cancer. Mol Cancer 2:4, 2003 
182. Mahurkar S, Reddy DN, Rao GV, Chandak GR: Genetic mechanisms 
underlying the pathogenesis of tropical calcific pancreatitis. World J Gastroenterol
15:264-269, 2009 
79
183. Witt H, Apte MV, Keim V, Wilson JS: Chronic pancreatitis: challenges and 
advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology
132:1557-1573, 2007 
184. Etemad B, Whitcomb DC: Chronic pancreatitis: diagnosis, classification, and 
new genetic developments. Gastroenterology 120:682-707, 2001 
185. Mitchell RM, Byrne MF, Baillie J: Pancreatitis. Lancet 361:1447-1455, 2003 
186. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP: The 
different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. 
Gastroenterology 107:1481-1487, 1994 
187. Stormon MO, Durie PR: Pathophysiologic basis of exocrine pancreatic 
dysfunction in childhood. J Pediatr Gastroenterol Nutr 35:8-21, 2002 
188. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, 
Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, 
Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP: Clinical and genetic 
characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol
2:252-261, 2004 
189. Le Marechal C, Masson E, Chen JM, Morel F, Ruszniewski P, Levy P, Ferec C: 
Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet
38:1372-1374, 2006 
190. Masson E, Le Marechal C, Chandak GR, Lamoril J, Bezieau S, Mahurkar S, 
Bhaskar S, Reddy DN, Chen JM, Ferec C: Trypsinogen copy number mutations in 
patients with idiopathic chronic pancreatitis. Clin Gastroenterol Hepatol 6:82-88, 
2008
191. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS: 
Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N
Engl J Med 339:653-658, 1998 
192. Cavestro GM, Comparato G, Nouvenne A, Sereni G, Bertolini S, Frulloni L, 
Dalla Valle R, Soliani P, Zanelli PF, Sianesi M, Franze A, Di Mario F: Genetics of 
chronic pancreatitis. Jop 6:53-59, 2005 
193. Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M, Braganza J: 
Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J 
Med 339:645-652, 1998 
194. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O, Becker M: 
Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are 
associated with chronic pancreatitis. Nat Genet 25:213-216, 2000 
195. Felderbauer P, Klein W, Bulut K, Ansorge N, Dekomien G, Werner I, Epplen 
JT, Schmitz F, Schmidt WE: Mutations in the calcium-sensing receptor: a new 
genetic risk factor for chronic pancreatitis? Scand J Gastroenterol 41:343-348, 2006 
196. Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvari B, Landt O, Schulz HU, 
Gress TM, Pfutzer R, Lohr M, Kovacs P, Bluher M, Stumvoll M, Choudhuri G, 
Hegyi P, te Morsche RH, Drenth JP, Truninger K, Macek M, Jr., Puhl G, Witt U, 
Schmidt H, Buning C, Ockenga J, Kage A, Groneberg DA, Nickel R, Berg T, 
Wiedenmann B, Bodeker H, Keim V, Mossner J, Teich N, Sahin-Toth M: 
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated 
with chronic pancreatitis. Nat Genet 40:78-82, 2008 
80
197. Witt H, Sahin-Toth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, 
Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, 
Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani C, Cavestro GM, Cerny 
M, Destro-Bisol G, Spedini G, Eiberg H, Jansen JB, Koudova M, Rausova E, Macek 
M, Jr., Malats N, Real FX, Menzel HJ, Moral P, Galavotti R, Pignatti PF, Rickards O, 
Spicak J, Zarnescu NO, Bock W, Gress TM, Friess H, Ockenga J, Schmidt H, Pfutzer 
R, Lohr M, Simon P, Weiss FU, Lerch MM, Teich N, Keim V, Berg T, Wiedenmann 
B, Luck W, Groneberg DA, Becker M, Keil T, Kage A, Bernardova J, Braun M, 
Guldner C, Halangk J, Rosendahl J, Witt U, Treiber M, Nickel R, Ferec C: A 
degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic 
pancreatitis. Nat Genet 38:668-673, 2006 
198. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, 
Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N: 
Positional cloning of the APECED gene. Nat Genet 17:393-398, 1997 
199. Scire G, Magliocca FM, Cianfarani S, Scalamandre A, Petrozza V, Bonamico 
M: Autoimmune polyendocrine candidiasis syndrome with associated chronic 
diarrhea caused by intestinal infection and pancreas insufficiency. J Pediatr 
Gastroenterol Nutr 13:224-227, 1991 
200. Betterle C, Greggio NA, Volpato M: Clinical review 93: Autoimmune 
polyglandular syndrome type 1. J Clin Endocrinol Metab 83:1049-1055, 1998 
201. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ, Garrett 
C, Gloyn AL, Edghill EL, Hattersley AT, Wellauer PK, Goodwin G, Houlston RS: 
Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 36:1301-
1305, 2004 
202. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C: Glucose tolerance in 
patients with cystic fibrosis: five year prospective study. BMJ 311:655-659, 1995 
203. Lombardo F, De Luca F, Rosano M, Sferlazzas C, Lucanto C, Arrigo T, Messina 
MF, Crisafulli G, Wasniewska M, Valenzise M, Cucinotta D: Natural history of 
glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic 
fibrosis patients with fasting euglycemia. Eur J Endocrinol 149:53-59, 2003 
204. Lombardi F, Raia V, Spagnuolo MI, Nugnes R, Valerio G, Ciccarelli G, 
Franzese A: Diabetes in an infant with cystic fibrosis. Pediatr Diabetes 5:199-201, 
2004
205. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, 
Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al.: Identification of the cystic 
fibrosis gene: chromosome walking and jumping. Science 245:1059-1065, 1989 
206. Filippi L, Tronchin M, Pezzati M, Chiti G, Dani C, Vichi GF, Rubaltelli FF: 
Shwachman syndrome in a preterm newborn associated with transient diabetes 
mellitus. J Pediatr Gastroenterol Nutr 34:219-223, 2002 
207. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, 
Rommens JM: Mutations in SBDS are associated with Shwachman-Diamond 
syndrome. Nat Genet 33:97-101, 2003 
208. Nagashima K, Yagi H, Kuroume T: A case of Johanson-Blizzard syndrome 
complicated by diabetes mellitus. Clin Genet 43:98-100, 1993 
209. Zenker M, Mayerle J, Lerch MM, Tagariello A, Zerres K, Durie PR, Beier M, 
Hulskamp G, Guzman C, Rehder H, Beemer FA, Hamel B, Vanlieferinghen P, 
81
Gershoni-Baruch R, Vieira MW, Dumic M, Auslender R, Gil-da-Silva-Lopes VL, 
Steinlicht S, Rauh M, Shalev SA, Thiel C, Ekici AB, Winterpacht A, Kwon YT, 
Varshavsky A, Reis A: Deficiency of UBR1, a ubiquitin ligase of the N-end rule 
pathway, causes pancreatic dysfunction, malformations and mental retardation 
(Johanson-Blizzard syndrome). Nat Genet 37:1345-1350, 2005 
210. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, 
Martin SP, Gates LK, Jr., Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, 
Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic 
trypsinogen gene. Nat Genet 14:141-145, 1996 
211. Holzinger A, Maier EM, Buck C, Mayerhofer PU, Kappler M, Haworth JC, 
Moroz SP, Hadorn HB, Sadler JE, Roscher AA: Mutations in the proenteropeptidase 
gene are the molecular cause of congenital enteropeptidase deficiency. Am J Hum 
Genet 70:20-25, 2002 
212. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: 
EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in 
patients with Wolcott-Rallison syndrome. Nat Genet 25:406-409, 2000 
213. Freeman HJ, Weinstein WW, Shnitka TK, Crockford PM, Herbert FA: Alpha1-
antitrypsin deficiency and pancreatic fibrosis. Ann Intern Med 85:73-76, 1976 
214. Lai EC, Kao FT, Law ML, Woo SL: Assignment of the alpha 1-antitrypsin gene 
and a sequence-related gene to human chromosome 14 by molecular hybridization. 
Am J Hum Genet 35:385-392, 1983 
215. Mohan V, Nagalotimath SJ, Yajnik CS, Tripathy BB: Fibrocalculous pancreatic 
diabetes. Diabetes Metab Rev 14:153-170, 1998 
216. Rossi L, Parvin S, Hassan Z, Hildebrand P, Keller U, Ali L, Beglinger C, Azad 
Khan AK, Whitcomb DC, Gyr N: Diabetes mellitus in Tropical Chronic Pancreatitis 
Is Not Just a Secondary Type of Diabetes. Pancreatology 4:461-467, 2004 
217. Mohan V, Farooq S, Deepa M: Prevalence of fibrocalculous pancreatic diabetes 
in Chennai in South India. JOP 9:489-492, 2008 
218. Hardt PD, Hauenschild A, Nalop J, Marzeion AM, Jaeger C, Teichmann J, 
Bretzel RG, Hollenhorst M, Kloer HU: High prevalence of exocrine pancreatic 
insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 
concentrations in 1,021 diabetic patients. Pancreatology 3:395-402, 2003 
219. Hardt PD, Krauss A, Bretz L, Porsch-Ozcurumez M, Schnell-Kretschmer H, 
Maser E, Bretzel RG, Zekhorn T, Klor HU: Pancreatic exocrine function in patients 
with type 1 and type 2 diabetes mellitus. Acta Diabetol 37:105-110, 2000 
220. Icks A, Haastert B, Giani G, Rathmann W: Low fecal elastase-1 in type I 
diabetes mellitus. Z Gastroenterol 39:823-830, 2001 
221. Rathmann W, Haastert B, Icks A, Giani G, Hennings S, Mitchell J, Curran S, 
Wareham NJ: Low faecal elastase 1 concentrations in type 2 diabetes mellitus. Scand
J Gastroenterol 36:1056-1061, 2001 
222. Nunes AC, Pontes JM, Rosa A, Gomes L, Carvalheiro M, Freitas D: Screening 
for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J 
Gastroenterol 98:2672-2675, 2003 
223. Cavalot F, Bonomo K, Perna P, Bacillo E, Salacone P, Gallo M, Mattiello L, 
Trovati M, Gaia E: Pancreatic elastase-1 in stools, a marker of exocrine pancreas 
82
function, correlates with both residual beta-cell secretion and metabolic control in 
type 1 diabetic subjects. Diabetes Care 27:2052-2054, 2004 
224. Laass MW, Henker J, Thamm K, Neumeister V, Kuhlisch E: Exocrine 
pancreatic insufficiency and its consequences on physical development and 
metabolism in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr
163:681-682, 2004 
225. Yilmaztepe A, Ulukaya E, Ersoy C, Yilmaz M, Tokullugil HA: Investigation of 
fecal pancreatic elastase-1 levels in type 2 diabetic patients. Turk J Gastroenterol
16:75-80, 2005 
226. Mancilla AC, Hurtado HC, Tobar AE, Orellana NI, Pineda BP, Castillo MI, 
Ledezma RR, Berger FZ: [Pancreatic exocrine function in diabetes mellitus. 
Determination of fecal elastase]. Rev Med Chil 134:407-414, 2006 
227. Ewald N, Bretzel RG, Fantus IG, Hollenhorst M, Kloer HU, Hardt PD: 
Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine 
pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a 
prospective multi-centre trial. Diabetes Metab Res Rev 23:386-391, 2007 
228. Cavalot F, Bonomo K, Fiora E, Bacillo E, Salacone P, Chirio M, Gaia E, Trovati 
M: Does pancreatic elastase-1 in stools predict steatorrhea in type 1 diabetes? 
Diabetes Care 29:719-721, 2006 
229. Hardt PD, Hauenschild A, Jaeger C, Teichmann J, Bretzel RG, Kloer HU: High 
prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine 
pancreatic insufficiency according to low fecal elastase 1 concentrations: a 
prospective multicenter study. Dig Dis Sci 48:1688-1692, 2003 
230. Creutzfeldt W, Gleichmann D, Otto J, Stockmann F, Maisonneuve P, Lankisch 
PG: Follow-up of exocrine pancreatic function in type-1 diabetes mellitus. Digestion
72:71-75, 2005 
231. Baron JH, Nabarro JD: Pancreatic exocrine function in maturity onset diabetes 
mellitus. Br Med J 4:25-27, 1973 
232. Layer P, Keller J: Lipase supplementation therapy: standards, alternatives, and 
perspectives. Pancreas 26:1-7, 2003 
233. Dutta SK, Rubin J, Harvey J: Comparative evaluation of the therapeutic efficacy 
of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional 
pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency. 
Gastroenterology 84:476-482, 1983 
234. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-
Insua M: Effect of the administration schedule on the therapeutic efficacy of oral 
pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a 
randomized, three-way crossover study. Aliment Pharmacol Ther 21:993-1000, 2005 
235. Heijerman HG, Lamers CB, Bakker W: Omeprazole enhances the efficacy of 
pancreatin (pancrease) in cystic fibrosis. Ann Intern Med 114:200-201, 1991 
236. Heijerman HG, Lamers CB, Bakker W, Dijkman JH: Improvement of fecal fat 
excretion after addition of omeprazole to pancrease in cystic fibrosis is related to 
residual exocrine function of the pancreas. Dig Dis Sci 38:1-6, 1993 
237. O'Keefe SJ, Cariem AK, Levy M: The exacerbation of pancreatic endocrine 
dysfunction by potent pancreatic exocrine supplements in patients with chronic 
pancreatitis. J Clin Gastroenterol 32:319-323, 2001 
83
238. Clee SM, Attie AD: The genetic landscape of type 2 diabetes in mice. Endocr
Rev 28:48-83, 2007 
239. Coleman DL, Hummel KP: The influence of genetic background on the 
expression of the obese (Ob) gene in the mouse. Diabetologia 9:287-293, 1973 
240. Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells from 
mouse embryos. Nature 292:154-156, 1981 
241. Thomas KR, Folger KR, Capecchi MR: High frequency targeting of genes to 
specific sites in the mammalian genome. Cell 44:419-428, 1986 
242. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of a DNA 
polymerase beta gene segment in T cells using cell type-specific gene targeting. 
Science 265:103-106, 1994 
243. Orban PC, Chui D, Marth JD: Tissue- and site-specific DNA recombination in 
transgenic mice. Proc Natl Acad Sci U S A 89:6861-6865, 1992 
244. Kuhn R, Schwenk F, Aguet M, Rajewsky K: Inducible gene targeting in mice. 
Science 269:1427-1429, 1995 
245. Zou YR, Muller W, Gu H, Rajewsky K: Cre-loxP-mediated gene replacement: a 
mouse strain producing humanized antibodies. Curr Biol 4:1099-1103, 1994 
246. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. 
Nature 431:343-349, 2004 
247. Goren HJ, Kulkarni RN, Kahn CR: Glucose homeostasis and tissue transcript 
content of insulin signaling intermediates in four inbred strains of mice: C57BL/6, 
C57BLKS/6, DBA/2, and 129X1. Endocrinology 145:3307-3323, 2004 
248. Kaku K, Fiedorek FT, Jr., Province M, Permutt MA: Genetic analysis of glucose 
tolerance in inbred mouse strains. Evidence for polygenic control. Diabetes 37:707-
713, 1988 
249. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE: Defective glucose-
stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11:206-
211, 1995 
250. Wencel HE, Smothers C, Opara EC, Kuhn CM, Feinglos MN, Surwit RS: 
Impaired second phase insulin response of diabetes-prone C57BL/6J mouse islets. 
Physiol Behav 57:1215-1220, 1995 
251. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, 
Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, Cox 
RD: A genetic and physiological study of impaired glucose homeostasis control in 
C57BL/6J mice. Diabetologia 48:675-686, 2005 
252. Almind K, Kahn CR: Genetic determinants of energy expenditure and insulin 
resistance in diet-induced obesity in mice. Diabetes 53:3274-3285, 2004 
253. Kulkarni RN, Almind K, Goren HJ, Winnay JN, Ueki K, Okada T, Kahn CR: 
Impact of genetic background on development of hyperinsulinemia and diabetes in 
insulin receptor/insulin receptor substrate-1 double heterozygous mice. Diabetes
52:1528-1534, 2003 
254. Jiang W, Anderson MS, Bronson R, Mathis D, Benoist C: Modifier loci 
condition autoimmunity provoked by Aire deficiency. J Exp Med 202:805-815, 2005 
255. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, 
Roberson RS, Ricordi C, O'Connell PJ, Gonzalez FJ, Kahn CR: Loss of 
84
ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in 
human type 2 diabetes. Cell 122:337-349, 2005 
256. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, 
Koller BH: An animal model for cystic fibrosis made by gene targeting. Science
257:1083-1088, 1992 
257. Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de 
Angelis M, Lendahl U, Edlund H: Notch signalling controls pancreatic cell 
differentiation. Nature 400:877-881, 1999 
258. Fajas L, Annicotte JS, Miard S, Sarruf D, Watanabe M, Auwerx J: Impaired 
pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/- )mice. J Clin 
Invest 113:1288-1295, 2004 
259. Iglesias A, Murga M, Laresgoiti U, Skoudy A, Bernales I, Fullaondo A, Moreno 
B, Lloreta J, Field SJ, Real FX, Zubiaga AM: Diabetes and exocrine pancreatic 
insufficiency in E2F1/E2F2 double-mutant mice. J Clin Invest 113:1398-1407, 2004 
260. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, 
Ron D: Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals 
a role for translational control in secretory cell survival. Mol Cell 7:1153-1163, 2001 
261. Zhang P, McGrath B, Li S, Frank A, Zambito F, Reinert J, Gannon M, Ma K, 
McNaughton K, Cavener DR: The PERK eukaryotic initiation factor 2 alpha kinase 
is required for the development of the skeletal system, postnatal growth, and the 
function and viability of the pancreas. Mol Cell Biol 22:3864-3874, 2002 
262. Guillam MT, Hummler E, Schaerer E, Yeh JI, Birnbaum MJ, Beermann F, 
Schmidt A, Deriaz N, Thorens B: Early diabetes and abnormal postnatal pancreatic 
islet development in mice lacking Glut-2. Nat Genet 17:327-330, 1997 
263. Sumazaki R, Shiojiri N, Isoyama S, Masu M, Keino-Masu K, Osawa M, 
Nakauchi H, Kageyama R, Matsui A: Conversion of biliary system to pancreatic 
tissue in Hes1-deficient mice. Nat Genet 36:83-87, 2004 
264. Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH: Pancreas dorsal lobe agenesis 
and abnormal islets of Langerhans in Hlxb9-deficient mice. Nat Genet 23:71-75, 
1999
265. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A, Pick AJ, 
Baldwin A, Velho G, Froguel P, Levisetti M, Bonner-Weir S, Bell GI, Yaniv M, 
Polonsky KS: Defective insulin secretion in hepatocyte nuclear factor 1alpha-
deficient mice. J Clin Invest 101:2215-2222, 1998 
266. Briancon N, Weiss MC: In vivo role of the HNF4alpha AF-1 activation domain 
revealed by exon swapping. EMBO J 25:1253-1262, 2006 
267. Jacquemin P, Durviaux SM, Jensen J, Godfraind C, Gradwohl G, Guillemot F, 
Madsen OD, Carmeliet P, Dewerchin M, Collen D, Rousseau GG, Lemaigre FP: 
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell 
differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol
20:4445-4454, 2000 
268. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD, Jose 
PA, Taylor SI, Westphal H: Early neonatal death in mice homozygous for a null 
allele of the insulin receptor gene. Nat Genet 12:106-109, 1996 
85
269. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR: 
Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an 
insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339, 1999 
270. Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, Peters JL, 
Shackman JG, Zhang M, Artner I, Satin LS, Stein R, Holzenberger M, Kennedy RT, 
Kahn CR, Kulkarni RN: Total insulin and IGF-I resistance in pancreatic beta cells 
causes overt diabetes. Nat Genet 38:583-588, 2006 
271. Jonsson J, Carlsson L, Edlund T, Edlund H: Insulin-promoter-factor 1 is 
required for pancreas development in mice. Nature 371:606-609, 1994 
272. Heller RS, Stoffers DA, Bock T, Svenstrup K, Jensen J, Horn T, Miller CP, 
Habener JF, Madsen OD, Serup P: Improved glucose tolerance and acinar 
dysmorphogenesis by targeted expression of transcription factor PDX-1 to the 
exocrine pancreas. Diabetes 50:1553-1561, 2001 
273. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, Kahn 
CR: Altered function of insulin receptor substrate-1-deficient mouse islets and 
cultured beta-cell lines. J Clin Invest 104:R69-75, 1999 
274. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, 
Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 
causes type 2 diabetes in mice. Nature 391:900-904, 1998 
275. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H: Independent requirement 
for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 385:257-260, 
1997
276. Casanova ML, Bravo A, Ramirez A, Morreale de Escobar G, Were F, Merlino 
G, Vidal M, Jorcano JL: Exocrine pancreatic disorders in transsgenic mice expressing 
human keratin 8. J Clin Invest 103:1587-1595, 1999 
277. Pin CL, Rukstalis JM, Johnson C, Konieczny SF: The bHLH transcription factor 
Mist1 is required to maintain exocrine pancreas cell organization and acinar cell 
identity. J Cell Biol 155:519-530, 2001 
278. Fazio EN, Everest M, Colman R, Wang R, Pin CL: Altered Glut-2 accumulation 
and beta-cell function in mice lacking the exocrine-specific transcription factor, 
Mist1. J Endocrinol 187:407-418, 2005 
279. Naya FJ, Huang HP, Qiu Y, Mutoh H, DeMayo FJ, Leiter AB, Tsai MJ: 
Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine 
differentiation in BETA2/neuroD-deficient mice. Genes Dev 11:2323-2334, 1997 
280. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, 
Rubenstein JL, German MS: Mice lacking the homeodomain transcription factor 
Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. 
Development 125:2213-2221, 1998 
281. Sander M, Sussel L, Conners J, Scheel D, Kalamaras J, Dela Cruz F, 
Schwitzgebel V, Hayes-Jordan A, German M: Homeobox gene Nkx6.1 lies 
downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. 
Development 127:5533-5540, 2000 
282. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P: The Pax4 gene is 
essential for differentiation of insulin-producing beta cells in the mammalian 
pancreas. Nature 386:399-402, 1997 
86
283. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P: Pax6 is 
required for differentiation of glucagon-producing alpha-cells in mouse pancreas. 
Nature 387:406-409, 1997 
284. Kim SK, Selleri L, Lee JS, Zhang AY, Gu X, Jacobs Y, Cleary ML: Pbx1 
inactivation disrupts pancreas development and in Ipf1-deficient mice promotes 
diabetes mellitus. Nat Genet 30:430-435, 2002 
285. Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, Takeda 
A, Tsuchihashi D, Nishizawa A, Ogawa W, Fujimoto Y, Okamura H, Arden KC, 
Herrera PL, Noda T, Kasuga M: Ablation of PDK1 in pancreatic beta cells induces 
diabetes as a result of loss of beta cell mass. Nat Genet 38:589-593, 2006 
286. Loftus SK, Cannons JL, Incao A, Pak E, Chen A, Zerfas PM, Bryant MA, 
Biesecker LG, Schwartzberg PL, Pavan WJ: Acinar Cell Apoptosis in Serpini2-
DeficientMice Models Pancreatic Insufficiency. PLoS Genet 1:e38, 2005 
287. Krapp A, Knofler M, Ledermann B, Burki K, Berney C, Zoerkler N, 
Hagenbuchle O, Wellauer PK: The bHLH protein PTF1-p48 is essential for the 
formation of the exocrine and the correct spatial organization of the endocrine 
pancreas. Genes Dev 12:3752-3763, 1998 
288. Matsumoto M, Miki T, Shibasaki T, Kawaguchi M, Shinozaki H, Nio J, Saraya 
A, Koseki H, Miyazaki M, Iwanaga T, Seino S: Noc2 is essential in normal 
regulation of exocytosis in endocrine and exocrine cells. Proc Natl Acad Sci U S A
101:8313-8318, 2004 
289. Chen Y, Chong MM, Darwiche R, Thomas HE, Kay TW: Severe pancreatitis 
with exocrine destruction and increased islet neogenesis in mice with suppressor of 
cytokine signaling-1 deficiency. Am J Pathol 165:913-921, 2004 
290. Bottinger EP, Jakubczak JL, Roberts IS, Mumy M, Hemmati P, Bagnall K, 
Merlino G, Wakefield LM: Expression of a dominant-negative mutant TGF-beta type 
II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of 
growth and differentiation in the exocrine pancreas. EMBO J 16:2621-2633, 1997 
291. Zhang Q, Davenport JR, Croyle MJ, Haycraft CJ, Yoder BK: Disruption of IFT 
results in both exocrine and endocrine abnormalities in the pancreas of Tg737(orpk) 
mutant mice. Lab Invest 85:45-64, 2005 
292. Lombardo D: Bile salt-dependent lipase: its pathophysiological implications. 
Biochim Biophys Acta 1533:1-28, 2001 
293. Hui DY, Howles PN: Carboxyl ester lipase: structure-function relationship and 
physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res
43:2017-2030, 2002 
294. Taylor AK, Zambaux JL, Klisak I, Mohandas T, Sparkes RS, Schotz MC, Lusis 
AJ: Carboxyl ester lipase: a highly polymorphic locus on human chromosome 9qter. 
Genomics 10:425-431, 1991 
295. Lidberg U, Nilsson J, Stromberg K, Stenman G, Sahlin P, Enerback S, Bjursell 
G: Genomic organization, sequence analysis, and chromosomal localization of the 
human carboxyl ester lipase (CEL) gene and a CEL-like (CELL) gene. Genomics
13:630-640, 1992 
296. Nilsson J, Blackberg L, Carlsson P, Enerback S, Hernell O, Bjursell G: cDNA 
cloning of human-milk bile-salt-stimulated lipase and evidence for its identity to 
pancreatic carboxylic ester hydrolase. Eur J Biochem 192:543-550, 1990 
87
297. Bengtsson-Ellmark SH, Nilsson J, Orho-Melander M, Dahlenborg K, Groop L, 
Bjursell G: Association between a polymorphism in the carboxyl ester lipase gene 
and serum cholesterol profile. Eur J Hum Genet 12:627-632, 2004 
298. Lindquist S, Blackberg L, Hernell O: Human bile salt-stimulated lipase has a 
high frequency of size variation due to a hypervariable region in exon 11. Eur J 
Biochem 269:759-767, 2002 
299. Gjellesvik DR, Lorens JB, Male R: Pancreatic carboxylester lipase from Atlantic 
salmon (Salmo salar). cDNA sequence and computer-assisted modelling of tertiary 
structure. Eur J Biochem 226:603-612, 1994 
300. Lidmer AS, Kannius M, Lundberg L, Bjursell G, Nilsson J: Molecular cloning 
and characterization of the mouse carboxyl ester lipase gene and evidence for 
expression in the lactating mammary gland. Genomics 29:115-122, 1995 
301. Han JH, Stratowa C, Rutter WJ: Isolation of full-length putative rat 
lysophospholipase cDNA using improved methods for mRNA isolation and cDNA 
cloning. Biochemistry 26:1617-1625, 1987 
302. Madeyski K, Lidberg U, Bjursell G, Nilsson J: Characterization of the gorilla 
carboxyl ester lipase locus, and the appearance of the carboxyl ester lipase 
pseudogene during primate evolution. Gene 239:273-282, 1999 
303. Warden CH, Davis RC, Yoon MY, Hui DY, Svenson K, Xia YR, Diep A, He 
KY, Lusis AJ: Chromosomal localization of lipolytic enzymes in the mouse: 
pancreatic lipase, colipase, hormone-sensitive lipase, hepatic lipase, and carboxyl 
ester lipase. J Lipid Res 34:1451-1455, 1993 
304. Nilsson J, Hellquist M, Bjursell G: The human carboxyl ester lipase-like (CELL) 
gene is ubiquitously expressed and contains a hypervariable region. Genomics
17:416-422, 1993 
305. Gilham D, Labonte ED, Rojas JC, Jandacek RJ, Howles PN, Hui DY: Carboxyl 
ester lipase deficiency exacerbates dietary lipid absorption abnormalities and 
resistance to diet-induced obesity in pancreatic triglyceride lipase knockout mice. J
Biol Chem 282:24642-24649, 2007 
306. Bruneau N, Richard S, Silvy F, Verine A, Lombardo D: Lectin-like Ox-LDL 
receptor is expressed in human INT-407 intestinal cells: involvement in the 
transcytosis of pancreatic bile salt-dependent lipase. Mol Biol Cell 14:2861-2875, 
2003
307. Auge N, Rebai O, Lepetit-Thevenin J, Bruneau N, Thiers JC, Mas E, Lombardo 
D, Negre-Salvayre A, Verine A: Pancreatic bile salt-dependent lipase induces smooth 
muscle cells proliferation. Circulation 108:86-91, 2003 
308. Rebai O, Le Petit-Thevenin J, Bruneau N, Lombardo D, Verine A: In vitro 
angiogenic effects of pancreatic bile salt-dependent lipase. Arterioscler Thromb Vasc 
Biol 25:359-364, 2005 
309. Panicot-Dubois L, Thomas GM, Furie BC, Furie B, Lombardo D, Dubois C: 
Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus 
formation in mice and humans. J Clin Invest, 2007 
310. Sbarra V, Ristorcelli E, Petit-Thevenin JL, Teissedre PL, Lombardo D, Verine 
A: In vitro polyphenol effects on activity, expression and secretion of pancreatic bile 
salt-dependent lipase. Biochim Biophys Acta 1736:67-76, 2005 
88
311. Kodvawala A, Ghering AB, Davidson WS, Hui DY: Carboxyl ester lipase 
expression in macrophages increases cholesteryl ester accumulation and promotes 
atherosclerosis. J Biol Chem 280:38592-38598, 2005 
312. Camarota LM, Chapman JM, Hui DY, Howles PN: Carboxyl ester lipase 
cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances 
selective uptake and hydrolysis of cholesteryl esters from HDL3. J Biol Chem
279:27599-27606, 2004 
313. Comte B, Franceschi C, Sadoulet MO, Silvy F, Lafitte D, Benkoel L, Nganga A, 
Daniel L, Bernard JP, Lombardo D, Mas E: Detection of bile salt-dependent lipase, a 
110 kDa pancreatic protein, in urines of healthy subjects. Kidney Int 69:1048-1055, 
2006
314. Wang X, Wang CS, Tang J, Dyda F, Zhang XC: The crystal structure of bovine 
bile salt activated lipase: insights into the bile salt activation mechanism. Structure
5:1209-1218, 1997 
315. Moore SA, Kingston RL, Loomes KM, Hernell O, Blackberg L, Baker HM, 
Baker EN: The structure of truncated recombinant human bile salt-stimulated lipase 
reveals bile salt-independent conformational flexibility at the active-site loop and 
provides insights into heparin binding. J Mol Biol 312:511-523, 2001 
316. Hansson L, Blackberg L, Edlund M, Lundberg L, Stromqvist M, Hernell O: 
Recombinant human milk bile salt-stimulated lipase. Catalytic activity is retained in 
the absence of glycosylation and the unique proline-rich repeats. J Biol Chem
268:26692-26698, 1993 
317. Downs D, Xu YY, Tang J, Wang CS: Proline-rich domain and glycosylation are 
not essential for the enzymic activity of bile salt-activated lipase. Kinetic studies of 
T-BAL, a truncated form of the enzyme, expressed in Escherichia coli. Biochemistry
33:7979-7985, 1994 
318. Hui DY, Kissel JA: Sequence identity between human pancreatic cholesterol 
esterase and bile salt-stimulated milk lipase. FEBS Lett 276:131-134, 1990 
319. Bruneau N, Nganga A, Fisher EA, Lombardo D: O-Glycosylation of C-terminal 
tandem-repeated sequences regulates the secretion of rat pancreatic bile salt-
dependent lipase. J Biol Chem 272:27353-27361, 1997 
320. Le Petit-Thevenin J, Verine A, Nganga A, Nobili O, Lombardo D, Bruneau N: 
Impairment of bile salt-dependent lipase secretion in AR4-2J rat pancreatic cells 
induces its degradation by the proteasome. Biochim Biophys Acta 1530:184-198, 
2001
321. Loomes KM, Senior HE, West PM, Roberton AM: Functional protective role for 
mucin glycosylated repetitive domains. Eur J Biochem 266:105-111, 1999 
322. Spilburg CA, Cox DG, Wang X, Bernat BA, Bosner MS, Lange LG: 
Identification of a species specific regulatory site in human pancreatic cholesterol 
esterase. Biochemistry 34:15532-15538, 1995 
323. Roudani S, Miralles F, Margotat A, Escribano MJ, Lombardo D: Bile salt-
dependent lipase transcripts in human fetal tissues. Biochim Biophys Acta 1264:141-
150, 1995 
324. Li F, Hui DY: Modified low density lipoprotein enhances the secretion of bile 
salt-stimulated cholesterol esterase by human monocyte-macrophages. species-
89
specific difference in macrophage cholesteryl ester hydrolase. J Biol Chem
272:28666-28671, 1997 
325. Reuss R, Aberle S, Klingel K, Sauter M, Greschniok A, Franke FE, Padberg W, 
Blin N: The expression of the carboxyl ester lipase gene in pancreas and pancreatic 
adenocarcinomas. Int J Oncol 29:649-654, 2006 
326. Kannius-Janson M, Lidberg U, Bjursell G, Nilsson J: The tissue-specific 
regulation of the carboxyl ester lipase gene in exocrine pancreas differs significantly 
between mouse and human. Biochem J 351 Pt 2:367-376, 2000 
327. Panicot L, Mas E, Thivolet C, Lombardo D: Circulating antibodies against an 
exocrine pancreatic enzyme in type 1 diabetes. Diabetes 48:2316-2323, 1999 
328. Aleman-Gomez JA, Colwell NS, Vyas K, Borecki I, Shonfeld G, Lange LG, 
Kumar VB: Relationship of human pancreatic cholesterol esterase gene structure with 
lipid phenotypes. Life Sci 64:2419-2427, 1999 
329. George VT, Elston RC, Amos CI, Ward LJ, Berenson GS: Association between 
polymorphic blood markers and risk factors for cardiovascular disease in a large 
pedigree. Genet Epidemiol 4:267-275, 1987 
330. Miyasaka K, Ohta M, Takano S, Hayashi H, Higuchi S, Maruyama K, Tando Y, 
Nakamura T, Takata Y, Funakoshi A: Carboxylester lipase gene polymorphism as a 
risk of alcohol-induced pancreatitis. Pancreas 30:e87-91, 2005 
331. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, Vestman EL, Stax 
MJ, Geijtenbeek TB, Pollakis G, Hernell O, Paxton WA: Bile salt-stimulated lipase 
from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 
transfer to CD4+ T cells. Antimicrob Agents Chemother 50:3367-3374, 2006 
332. Kaisaki PJ, Menzel S, Lindner T, Oda N, Rjasanowski I, Sahm J, Meincke G, 
Schulze J, Schmechel H, Petzold C, Ledermann HM, Sachse G, Boriraj VV, Menzel 
R, Kerner W, Turner RC, Yamagata K, Bell GI: Mutations in the hepatocyte nuclear 
factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational 
hotspot in exon 4. Diabetes 46:528-535, 1997 
333. Raile K, Klopocki E, Holder M, Wessel T, Galler A, Deiss D, Muller D, Riebel 
T, Horn D, Maringa M, Weber J, Ullmann R, Gruters A: Expanded clinical spectrum 
in HNF1B-MODY. J Clin Endocrinol Metab, 2009 
334. Maestro MA, Boj SF, Luco RF, Pierreux CE, Cabedo J, Servitja JM, German 
MS, Rousseau GG, Lemaigre FP, Ferrer J: Hnf6 and Tcf2 (MODY5) are linked in a 
gene network operating in a precursor cell domain of the embryonic pancreas. Hum
Mol Genet 12:3307-3314, 2003 
335. Maestro MA, Cardalda C, Boj SF, Luco RF, Servitja JM, Ferrer J: Distinct roles 
of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-
cell function and growth. Endocr Dev 12:33-45, 2007 
336. Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, Cereghini S: 
Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses 
carrying novel HNF1beta/MODY5 mutations. Hum Mol Genet 15:2363-2375, 2006 
337. Eisenbarth GS, Connelly J, Soeldner JS: The "natural" history of type I diabetes. 
Diabetes Metab Rev 3:873-891, 1987 
338. Porte D, Jr.: Banting lecture 1990. Beta-cells in type II diabetes mellitus. 
Diabetes 40:166-180, 1991 
90
339. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell 
deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes
52:102-110, 2003 
340. Zhang W, Feng D, Li Y, Iida K, McGrath B, Cavener DR: PERK EIF2AK3 
control of pancreatic beta cell differentiation and proliferation is required for 
postnatal glucose homeostasis. Cell Metab 4:491-497, 2006 
341. Nammo T, Yamagata K, Hamaoka R, Zhu Q, Akiyama TE, Gonzalez FJ, 
Miyagawa J, Matsuzawa Y: Expression profile of MODY3/HNF-1alpha protein in 
the developing mouse pancreas. Diabetologia 45:1142-1153, 2002 
342. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, 
Butler PC: Pancreas volumes in humans from birth to age one hundred taking into 
account sex, obesity, and presence of type-2 diabetes. Clin Anat 20:933-942, 2007 
343. Williams AJ, Chau W, Callaway MP, Dayan CM: Magnetic resonance imaging: 
a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabet Med
24:35-40, 2007 
344. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, 
Kosaka K, Hara M: Relationships among residual beta cells, exocrine pancreas, and 
islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism 42:196-203, 
1993
345. Hardt PD, Brendel MD, Kloer HU, Bretzel RG: Is pancreatic diabetes (type 3c 
diabetes) underdiagnosed and misdiagnosed? Diabetes Care 31 Suppl 2:S165-169, 
2008
346. Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD: 
Determinants of Exocrine Pancreatic Function as Measured by Fecal Elastase-1 
Concentrations (FEC) in Patients with Diabetes mellitus. Eur J Med Res 14:118-122, 
2009
347. Hardt PD, Killinger A, Nalop J, Schnell-Kretschmer H, Zekorn T, Klor HU: 
Chronic pancreatitis and diabetes mellitus. A retrospective analysis of 156 ERCP 
investigations in patients with insulin-dependent and non-insulin-dependent diabetes 
mellitus. Pancreatology 2:30-33, 2002 
348. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, 
Hashimoto M, Fukuchi S, Kosaka K: Exocrine pancreatic ductograms in insulin-
dependent diabetes mellitus. Am J Gastroenterol 89:762-766, 1994 
349. Sodhi KS, Thapa BR, Khandelwal S, Suri S: Pancreatic lipomatosis in an infant 
with cystic fibrosis. Pediatr Radiol 35:1157-1158, 2005 
350. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, 
Schindhelm RK, Mari A, Heine RJ, Diamant M: Pancreatic fat content and beta-cell 
function in men with and without type 2 diabetes. Diabetes Care 30:2916-2921, 2007 
351. Wang LW, Li ZS, Li SD, Jin ZD, Zou DW, Chen F: Prevalence and clinical 
features of chronic pancreatitis in China: a retrospective multicenter analysis over 10 
years. Pancreas 38:248-254, 2009 
352. Foulis AK, Stewart JA: The pancreas in recent-onset type 1 (insulin-dependent) 
diabetes mellitus: insulin content of islets, insulitis and associated changes in the 
exocrine acinar tissue. Diabetologia 26:456-461, 1984 
353. Dyck WP, Rudick J, Hoexter B, Janowitz HD: Influence of glucagon on 
pancreatic exocrine secretion. Gastroenterology 56:531-537, 1969 
91
354. Ertan A, Arimura A, Akdamar K, Shibata T, Groot K, Luciano M, Mather FJ, 
Degertekin H, Agrawal N, Ryan J: Pancreatic immunoreactive somatostatin and 
diabetes mellitus. Dig Dis Sci 29:625-630, 1984 
355. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC: Sustained beta cell 
apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet 
regeneration? Diabetologia 48:2221-2228, 2005 
356. Hardt PD, Ewald N, Brockling K, Tanaka S, Endo T, Kloer HU, Bretzel RG, 
Jaeger C, Shimura H, Kobayashi T: Distinct autoantibodies against exocrine 
pancreatic antigens in European patients with type 1 diabetes mellitus and non-
alcoholic chronic pancreatitis. JOP 9:683-689, 2008 
357. Hayden MR, Patel K, Habibi J, Gupta D, Tekwani SS, Whaley-Connell A, 
Sowers JR: Attenuation of endocrine-exocrine pancreatic communication in type 2 
diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab 
Syndr 3:234-243, 2008 
358. Waljee AK, Dimagno MJ, Wu BU, Schoenfeld PS, Conwell DL: Systematic 
review: pancreatic enzyme treatment of malabsorption associated with chronic 
pancreatitis. Aliment Pharmacol Ther 29:235-246, 2009 
359. Glasbrenner B, Malfertheiner P, Kerner W, Scherbaum WA, Ditschuneit H: 
[Effect of pancreatin on diabetes mellitus in chronic pancreatitis]. Z Gastroenterol
28:275-279, 1990 
360. Mohan V, Poongothai S, Pitchumoni CS: Oral pancreatic enzyme therapy in the 
control of diabetes mellitus in tropical calculous pancreatitis. Int J Pancreatol 24:19-
22, 1998 
361. Ebert R, Creutzfeldt W: Reversal of impaired GIP and insulin secretion in 
patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia
19:198-204, 1980 
362. Mann ST, Stracke H, Lange U, Klor HU, Teichmann J: Alterations of bone 
mineral density and bone metabolism in patients with various grades of chronic 
pancreatitis. Metabolism 52:579-585, 2003 
363. Harding AE, Matthews S, Jones S, Ellis CJ, Booth IW, Muller DP: 
Spinocerebellar degeneration associated with a selective defect of vitamin E 
absorption. N Engl J Med 313:32-35, 1985 
364. Martinello F, Fardin P, Ottina M, Ricchieri GL, Koenig M, Cavalier L, Trevisan 
CP: Supplemental therapy in isolated vitamin E deficiency improves the peripheral 
neuropathy and prevents the progression of ataxia. J Neurol Sci 156:177-179, 1998 
365. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky 
FM, Duncan SA, Kaestner KH: The MODY1 gene HNF-4alpha regulates selected 
genes involved in insulin secretion. J Clin Invest, 2005 
366. Howles PN, Carter CP, Hui DY: Dietary free and esterified cholesterol 
absorption in cholesterol esterase (bile salt-stimulated lipase) gene-targeted mice. J
Biol Chem 271:7196-7202, 1996 
367. Weng W, Li L, van Bennekum AM, Potter SH, Harrison EH, Blaner WS, 
Breslow JL, Fisher EA: Intestinal absorption of dietary cholesteryl ester is decreased 
but retinyl ester absorption is normal in carboxyl ester lipase knockout mice. 
Biochemistry 38:4143-4149, 1999 
92
368. van Bennekum AM, Li L, Piantedosi R, Shamir R, Vogel S, Fisher EA, Blaner 
WS, Harrison EH: Carboxyl ester lipase overexpression in rat hepatoma cells and 
CEL deficiency in mice have no impact on hepatic uptake or metabolism of 
chylomicron-retinyl ester. Biochemistry 38:4150-4156, 1999 
369. van Bennekum AM, Fisher EA, Blaner WS, Harrison EH: Hydrolysis of retinyl 
esters by pancreatic triglyceride lipase. Biochemistry 39:4900-4906, 2000 
370. Leiter EH, Chapman HD, Coleman DL: The influence of genetic background on 
the expression of mutations at the diabetes locus in the mouse. V. Interaction between 
the db gene and hepatic sex steroid sulfotransferases correlates with gender-
dependent susceptibility to hyperglycemia. Endocrinology 124:912-922, 1989 
371. Shiga T, Moriyoshi Y, Nagahara H, Shiratori K: Nonalcoholic fatty liver is a 
risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. J
Gastroenterol, 2009 
372. Shwachman H, Diamond LK, Oski FA, Khaw KT: The Syndrome of Pancreatic 
Insufficiency and Bone Marrow Dysfunction. J Pediatr 65:645-663, 1964 
373. Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, Lillemoe 
KD: Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J
Am Coll Surg 208:989-994; discussion 994-986, 2009 
374. Jandacek RJ, Heubi JE, Tso P: A novel, noninvasive method for the 
measurement of intestinal fat absorption. Gastroenterology 127:139-144, 2004 
375. Scheuner D, Vander Mierde D, Song B, Flamez D, Creemers JW, Tsukamoto K, 
Ribick M, Schuit FC, Kaufman RJ: Control of mRNA translation preserves 
endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nat
Med 11:757-764, 2005 
376. Leiter EH: Mice with targeted gene disruptions or gene insertions for diabetes 
research: problems, pitfalls, and potential solutions. Diabetologia 45:296-308, 2002 
377. Jimenez-Sanchez G, Childs B, Valle D: Human disease genes. Nature 409:853-
855, 2001 
378. Jones NL, Hofley PM, Durie PR: Pathophysiology of the pancreatic defect in 
Johanson-Blizzard syndrome: a disorder of acinar development. J Pediatr 125:406-
408, 1994 
379. Kopelman H, Durie P, Gaskin K, Weizman Z, Forstner G: Pancreatic fluid 
secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med 312:329-
334, 1985 
